
Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries

In the format provided by the authors and unedited

Supplementary Information

Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries

Dorit Talia Stein, Marissa B. Reitsma, Pascal Geldsetzer, Kokou Agoudavi, Krishna Kumar Aryal, Silver Bahendeka, Luisa C C Brant, Farshad Farzadfar, Mongal Singh Gurung, David Guwatudde, Yessito Corine Nadège Houehanou, Deborah Carvalho Malta, João Soares Martins, Sahar Saeedi Moghaddam, Kibachio Joseph Mwangi, Bolormaa Norov, Lela Sturua, Zhaxybay Zhumadilov, Till Bärnighausen, Justine I. Davies, David Flood, Maja E. Marcus, Michaela Theilmann, Sebastian Vollmer, Jennifer Manne-Goehler, Rifat Atun, Nikkil Sudharsanan, Stéphane Verguet

Contents

Supplementary Table 1. Countries included in the analysis	5
Baseline	7
Supplementary Table 2. Mean (95% confidence interval) proportion of people living with hypertension aware of their diagnosis, on treatment, and with controlled hypertension by country and wealth quintile	7
Supplementary Table 3. Mean (95% confidence interval) proportion of people living with hypertension aware of their diagnosis, on treatment, and with controlled hypertension by wealth quintile and country-level income group	12
Supplementary Table 4. Ranked gap in hypertension care cascade performance comparing top (Q5) and bottom (Q1) wealth quintiles at baseline by country ('baseline cascade gap')	13
Targets	15
Supplementary Table 5. Diagnosis scenario linkage to treatment and treatment coverage levels by country and wealth quintile	15
Supplementary Table 6. Sensitivity analysis: performance-based targets by baseline performance tercile and scenario	18
Supplementary Table 7. Sensitivity analysis: relative increase targets by country, wealth quintile, and scenario	19
Supplementary Table 8. Sensitivity analysis: within-country targets by country and scenario	22
Supplementary Table 9. Sensitivity analysis: education group targets by scenario	24
Results	25
Supplementary Table 10. Mean (95% confidence/uncertainty interval) 10-year CVD risk by country and wealth quintile in Baseline, Diagnosis, and Treatment scenarios	25
Supplementary Table 11. Absolute (percentage point) difference in mean 10-year cardiovascular disease risk comparing the bottom (Q1) and top (Q5) wealth quintiles by country and modelled scenario, either Baseline, Diagnosis or Treatment scenario	30
Supplementary Table 12. Mean difference (95% uncertainty interval) in CVD cases per 1,000 people living with hypertension compared to baseline by country, wealth quintile, and scenario	35
Supplementary Table 13. Mean (95% uncertainty interval) relative decline (%) in CVD risk compared to baseline by country, wealth quintile, and scenario	38
By Baseline Cascade Gap	41
Supplementary Table 14. Cardiovascular disease cases averted per 1,000 people living with hypertension compared to baseline across wealth quintiles, by modelled scenario (either Diagnosis or Treatment scenario) and baseline cascade gap	41

Supplementary Table 15. Percent of total estimated cardiovascular disease cases averted compared to baseline across wealth quintiles, by modelled scenario (either Diagnosis or Treatment scenario) and baseline cascade gap	42
By World Health Organization (WHO) Region	43
Supplementary Table 16. Cardiovascular disease cases averted per 1,000 people living with hypertension compared to baseline across wealth quintiles, by modelled scenario (either Diagnosis or Treatment scenario) and WHO region	43
Supplementary Table 17. Percent of total estimated cardiovascular disease cases averted compared to baseline across wealth quintiles, by modelled scenario (either Diagnosis or Treatment scenario) and WHO region	44
By Sensitivity Analysis	45
Supplementary Table 18. Performance-based targets sensitivity analysis: Mean (95% uncertainty interval) 10-year CVD risk by country and wealth quintile in Diagnosis and Treatment scenarios	45
Supplementary Table 19. Performance-based targets sensitivity analysis: Absolute (percentage point) difference in mean 10-year cardiovascular disease risk comparing the bottom (Q1) and top (Q5) wealth quintiles by country and modelled scenario, either Baseline, Diagnosis or Treatment scenario	48
Supplementary Table 20. Performance-based targets sensitivity analysis: Mean difference (95% uncertainty interval) in CVD cases per 1,000 people living with hypertension compared to baseline by country, wealth quintile, and scenario	53
Supplementary Table 21. Performance-based targets sensitivity analysis: Mean (95% uncertainty interval) relative decline (%) in CVD risk compared to baseline by country, wealth quintile, and scenario	56
Supplementary Table 22. Relative increase targets sensitivity analysis: Mean (95% uncertainty interval) 10-year CVD risk by country and wealth quintile in Diagnosis and Treatment scenarios	59
Supplementary Table 23. Relative increase targets sensitivity analysis: Absolute (percentage point) difference in mean 10-year cardiovascular disease risk comparing the bottom (Q1) and top (Q5) wealth quintiles by country and modelled scenario, either Baseline, Diagnosis or Treatment scenario	62
Supplementary Table 24. Relative increase targets sensitivity analysis: Mean difference (95% uncertainty interval) in CVD cases per 1,000 people living with hypertension compared to baseline by country, wealth quintile, and scenario	67
Supplementary Table 25. Relative increase targets sensitivity analysis: Mean (95% uncertainty interval) relative decline (%) in CVD risk compared to baseline by country, wealth quintile, and scenario	70
Supplementary Table 26. Within-country targets sensitivity analysis: Mean (95% uncertainty interval) 10-year CVD risk by country and wealth quintile in Diagnosis and Treatment scenarios	73
Supplementary Table 27. Within-country targets sensitivity analysis: Absolute (percentage point) difference in mean 10-year cardiovascular disease risk comparing the bottom (Q1) and top (Q5) wealth quintiles by country and modelled scenario, either Baseline, Diagnosis or Treatment scenario	76

Supplementary Table 28. Within-country targets sensitivity analysis: Mean difference (95% uncertainty interval) in CVD cases per 1,000 people living with hypertension compared to baseline by country, wealth quintile, and scenario	81
Supplementary Table 29. Within country targets sensitivity analysis: Mean (95% uncertainty interval) relative decline (%) in CVD risk compared to baseline by country, wealth quintile, and scenario	84
Supplementary Table 30. Education group targets sensitivity analysis: Mean proportion (%) of people living with hypertension aware of their diagnosis, on treatment, and with controlled blood pressure by education category across countries	87
Supplementary Table 31. Education group targets sensitivity analysis: Mean 10-year CVD risk by country and wealth quintile in Baseline, Diagnosis, and Treatment scenarios and CVD cases averted per 1,000 people living with hypertension compared to baseline by scenario and education category	92
Methods	111
Supplementary Table 32. Information on country-specific surveys	111
Supplementary Table 33. Missing data percent (%) by country and variable	118
Supplementary Table 34. Details of blood pressure measurement methodology by country	121
Supplementary Table 35. Household wealth measures by country	124
Supplementary Table 36. Relative risks from Law et al. (2009) by age group	125
Country-specific Figures	127
Supplementary Figure 1. Country-specific plots of baseline hypertension care cascade performance, mean CVD risk (%), mean difference in CVD cases per 1,000 people living with hypertension, and mean relative decline (%) in CVD risk compared to baseline, by wealth quintile and scenario	127

Supplementary Table 1. Countries included in the analysis

- Countries included in the analysis and corresponding World Bank country-level income grouping¹, World Health Organization Region², Baseline Performance Tercile, Baseline Cascade Gap Tercile, and 3-letter Country Code

Country	World Bank Income Group	WHO Region	Baseline Performance Tercile	Baseline Cascade Gap Tercile	Country Code
Afghanistan	Low-income	Eastern Mediterranean	Top	Mid Gap	AFG
Albania	Upper-middle Income	Europe	Bottom	Mid Gap	ALB
Algeria	Upper-middle Income	Africa	Middle	Low Gap	DZA
Azerbaijan	Upper-middle Income	Europe	Top	Low Gap	AZE
Benin	Low-income	Africa	Bottom	Mid Gap	BEN
Bhutan	Lower-middle Income	South-East Asia	Middle	Low Gap	BTN
Botswana	Upper-middle Income	Africa	Top	Mid Gap	BWA
Brazil	Upper-middle Income	Americas	Top	Mid Gap	BRA
Cambodia	Low-income	Western Pacific	Top	High Gap	KHM
China	Upper-middle Income	Western Pacific	Middle	Mid Gap	CHN
Ecuador	Upper-middle Income	Americas	Top	High Gap	ECU
Eritrea	Low-income	Africa	Middle	Mid Gap	ERI
Eswatini	Lower-middle Income	Africa	Top	Mid Gap	SWZ
Ethiopia	Low-income	Africa	Bottom	Low Gap	ETH
Gambia	Low-income	Africa	Bottom	Mid Gap	GMB
Ghana	Lower-middle Income	Africa	Bottom	High Gap	GHA
India	Lower-middle Income	South-East Asia	Middle	High Gap	IND
Indonesia	Lower-middle Income	South-East Asia	Bottom	Mid Gap	IDN
Jordan	Upper-middle Income	Eastern Mediterranean	Top	Low Gap	JOR
Kenya	Lower-middle Income	Africa	Middle	High Gap	KEN
Kiribati	Lower-middle Income	Western Pacific	Bottom	Mid Gap	KIR
Kyrgyzstan	Lower-middle Income	Europe	Middle	Low Gap	KGZ
Laos	Lower-middle Income	Western Pacific	Middle	Mid Gap	LAO

¹<https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>

²<https://www.who.int/countries>

(continued)

Country	World Bank Income Group	WHO Region	Baseline Performance Tercile	Baseline Cascade Gap Tercile	Country Code
Lesotho	Lower-middle Income	Africa	Top	Mid Gap	LSO
Moldova	Lower-middle Income	Europe	Middle	Low Gap	MDA
Morocco	Lower-middle Income	Eastern Mediterranean	Middle	Low Gap	MAR
Myanmar	Lower-middle Income	South-East Asia	Middle	High Gap	MMR
Namibia	Upper-middle Income	Africa	Top	High Gap	NAM
Niger	Low-income	Africa	Bottom	Low Gap	NER
Russian Federation	Upper-middle Income	Europe	Top	High Gap	RUS
Rwanda	Low-income	Africa	Bottom	Low Gap	RWA
Samoa	Lower-middle Income	Western Pacific	Bottom	Low Gap	WSM
Sao Tome and Principe	Lower-middle Income	Africa	Bottom	Low Gap	STP
Solomon Islands	Lower-middle Income	Western Pacific	Middle	High Gap	SLB
South Africa	Upper-middle Income	Africa	Top	High Gap	ZAF
Sri Lanka	Lower-middle Income	South-East Asia	Top	Mid Gap	LKA
St. Vincent & the Grenadines	Upper-middle Income	Americas	Top	Low Gap	VCT
Sudan	Lower-middle Income	Eastern Mediterranean	Middle	High Gap	SDN
Tanzania	Low-income	Africa	Bottom	Low Gap	TZA
Timor Leste	Lower-middle Income	South-East Asia	Middle	High Gap	TLS
Togo	Low-income	Africa	Bottom	Mid Gap	TGO
Uganda	Low-income	Africa	Bottom	High Gap	UGA
Vanuatu	Lower-middle Income	Western Pacific	Bottom	Low Gap	VUT
Zambia	Lower-middle Income	Africa	Middle	High Gap	ZMB

Baseline

Supplementary Table 2. Mean (95% confidence interval) proportion of people living with hypertension aware of their diagnosis, on treatment, and with controlled hypertension by country and wealth quintile

Country	Cascade Step	Q1	Q2	Q3	Q4	Q5
Afghanistan	Aware	64.7 (48.5,78.1)	58.3 (42.4,72.7)	50.3 (33.0,67.5)	69.0 (56.0,79.6)	68.2 (48.8,82.8)
Afghanistan	Treated	58.6 (42.2,73.4)	52.3 (36.2,67.9)	32.0 (21.3,45.0)	51.0 (37.7,64.1)	66.9 (47.4,81.9)
Afghanistan	Controlled	10.1 (4.5,21.1)	28.5 (13.9,49.5)	12.7 (5.5,26.8)	12.6 (6.2,23.9)	13.7 (5.7,29.5)
Albania	Aware	18.3 (11.4,28.0)	16.7 (11.4,23.8)	22.5 (16.3,30.1)	25.2 (18.5,33.2)	29.2 (21.0,39.0)
Albania	Treated	6.7 (3.1,13.8)	7.9 (4.3,13.9)	10.9 (6.7,17.3)	14.8 (9.5,22.3)	19.7 (13.5,27.8)
Albania	Controlled	1.3 (0.3,6.2)	1.6 (0.4,6.3)	3.4 (1.4,7.9)	3.1 (1.2,7.6)	6.3 (3.2,12.1)
Algeria	Aware	47.3 (41.4,53.3)	42.2 (35.6,49.0)	46.8 (39.8,53.9)	50.4 (44.0,56.7)	49.8 (42.9,56.7)
Algeria	Treated	31.9 (26.7,37.7)	27.5 (21.9,33.8)	33.7 (27.0,41.1)	35.8 (29.6,42.5)	35.3 (29.6,41.4)
Algeria	Controlled	10.0 (7.1,13.8)	10.1 (6.7,14.8)	14.2 (9.9,20.1)	12.8 (8.7,18.4)	14.8 (10.6,20.5)
Azerbaijan	Aware	54.6 (46.5,62.4)	50.1 (38.3,61.9)	54.3 (44.2,64.1)	69.7 (60.4,77.7)	56.5 (41.5,70.5)
Azerbaijan	Treated	40.0 (31.8,48.8)	39.3 (28.5,51.3)	42.5 (33.1,52.5)	41.2 (31.5,51.7)	38.8 (27.0,52.0)
Azerbaijan	Controlled	7.7 (4.7,12.4)	13.1 (6.6,24.3)	9.2 (5.3,15.4)	9.5 (5.7,15.5)	12.5 (6.2,23.4)
Benin	Aware	17.6 (9.7,29.9)	17.4 (10.4,27.6)	12.6 (7.1,21.3)	20.9 (14.1,29.9)	29.4 (20.6,40.0)
Benin	Treated	12.6 (6.7,22.4)	9.4 (5.5,15.7)	10.9 (5.8,19.7)	14.1 (8.3,22.9)	15.2 (10.0,22.5)
Benin	Controlled	3.4 (1.4,8.4)	2.9 (0.8,10.5)	2.0 (0.5,8.0)	1.2 (0.3,4.1)	1.9 (0.4,7.7)
Bhutan	Aware	41.0 (31.7,51.1)	44.0 (33.2,55.3)	34.0 (24.4,45.1)	54.9 (44.5,64.9)	44.1 (32.8,56.1)
Bhutan	Treated	20.6 (14.4,28.6)	23.0 (15.6,32.7)	17.9 (11.2,27.3)	24.3 (15.1,36.7)	21.7 (13.9,32.3)
Bhutan	Controlled	2.9 (1.3,6.4)	7.0 (3.6,13.2)	6.1 (2.5,14.2)	7.8 (3.2,17.9)	3.1 (1.2,7.6)
Botswana	Aware	57.2 (41.6,71.4)	54.1 (39.6,68.0)	62.1 (50.5,72.4)	55.8 (41.9,68.8)	60.3 (45.3,73.5)
Botswana	Treated	35.2 (24.7,47.4)	43.6 (29.9,58.3)	42.4 (31.8,53.8)	31.9 (22.9,42.5)	43.1 (30.9,56.1)
Botswana	Controlled	11.9 (6.1,22.1)	9.7 (5.3,17.2)	20.7 (11.9,33.4)	7.8 (3.9,15.1)	19.7 (8.8,38.5)
Brazil	Aware	60.6 (57.2,63.9)	64.9 (61.8,68.0)	67.8 (64.5,70.9)	68.7 (65.5,71.7)	67.9 (64.9,70.8)
Brazil	Treated	55.0 (51.5,58.4)	57.7 (54.3,61.0)	61.6 (58.3,64.9)	62.6 (59.4,65.7)	62.8 (59.5,65.9)
Brazil	Controlled	25.8 (22.7,29.0)	28.3 (25.6,31.2)	32.2 (29.3,35.3)	33.2 (30.3,36.3)	37.0 (33.9,40.2)
Cambodia	Aware	32.2 (23.9,42.0)	36.6 (27.5,46.7)	38.1 (27.7,49.6)	49.0 (39.6,58.5)	55.9 (44.2,66.9)
Cambodia	Treated	20.7 (14.2,29.3)	27.5 (19.8,36.9)	25.0 (16.0,36.9)	30.5 (22.5,39.8)	39.7 (29.1,51.4)
Cambodia	Controlled	11.2 (6.5,18.7)	19.2 (13.0,27.4)	12.0 (5.7,23.5)	15.4 (10.2,22.6)	26.9 (19.0,36.5)
China	Aware	40.4 (35.0,46.0)	42.4 (37.9,47.1)	38.0 (32.8,43.4)	46.5 (41.5,51.6)	49.9 (44.1,55.7)

(continued)

Country	Cascade Step	Q1	Q2	Q3	Q4	Q5
China	Treated	33.9 (28.7,39.6)	35.7 (31.3,40.3)	32.7 (27.7,38.1)	39.3 (34.4,44.4)	44.7 (38.7,50.8)
China	Controlled	9.1 (6.5,12.5)	9.0 (6.7,12.1)	6.8 (4.8,9.7)	8.5 (5.8,12.2)	14.9 (11.4,19.2)
Ecuador	Aware	49.1 (38.6,59.7)	58.7 (51.0,66.0)	65.0 (52.8,75.5)	67.7 (55.0,78.2)	59.9 (47.7,70.9)
Ecuador	Treated	35.9 (26.4,46.6)	47.4 (40.0,54.8)	49.7 (38.1,61.4)	50.9 (38.2,63.5)	55.8 (43.5,67.4)
Ecuador	Controlled	23.9 (16.3,33.6)	22.9 (17.1,29.9)	31.7 (21.2,44.5)	31.3 (19.7,45.7)	31.6 (22.6,42.2)
Eritrea	Aware	27.1 (20.9,34.5)	24.1 (12.1,42.3)	29.9 (21.6,39.8)	40.1 (32.3,48.5)	38.4 (25.8,52.8)
Eritrea	Treated	14.9 (10.2,21.3)	18.8 (8.0,37.9)	21.8 (14.2,32.0)	25.6 (18.1,34.9)	22.0 (13.7,33.3)
Eritrea	Controlled	4.6 (2.6,8.0)	4.9 (1.0,20.5)	14.0 (8.3,22.6)	7.7 (4.3,13.4)	8.1 (4.0,15.5)
Eswatini	Aware	47.4 (36.5,58.6)	46.4 (35.7,57.4)	56.4 (41.8,70.0)	54.4 (39.5,68.5)	58.1 (41.5,73.1)
Eswatini	Treated	28.6 (19.1,40.6)	27.5 (19.6,37.1)	34.5 (20.0,52.6)	36.5 (23.4,51.9)	42.5 (27.1,59.5)
Eswatini	Controlled	11.8 (6.3,21.2)	4.5 (2.0,10.0)	14.7 (4.0,41.5)	11.2 (4.1,27.4)	13.6 (5.7,29.0)
Ethiopia	Aware	22.4 (14.8,32.4)	28.6 (17.9,42.5)	16.4 (9.0,27.9)	25.4 (14.7,40.3)	24.9 (16.5,35.6)
Ethiopia	Treated	9.0 (4.3,17.8)	15.6 (7.8,28.8)	8.3 (3.1,20.6)	10.4 (5.1,20.2)	13.0 (7.5,21.5)
Ethiopia	Controlled	2.8 (0.8,8.7)	4.2 (1.4,11.7)	1.6 (0.3,9.3)	1.8 (0.6,5.6)	2.7 (1.2,5.9)
Gambia	Aware	27.5 (18.1,39.4)	31.9 (22.0,43.8)	29.1 (21.2,38.6)	35.0 (24.3,47.5)	44.3 (31.8,57.6)
Gambia	Treated	17.9 (10.2,29.4)	20.9 (13.0,31.8)	17.7 (10.5,28.2)	23.5 (13.5,37.6)	22.1 (12.4,36.2)
Gambia	Controlled	6.0 (2.9,12.2)	6.2 (2.2,16.2)	1.8 (0.4,6.9)	4.0 (1.0,14.8)	5.2 (2.0,12.7)
Ghana	Aware	7.2 (4.6,11.0)	9.3 (5.2,16.2)	14.4 (8.6,23.2)	32.5 (22.7,44.1)	27.3 (18.6,38.3)
Ghana	Treated	3.9 (2.4,6.4)	7.1 (3.4,14.4)	10.4 (5.6,18.6)	24.1 (15.9,34.8)	20.0 (12.9,29.7)
Ghana	Controlled	1.1 (0.5,2.5)	0.7 (0.2,1.7)	0.8 (0.3,2.7)	4.0 (1.2,12.6)	7.9 (3.9,15.4)
India	Aware	16.1 (14.5,17.9)	21.9 (20.2,23.8)	29.4 (27.2,31.8)	31.9 (30.0,34.0)	38.3 (36.2,40.5)
India	Treated	10.1 (8.7,11.7)	13.3 (11.9,14.8)	18.0 (16.3,19.8)	20.5 (18.9,22.1)	26.4 (24.4,28.4)
India	Controlled	4.6 (3.9,5.5)	5.9 (5.0,7.0)	8.5 (7.2,10.0)	8.7 (7.8,9.8)	12.4 (10.8,14.2)
Indonesia	Aware	34.4 (29.7,39.4)	36.4 (33.7,39.2)	40.6 (36.5,44.7)	42.9 (39.0,46.9)	43.9 (39.7,48.0)
Indonesia	Treated	9.3 (6.8,12.6)	12.8 (10.6,15.6)	14.3 (11.1,18.2)	17.4 (14.4,21.0)	20.3 (17.9,23.0)
Indonesia	Controlled	2.5 (1.7,3.6)	2.6 (1.8,3.7)	2.8 (1.8,4.4)	3.4 (2.4,4.9)	4.2 (2.6,6.4)
Jordan	Aware	65.1 (53.0,75.4)	71.9 (62.9,79.4)	74.6 (64.8,82.4)	60.6 (49.4,70.9)	62.6 (54.6,70.0)
Jordan	Treated	53.8 (42.6,64.5)	66.5 (56.9,74.9)	61.9 (50.4,72.3)	53.0 (41.9,63.8)	55.1 (47.0,62.9)
Jordan	Controlled	32.7 (23.5,43.5)	39.8 (30.6,49.8)	30.4 (21.3,41.3)	34.5 (24.0,46.6)	34.4 (27.0,42.6)
Kenya	Aware	16.4 (9.9,26.0)	21.9 (16.4,28.6)	32.1 (22.4,43.7)	30.6 (21.5,41.5)	49.6 (38.3,60.9)
Kenya	Treated	5.4 (1.7,16.1)	7.7 (4.0,14.3)	15.4 (10.0,23.0)	11.2 (5.7,20.9)	18.9 (10.6,31.5)
Kenya	Controlled	3.8 (0.7,17.1)	5.5 (2.3,12.3)	3.5 (1.4,8.2)	2.2 (0.7,6.3)	8.8 (2.3,28.2)
Kiribati	Aware	19.5 (9.0,37.1)	17.9 (4.6,49.5)	39.6 (11.1,77.5)	25.9 (13.2,44.4)	44.5 (23.2,68.0)

(continued)

Country	Cascade Step	Q1	Q2	Q3	Q4	Q5
Kiribati	Treated	7.3 (2.0,23.6)	9.5 (1.6,40.0)	6.6 (2.2,18.0)	6.0 (1.4,22.2)	11.9 (3.5,33.4)
Kiribati	Controlled	6.0 (1.4,23.0)	1.5 (0.1,13.6)	1.7 (0.3,7.8)	3.0 (0.8,11.1)	0.8 (0.1,7.1)
Kyrgyzstan	Aware	39.6 (33.6,46.0)	51.8 (43.4,60.1)	48.4 (35.1,61.9)	47.7 (39.5,56.0)	46.6 (33.6,60.0)
Kyrgyzstan	Treated	24.6 (19.1,31.1)	35.6 (28.6,43.4)	21.2 (14.5,29.9)	24.6 (18.0,32.6)	24.4 (16.4,34.8)
Kyrgyzstan	Controlled	0.3 (0.1,1.4)	5.8 (2.5,12.7)	2.0 (0.7,5.7)	3.2 (1.2,8.6)	3.4 (1.4,8.3)
Laos	Aware	23.3 (12.5,39.2)	34.5 (19.2,53.9)	36.1 (23.3,51.3)	53.0 (39.5,66.1)	35.7 (22.3,51.8)
Laos	Treated	15.5 (6.9,31.4)	26.1 (13.6,44.1)	19.5 (11.0,32.3)	35.2 (23.2,49.4)	23.7 (13.8,37.6)
Laos	Controlled	7.2 (2.3,20.1)	4.6 (1.1,17.2)	3.0 (0.7,12.8)	12.4 (6.9,21.3)	7.3 (2.6,18.8)
Lesotho	Aware	42.8 (29.3,57.4)	49.5 (38.2,61.0)	35.3 (22.9,50.0)	54.6 (40.1,68.4)	57.3 (47.8,66.3)
Lesotho	Treated	38.0 (23.3,55.4)	39.5 (28.2,51.9)	29.0 (17.4,44.1)	49.8 (35.5,64.2)	50.3 (39.2,61.4)
Lesotho	Controlled	21.9 (10.1,41.2)	21.4 (11.4,36.5)	4.7 (1.8,11.7)	24.1 (14.4,37.3)	17.6 (11.4,26.1)
Moldova	Aware	52.8 (46.8,58.6)	57.3 (51.5,62.9)	57.9 (51.3,64.2)	53.4 (45.1,61.6)	53.0 (45.8,60.0)
Moldova	Treated	28.6 (24.0,33.9)	33.1 (27.1,39.7)	34.7 (28.7,41.2)	35.8 (28.5,43.9)	31.3 (25.6,37.6)
Moldova	Controlled	3.6 (1.9,6.7)	3.9 (2.4,6.5)	3.7 (2.1,6.2)	5.7 (3.0,10.6)	4.3 (2.5,7.6)
Morocco	Aware	38.5 (33.9,43.3)	37.4 (29.6,46.0)	43.8 (35.7,52.2)	39.1 (30.4,48.6)	39.8 (33.6,46.4)
Morocco	Treated	26.6 (22.6,31.0)	23.9 (17.4,31.8)	27.6 (20.8,35.6)	21.6 (15.2,29.8)	26.8 (21.6,32.8)
Morocco	Controlled	6.8 (4.8,9.6)	4.5 (2.3,8.6)	8.9 (5.0,15.4)	5.4 (2.5,11.1)	6.2 (3.9,9.9)
Myanmar	Aware	45.2 (35.2,55.5)	50.4 (38.3,62.4)	56.7 (46.3,66.5)	52.7 (43.7,61.4)	59.8 (52.9,66.3)
Myanmar	Treated	19.4 (11.2,31.6)	27.9 (22.7,33.7)	31.8 (23.9,40.9)	32.5 (25.4,40.4)	37.2 (27.9,47.5)
Myanmar	Controlled	10.1 (4.9,19.5)	8.4 (4.7,14.6)	10.7 (6.1,17.9)	5.4 (2.9,9.7)	17.1 (12.6,22.8)
Namibia	Aware	32.7 (25.5,40.8)	41.6 (35.0,48.4)	52.0 (44.4,59.5)	50.7 (42.5,59.0)	68.4 (60.9,75.0)
Namibia	Treated	27.4 (20.9,35.0)	33.3 (27.2,40.0)	46.2 (38.7,53.8)	45.1 (37.2,53.2)	58.5 (50.5,66.0)
Namibia	Controlled	14.4 (9.9,20.4)	10.8 (7.3,15.6)	17.6 (12.7,23.9)	19.9 (14.4,26.8)	26.9 (19.5,35.8)
Niger	Aware	5.4 (2.5,11.7)	0.8 (0.1,5.7)	3.1 (1.0,9.4)	6.7 (3.3,12.8)	11.9 (6.8,19.9)
Niger	Treated	3.6 (1.4,9.4)	0.0 (0.0,0.0)	1.0 (0.1,7.2)	2.5 (0.8,7.6)	5.9 (2.7,12.7)
Niger	Controlled	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.8 (0.1,5.8)	1.0 (0.1,6.8)
Russian Federation	Aware	59.3 (48.4,69.3)	75.8 (65.6,83.8)	73.9 (65.6,80.8)	51.2 (26.5,75.4)	73.7 (59.2,84.3)
Russian Federation	Treated	39.6 (30.6,49.3)	53.9 (41.7,65.6)	62.6 (54.1,70.5)	46.8 (24.6,70.3)	66.0 (50.3,78.9)
Russian Federation	Controlled	5.7 (3.1,10.2)	9.5 (5.8,15.2)	9.6 (6.0,15.0)	8.9 (5.2,14.8)	16.4 (8.0,30.9)
Rwanda	Aware	8.9 (4.8,16.0)	7.2 (3.0,15.9)	7.9 (4.2,14.3)	11.4 (6.1,20.4)	12.5 (7.6,19.9)
Rwanda	Treated	4.0 (1.4,10.6)	4.3 (1.3,13.2)	1.7 (0.4,6.6)	1.1 (0.1,7.5)	4.0 (1.6,9.6)
Rwanda	Controlled	2.0 (0.5,8.4)	3.5 (1.1,10.5)	1.7 (0.4,6.6)	1.1 (0.1,7.5)	1.9 (0.5,7.7)
Samoa	Aware	18.0 (8.5,34.2)	0.9 (0.2,3.8)	29.6 (13.4,53.4)	20.1 (6.0,49.9)	21.8 (10.6,39.5)
Samoa	Treated	16.1 (5.9,36.8)	0.9 (0.2,3.8)	20.4 (6.3,49.5)	9.9 (2.1,35.8)	14.8 (6.6,30.2)

(continued)

Country	Cascade Step	Q1	Q2	Q3	Q4	Q5
Samoa	Controlled	2.1 (0.3,12.5)	0.0 (0.0,0.0)	16.0 (3.4,50.9)	3.5 (0.3,26.9)	3.7 (0.6,20.3)
Sao Tome and Principe	Aware	36.8 (27.1,47.8)	31.5 (22.5,42.3)	27.0 (21.9,32.7)	42.9 (32.1,54.3)	36.6 (29.0,44.9)
Sao Tome and Principe	Treated	21.0 (14.4,29.5)	14.8 (8.6,24.2)	16.6 (10.3,25.6)	20.3 (12.1,32.1)	24.1 (16.6,33.6)
Sao Tome and Principe	Controlled	4.4 (2.1,9.0)	1.6 (0.3,6.8)	1.7 (0.3,9.4)	5.3 (2.2,12.6)	4.5 (2.3,8.4)
Solomon Islands	Aware	29.4 (20.4,40.3)	23.4 (13.8,36.9)	31.0 (18.2,47.4)	30.7 (18.2,46.9)	54.4 (36.3,71.4)
Solomon Islands	Treated	7.6 (3.4,16.0)	6.2 (2.2,16.6)	9.4 (4.7,18.2)	5.1 (1.1,19.8)	20.7 (9.7,38.7)
Solomon Islands	Controlled	1.9 (0.5,7.5)	0.0 (0.0,0.0)	2.7 (0.8,8.5)	3.4 (0.4,20.9)	10.3 (3.3,28.1)
South Africa	Aware	37.9 (31.6,44.6)	42.5 (37.0,48.1)	54.6 (48.2,60.9)	57.6 (51.6,63.4)	56.9 (50.5,63.0)
South Africa	Treated	33.0 (27.0,39.6)	38.3 (33.0,43.9)	51.3 (45.0,57.7)	53.2 (47.1,59.2)	53.5 (47.1,59.8)
South Africa	Controlled	9.7 (7.2,12.9)	14.4 (10.2,20.0)	18.8 (13.9,24.8)	19.7 (15.5,24.8)	19.8 (15.2,25.3)
Sri Lanka	Aware	44.6 (37.7,51.7)	40.9 (35.4,46.6)	38.9 (31.7,46.7)	50.9 (41.6,60.1)	58.3 (48.2,67.8)
Sri Lanka	Treated	31.2 (24.7,38.6)	28.9 (23.9,34.5)	29.7 (23.7,36.4)	39.5 (31.3,48.4)	41.3 (31.2,52.1)
Sri Lanka	Controlled	10.7 (7.0,16.0)	8.3 (5.6,12.2)	12.8 (8.9,18.2)	14.6 (9.6,21.7)	16.9 (10.7,25.8)
St. Vincent & the Grenadines	Aware	65.0 (57.8,71.7)	61.2 (51.8,69.8)	57.4 (45.5,68.6)	52.4 (41.5,63.0)	65.7 (59.3,71.5)
St. Vincent & the Grenadines	Treated	50.0 (40.6,59.4)	40.3 (32.7,48.3)	40.1 (27.2,54.6)	36.7 (26.1,48.7)	51.6 (41.5,61.6)
St. Vincent & the Grenadines	Controlled	18.2 (12.7,25.5)	18.7 (11.8,28.4)	20.8 (12.7,32.0)	20.2 (13.8,28.6)	26.5 (22.0,31.6)
Sudan	Aware	15.2 (10.3,21.8)	26.4 (22.0,31.4)	31.7 (26.4,37.5)	32.7 (24.8,41.8)	48.9 (33.9,64.1)
Sudan	Treated	10.9 (7.1,16.5)	20.3 (16.2,25.2)	21.0 (16.4,26.4)	22.5 (15.4,31.6)	44.0 (30.4,58.6)
Sudan	Controlled	1.7 (0.7,4.3)	4.1 (2.6,6.5)	5.8 (3.4,9.8)	5.2 (2.9,9.2)	15.7 (6.8,32.2)
Tanzania	Aware	16.6 (11.0,24.2)	24.8 (18.0,33.2)	18.9 (12.2,28.2)	16.7 (10.9,24.8)	26.1 (18.5,35.6)
Tanzania	Treated	10.7 (6.7,16.5)	15.7 (9.7,24.4)	9.0 (5.0,15.8)	3.8 (1.9,7.4)	8.0 (3.6,16.6)
Tanzania	Controlled	2.0 (0.8,4.7)	6.0 (2.6,13.0)	0.7 (0.2,2.3)	0.6 (0.2,1.7)	2.1 (0.8,5.8)
Timor Leste	Aware	18.0 (9.3,32.1)	26.5 (18.0,37.2)	30.0 (19.9,42.6)	36.8 (25.9,49.2)	53.5 (42.2,64.5)
Timor Leste	Treated	6.0 (1.8,17.8)	15.3 (8.8,25.4)	18.6 (10.8,30.0)	26.5 (17.2,38.4)	29.6 (19.1,42.7)
Timor Leste	Controlled	2.0 (0.3,13.7)	7.1 (3.2,15.2)	1.4 (0.2,9.7)	11.8 (5.9,22.0)	9.9 (4.7,19.5)
Togo	Aware	21.7 (12.1,35.7)	25.0 (15.6,37.5)	28.5 (17.9,42.1)	27.8 (16.4,43.1)	36.6 (25.0,49.9)
Togo	Treated	8.4 (2.9,22.2)	9.3 (3.7,21.5)	13.7 (7.2,24.5)	7.7 (2.8,19.7)	17.9 (10.3,29.2)
Togo	Controlled	3.0 (0.8,11.0)	5.0 (1.5,15.9)	3.4 (0.8,12.9)	5.7 (1.7,17.0)	7.4 (2.9,17.8)
Uganda	Aware	13.8 (8.0,22.7)	24.3 (15.2,36.6)	29.3 (19.1,42.1)	21.4 (12.3,34.6)	49.8 (28.1,71.5)
Uganda	Treated	9.9 (5.1,18.4)	8.4 (4.1,16.7)	15.1 (7.9,27.0)	9.4 (3.9,21.0)	15.6 (7.1,31.1)
Uganda	Controlled	2.2 (0.5,8.9)	2.7 (0.7,10.2)	4.9 (1.8,12.8)	2.7 (0.5,12.7)	3.0 (0.7,12.4)
Vanuatu	Aware	8.0 (4.6,13.7)	21.6 (13.9,32.1)	15.7 (10.1,23.4)	21.9 (15.1,30.8)	17.6 (12.8,23.7)
Vanuatu	Treated	2.4 (1.0,5.8)	2.5 (1.0,6.3)	1.9 (0.5,6.6)	1.7 (0.5,5.7)	3.4 (1.5,7.6)

(continued)

Country	Cascade Step	Q1	Q2	Q3	Q4	Q5
Vanuatu	Controlled	0.0 (0.0,0.0)	0.4 (0.0,2.5)	1.4 (0.3,6.4)	0.0 (0.0,0.0)	0.0 (0.0,0.0)
Zambia	Aware	35.2 (25.6,46.2)	37.9 (22.9,55.6)	32.1 (20.2,47.0)	55.4 (41.8,68.3)	58.9 (42.6,73.4)
Zambia	Treated	16.3 (10.6,24.3)	22.4 (11.6,38.9)	16.3 (9.5,26.5)	22.0 (12.3,36.2)	28.1 (14.2,47.8)
Zambia	Controlled	6.0 (2.8,12.3)	9.9 (2.9,28.4)	6.7 (3.0,14.4)	8.6 (3.5,19.5)	6.2 (2.2,15.8)

Note. 'Aware' refers to the proportion of people living with hypertension who are aware of their diagnosis. 'Treated' refers to the proportion of people living with hypertension who reported being on treatment for hypertension. 'Controlled' refers to the proportion of people living with hypertension who have controlled blood pressure.

Supplementary Table 3. Mean (95% confidence interval) proportion of people living with hypertension aware of their diagnosis, on treatment, and with controlled hypertension by wealth quintile and country-level income group

World Bank Income Group	Cascade Step	Q1	Q2	Q3	Q4	Q5
Low-income	Aware	29.7 (23.9, 36.2)	32.4 (26.8, 38.5)	31.0 (24.0, 39.0)	40.1 (33.7, 46.9)	41.2 (32.6, 50.2)
Low-income	Treated	21.8 (16.0, 29.0)	21.7 (16.6, 27.9)	18.3 (13.9, 23.8)	25.0 (19.3, 31.6)	27.8 (19.0, 38.8)
Low-income	Controlled	4.8 (3.2, 7.3)	10.3 (6.3, 16.3)	6.4 (3.8, 10.8)	6.6 (4.1, 10.5)	7.1 (4.4, 11.1)
Lower-middle Income	Aware	33.3 (28.6, 38.4)	39.1 (35.4, 43.0)	39.7 (35.3, 44.3)	45.4 (41.3, 49.5)	49.9 (45.4, 54.4)
Lower-middle Income	Treated	17.2 (13.6, 21.5)	23.8 (21.5, 26.2)	23.3 (20.0, 27.0)	27.8 (24.3, 31.7)	30.2 (25.6, 35.3)
Lower-middle Income	Controlled	6.1 (3.9, 9.5)	6.5 (4.9, 8.6)	6.8 (5.0, 9.2)	5.6 (4.0, 7.6)	12.4 (9.6, 15.8)
Upper-middle Income	Aware	38.4 (32.3, 44.9)	43.5 (38.2, 48.8)	55.1 (48.9, 61.1)	57.7 (51.9, 63.2)	57.1 (50.9, 63.1)
Upper-middle Income	Treated	33.3 (27.5, 39.7)	38.9 (33.8, 44.2)	51.6 (45.5, 57.7)	53.2 (47.3, 59.0)	53.7 (47.5, 59.8)
Upper-middle Income	Controlled	9.8 (7.4, 13.0)	14.6 (10.5, 20.0)	18.9 (14.2, 24.7)	19.7 (15.6, 24.6)	20.0 (15.5, 25.3)

Supplementary Table 4. Ranked gap in hypertension care cascade performance comparing top (Q5) and bottom (Q1) wealth quintiles at baseline by country ('baseline cascade gap')

Country	Q5-Q1 Cascade Performance Gap	Tercile Ranking
Sudan	57.0	3
Namibia	55.2	3
Timor Leste	45.3	3
Russian Federation	39.0	3
Cambodia	38.6	3
South Africa	35.1	3
Kenya	32.6	3
India	31.3	3
Solomon Islands	29.8	3
Ghana	29.6	3
Ecuador	29.2	3
Myanmar	28.6	3
Uganda	24.1	3
Zambia	23.7	3
Albania	21.0	3
Eswatini	20.0	2
Sri Lanka	20.0	2
Togo	19.1	2
China	18.4	2
Lesotho	17.3	2
Brazil	17.1	2
Indonesia	16.6	2
Kiribati	14.5	2
Eritrea	14.4	2
Laos	14.4	2
Botswana	13.3	2
Gambia	12.2	2
Afghanistan	11.8	2
Benin	7.7	2
Algeria	7.0	1
St. Vincent & the Grenadines	6.1	1

(continued)

Country	Q5-Q1 Cascade Performance Gap	Tercile Ranking
Niger	6.0	1
Vanuatu	5.8	1
Ethiopia	5.2	1
Kyrgyzstan	4.8	1
Moldova	3.1	1
Sao Tome and Principe	3.1	1
Bhutan	2.8	1
Azerbaijan	2.2	1
Tanzania	2.2	1
Rwanda	1.8	1
Samoa	1.5	1
Jordan	0.9	1
Morocco	0.6	1

Note. Performance gap was calculated by taking the difference in the area under the cascade between the top and bottom wealth quintiles in each country. Countries were sorted by the performance gap and split in terciles representing the top, middle, and bottom third across countries. Tercile 1 corresponds to the lowest ranking countries while Tercile 3 is the highest ranking countries (i.e. countries with the largest difference in area under the cascades between the bottom and top wealth quintiles).

Targets

Supplementary Table 5. Diagnosis scenario linkage to treatment and treatment coverage levels by country and wealth quintile

Country	Variable	Q1	Q2	Q3	Q4	Q5
Afghanistan	Linkage to treatment (%)	90.6	89.7	63.6	73.9	98.1
Afghanistan	Average treatment level (%) in Diagnosis scenario	68.7	68.0	48.2	56.0	74.4
Albania	Linkage to treatment (%)	36.7	47.3	48.6	58.6	67.3
Albania	Average treatment level (%) in Diagnosis scenario	27.8	35.9	36.8	44.5	51.0
Algeria	Linkage to treatment (%)	67.5	65.1	72.0	71.1	71.0
Algeria	Average treatment level (%) in Diagnosis scenario	51.2	49.4	54.6	53.9	53.8
Azerbaijan	Linkage to treatment (%)	73.3	78.4	78.3	59.1	68.6
Azerbaijan	Average treatment level (%) in Diagnosis scenario	55.6	59.5	59.4	44.8	52.0
Benin	Linkage to treatment (%)	71.2	54.3	86.8	67.4	51.9
Benin	Average treatment level (%) in Diagnosis scenario	54.0	41.2	65.8	51.2	39.3
Bhutan	Linkage to treatment (%)	50.2	52.4	52.6	44.3	49.2
Bhutan	Average treatment level (%) in Diagnosis scenario	38.0	39.7	39.9	33.6	37.3
Botswana	Linkage to treatment (%)	61.6	80.5	68.3	57.3	71.4
Botswana	Average treatment level (%) in Diagnosis scenario	46.7	61.1	51.8	43.4	54.2
Brazil	Linkage to treatment (%)	90.7	88.9	91.0	91.1	92.4
Brazil	Average treatment level (%) in Diagnosis scenario	68.8	67.4	69.0	69.1	70.1
Cambodia	Linkage to treatment (%)	64.3	75.2	65.8	62.2	71.1
Cambodia	Average treatment level (%) in Diagnosis scenario	48.7	57.0	49.9	47.1	53.9
China	Linkage to treatment (%)	84.0	84.0	86.1	84.4	89.5
China	Average treatment level (%) in Diagnosis scenario	63.7	63.7	65.3	64.0	67.9
Ecuador	Linkage to treatment (%)	73.1	80.7	76.5	75.2	93.2
Ecuador	Average treatment level (%) in Diagnosis scenario	55.4	61.2	58.0	57.0	70.6
Eritrea	Linkage to treatment (%)	55.1	77.8	72.9	63.8	57.2
Eritrea	Average treatment level (%) in Diagnosis scenario	41.8	59.0	55.3	48.4	43.3
Eswatini	Linkage to treatment (%)	60.4	59.3	61.2	67.1	73.1
Eswatini	Average treatment level (%) in Diagnosis scenario	45.8	45.0	46.4	50.9	55.4
Ethiopia	Linkage to treatment (%)	40.1	54.5	50.9	41.1	52.3
Ethiopia	Average treatment level (%) in Diagnosis scenario	30.4	41.3	38.6	31.2	39.6
Gambia	Linkage to treatment (%)	64.9	65.4	60.6	67.0	49.8

(continued)

Country	Variable	Q1	Q2	Q3	Q4	Q5
Gambia	Average treatment level (%) in Diagnosis scenario	49.3	49.6	46.0	50.8	37.8
Ghana	Linkage to treatment (%)	54.8	76.2	72.4	74.2	73.4
Ghana	Average treatment level (%) in Diagnosis scenario	41.6	57.8	54.9	56.3	55.7
India	Linkage to treatment (%)	62.7	60.6	61.2	64.1	68.8
India	Average treatment level (%) in Diagnosis scenario	47.5	45.9	46.4	48.6	52.2
Indonesia	Linkage to treatment (%)	27.1	35.3	35.2	40.6	46.3
Indonesia	Average treatment level (%) in Diagnosis scenario	20.5	26.7	26.7	30.8	35.1
Jordan	Linkage to treatment (%)	82.6	92.5	83.0	87.4	87.9
Jordan	Average treatment level (%) in Diagnosis scenario	62.7	70.2	63.0	66.3	66.7
Kenya	Linkage to treatment (%)	32.8	35.2	48.0	36.7	38.2
Kenya	Average treatment level (%) in Diagnosis scenario	24.9	26.7	36.4	27.8	28.9
Kiribati	Linkage to treatment (%)	37.7	53.2	16.6	23.3	26.8
Kiribati	Average treatment level (%) in Diagnosis scenario	28.6	40.3	12.6	17.7	20.3
Kyrgyzstan	Linkage to treatment (%)	62.1	68.7	43.8	51.6	52.4
Kyrgyzstan	Average treatment level (%) in Diagnosis scenario	47.1	52.1	33.3	39.1	39.8
Laos	Linkage to treatment (%)	66.8	75.5	54.0	66.4	66.4
Laos	Average treatment level (%) in Diagnosis scenario	50.6	57.3	40.9	50.4	50.4
Lesotho	Linkage to treatment (%)	89.0	79.6	82.2	91.2	87.8
Lesotho	Average treatment level (%) in Diagnosis scenario	67.5	60.4	62.3	69.2	66.6
Moldova	Linkage to treatment (%)	54.3	57.8	59.9	67.0	59.1
Moldova	Average treatment level (%) in Diagnosis scenario	41.2	43.8	45.4	50.8	44.8
Morocco	Linkage to treatment (%)	69.1	63.9	63.1	55.2	67.3
Morocco	Average treatment level (%) in Diagnosis scenario	52.4	48.4	47.8	41.9	51.1
Myanmar	Linkage to treatment (%)	42.9	55.4	56.1	61.6	62.2
Myanmar	Average treatment level (%) in Diagnosis scenario	32.6	42.0	42.5	46.7	47.2
Namibia	Linkage to treatment (%)	83.7	80.1	88.8	88.8	85.5
Namibia	Average treatment level (%) in Diagnosis scenario	63.5	60.7	67.3	67.4	64.8
Niger	Linkage to treatment (%)	66.8	0.0	33.2	37.5	50.0
Niger	Average treatment level (%) in Diagnosis scenario	50.7	0.0	25.2	28.4	37.9
Russian Federation	Linkage to treatment (%)	66.8	71.1	84.8	91.3	89.6
Russian Federation	Average treatment level (%) in Diagnosis scenario	50.7	53.9	64.3	69.3	68.0
Rwanda	Linkage to treatment (%)	44.8	59.8	22.0	9.4	32.2
Rwanda	Average treatment level (%) in Diagnosis scenario	34.0	45.3	16.7	7.1	24.4

(continued)

Country	Variable	Q1	Q2	Q3	Q4	Q5
Samoa	Linkage to treatment (%)	89.0	100.0	68.7	49.4	68.2
Samoa	Average treatment level (%) in Diagnosis scenario	67.5	75.8	52.1	37.4	51.7
Sao Tome and Principe	Linkage to treatment (%)	56.9	46.9	61.4	47.5	65.9
Sao Tome and Principe	Average treatment level (%) in Diagnosis scenario	43.1	35.5	46.6	36.0	50.0
Solomon Islands	Linkage to treatment (%)	25.8	26.6	30.5	16.5	38.0
Solomon Islands	Average treatment level (%) in Diagnosis scenario	19.6	20.2	23.1	12.5	28.9
South Africa	Linkage to treatment (%)	87.1	90.0	94.0	92.4	94.1
South Africa	Average treatment level (%) in Diagnosis scenario	66.0	68.3	71.3	70.0	71.4
Sri Lanka	Linkage to treatment (%)	70.0	70.7	76.2	77.6	70.8
Sri Lanka	Average treatment level (%) in Diagnosis scenario	53.1	53.6	57.8	58.9	53.7
St. Vincent & the Grenadines	Linkage to treatment (%)	76.9	65.8	69.9	70.1	78.6
St. Vincent & the Grenadines	Average treatment level (%) in Diagnosis scenario	58.3	49.9	53.0	53.1	59.6
Sudan	Linkage to treatment (%)	71.9	76.9	66.0	68.7	90.1
Sudan	Average treatment level (%) in Diagnosis scenario	54.6	58.3	50.1	52.1	68.3
Tanzania	Linkage to treatment (%)	64.3	63.2	47.8	22.5	30.6
Tanzania	Average treatment level (%) in Diagnosis scenario	48.8	48.0	36.2	17.1	23.2
Timor Leste	Linkage to treatment (%)	33.3	57.7	61.9	72.0	55.3
Timor Leste	Average treatment level (%) in Diagnosis scenario	25.3	43.8	46.9	54.6	41.9
Togo	Linkage to treatment (%)	38.9	37.2	48.3	27.7	48.9
Togo	Average treatment level (%) in Diagnosis scenario	29.5	28.2	36.6	21.0	37.1
Uganda	Linkage to treatment (%)	71.8	34.7	51.7	43.8	31.4
Uganda	Average treatment level (%) in Diagnosis scenario	54.4	26.3	39.2	33.2	23.8
Vanuatu	Linkage to treatment (%)	30.3	11.5	12.0	7.7	19.6
Vanuatu	Average treatment level (%) in Diagnosis scenario	23.0	8.7	9.1	5.8	14.9
Zambia	Linkage to treatment (%)	46.4	59.2	50.7	39.7	47.6
Zambia	Average treatment level (%) in Diagnosis scenario	35.2	44.9	38.5	30.1	36.1

Supplementary Table 6. Sensitivity analysis: performance-based targets by baseline performance tercile and scenario

Baseline Performance Tercile	Diagnosis scenario target (%)	Treatment scenario target (%)
Bottom Tercile Baseline Performance	49.8	24.1
Mid Tercile Baseline Performance	59.8	44.7
Top Tercile Baseline Performance	75.8	66.9

Supplementary Table 7. Sensitivity analysis: relative increase targets by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario target (%)	97.1	87.5	75.5	100.0	100.0
Afghanistan	Treatment scenario target (%)	88.0	78.4	48.0	76.5	100.0
Albania	Diagnosis scenario target (%)	27.4	25.0	33.7	37.7	43.9
Albania	Treatment scenario target (%)	10.1	11.8	16.4	22.1	29.5
Algeria	Diagnosis scenario target (%)	71.0	63.3	70.2	75.6	74.6
Algeria	Treatment scenario target (%)	47.9	41.2	50.6	53.7	53.0
Azerbaijan	Diagnosis scenario target (%)	81.9	75.2	81.5	100.0	84.8
Azerbaijan	Treatment scenario target (%)	60.0	58.9	63.8	61.8	58.2
Benin	Diagnosis scenario target (%)	26.5	26.1	18.9	31.4	44.0
Benin	Treatment scenario target (%)	18.8	14.2	16.4	21.2	22.8
Bhutan	Diagnosis scenario target (%)	61.5	66.0	51.0	82.3	66.2
Bhutan	Treatment scenario target (%)	30.9	34.6	26.8	36.5	32.6
Botswana	Diagnosis scenario target (%)	85.7	81.2	93.1	83.6	90.4
Botswana	Treatment scenario target (%)	52.8	65.4	63.6	47.9	64.6
Brazil	Diagnosis scenario target (%)	90.9	97.4	100.0	100.0	100.0
Brazil	Treatment scenario target (%)	82.4	86.6	92.4	93.9	94.2
Cambodia	Diagnosis scenario target (%)	48.4	54.9	57.1	73.5	83.8
Cambodia	Treatment scenario target (%)	31.1	41.2	37.6	45.7	59.5
China	Diagnosis scenario target (%)	60.6	63.7	56.9	69.7	74.8
China	Treatment scenario target (%)	50.9	53.5	49.0	58.9	67.0
Ecuador	Diagnosis scenario target (%)	73.6	88.1	97.5	100.0	89.8
Ecuador	Treatment scenario target (%)	53.8	71.1	74.6	76.4	83.7
Eritrea	Diagnosis scenario target (%)	40.7	36.2	44.9	60.2	57.6
Eritrea	Treatment scenario target (%)	22.4	28.2	32.7	38.4	32.9
Eswatini	Diagnosis scenario target (%)	71.2	69.5	84.6	81.5	87.2
Eswatini	Treatment scenario target (%)	43.0	41.2	51.8	54.7	63.7
Ethiopia	Diagnosis scenario target (%)	33.6	42.9	24.5	38.1	37.3
Ethiopia	Treatment scenario target (%)	13.5	23.4	12.5	15.7	19.5
Gambia	Diagnosis scenario target (%)	41.2	47.9	43.7	52.5	66.5
Gambia	Treatment scenario target (%)	26.8	31.4	26.5	35.2	33.1
Ghana	Diagnosis scenario target (%)	10.8	14.0	21.6	48.7	41.0
Ghana	Treatment scenario target (%)	5.9	10.7	15.6	36.2	30.1

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario target (%)	24.2	32.9	44.1	47.9	57.5
India	Treatment scenario target (%)	15.2	19.9	27.0	30.7	39.5
Indonesia	Diagnosis scenario target (%)	51.6	54.6	60.9	64.4	65.8
Indonesia	Treatment scenario target (%)	14.0	19.3	21.4	26.1	30.5
Jordan	Diagnosis scenario target (%)	97.6	100.0	100.0	91.0	93.9
Jordan	Treatment scenario target (%)	80.6	99.8	92.9	79.5	82.6
Kenya	Diagnosis scenario target (%)	24.6	32.9	48.2	45.9	74.4
Kenya	Treatment scenario target (%)	8.1	11.6	23.1	16.8	28.4
Kiribati	Diagnosis scenario target (%)	29.2	26.8	59.4	38.8	66.7
Kiribati	Treatment scenario target (%)	11.0	14.3	9.9	9.0	17.9
Kyrgyzstan	Diagnosis scenario target (%)	59.5	77.8	72.6	71.5	69.9
Kyrgyzstan	Treatment scenario target (%)	36.9	53.4	31.8	36.9	36.6
Laos	Diagnosis scenario target (%)	34.9	51.8	54.2	79.5	53.6
Laos	Treatment scenario target (%)	23.3	39.1	29.3	52.8	35.6
Lesotho	Diagnosis scenario target (%)	64.1	74.3	52.9	81.9	86.0
Lesotho	Treatment scenario target (%)	57.1	59.2	43.5	74.7	75.4
Moldova	Diagnosis scenario target (%)	79.1	86.0	86.9	80.1	79.4
Moldova	Treatment scenario target (%)	43.0	49.7	52.0	53.7	46.9
Morocco	Diagnosis scenario target (%)	57.7	56.1	65.7	58.7	59.8
Morocco	Treatment scenario target (%)	39.9	35.8	41.4	32.4	40.2
Myanmar	Diagnosis scenario target (%)	67.8	75.6	85.0	79.0	89.7
Myanmar	Treatment scenario target (%)	29.1	41.8	47.7	48.7	55.7
Namibia	Diagnosis scenario target (%)	49.1	62.3	78.0	76.1	100.0
Namibia	Treatment scenario target (%)	41.1	49.9	69.3	67.6	87.7
Niger	Diagnosis scenario target (%)	8.2	1.2	4.7	10.0	17.8
Niger	Treatment scenario target (%)	5.5	0.0	1.6	3.8	8.9
Russian Federation	Diagnosis scenario target (%)	88.9	100.0	100.0	76.9	100.0
Russian Federation	Treatment scenario target (%)	59.4	80.9	94.0	70.2	99.0
Rwanda	Diagnosis scenario target (%)	13.4	10.7	11.8	17.2	18.8
Rwanda	Treatment scenario target (%)	6.0	6.4	2.6	1.6	6.1
Samoa	Diagnosis scenario target (%)	27.1	1.4	44.5	30.1	32.7
Samoa	Treatment scenario target (%)	24.1	1.4	30.6	14.9	22.3
Sao Tome and Principe	Diagnosis scenario target (%)	55.2	47.3	40.4	64.3	54.9

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario target (%)	31.4	22.2	24.8	30.5	36.2
Solomon Islands	Diagnosis scenario target (%)	44.1	35.1	46.5	46.1	81.5
Solomon Islands	Treatment scenario target (%)	11.4	9.4	14.2	7.6	31.0
South Africa	Diagnosis scenario target (%)	56.8	63.7	81.9	86.4	85.3
South Africa	Treatment scenario target (%)	49.5	57.4	77.0	79.8	80.3
Sri Lanka	Diagnosis scenario target (%)	66.9	61.3	58.4	76.3	87.5
Sri Lanka	Treatment scenario target (%)	46.9	43.4	44.5	59.2	61.9
St. Vincent & the Grenadines	Diagnosis scenario target (%)	97.5	91.8	86.1	78.5	98.5
St. Vincent & the Grenadines	Treatment scenario target (%)	75.0	60.4	60.2	55.0	77.4
Sudan	Diagnosis scenario target (%)	22.7	39.7	47.6	49.1	73.3
Sudan	Treatment scenario target (%)	16.4	30.5	31.4	33.8	66.1
Tanzania	Diagnosis scenario target (%)	24.9	37.2	28.4	25.0	39.2
Tanzania	Treatment scenario target (%)	16.0	23.5	13.6	5.6	12.0
Timor Leste	Diagnosis scenario target (%)	27.0	39.8	45.0	55.1	80.3
Timor Leste	Treatment scenario target (%)	9.0	23.0	27.9	39.7	44.4
Togo	Diagnosis scenario target (%)	32.6	37.5	42.7	41.7	54.9
Togo	Treatment scenario target (%)	12.7	14.0	20.6	11.6	26.8
Uganda	Diagnosis scenario target (%)	20.7	36.5	43.9	32.2	74.7
Uganda	Treatment scenario target (%)	14.9	12.7	22.7	14.1	23.4
Vanuatu	Diagnosis scenario target (%)	12.0	32.4	23.5	32.9	26.3
Vanuatu	Treatment scenario target (%)	3.6	3.7	2.8	2.5	5.2
Zambia	Diagnosis scenario target (%)	52.8	56.8	48.2	83.1	88.3
Zambia	Treatment scenario target (%)	24.5	33.6	24.4	33.0	42.1

Supplementary Table 8. Sensitivity analysis: within-country targets by country and scenario

Country	Diagnosis scenario target (%)	Treatment scenario target (%)
Afghanistan	69.0	66.9
Albania	29.2	19.7
Algeria	50.4	35.8
Azerbaijan	69.7	42.5
Benin	29.4	15.2
Bhutan	54.9	24.3
Botswana	62.1	43.6
Brazil	68.7	62.8
Cambodia	55.9	39.7
China	49.9	44.7
Ecuador	67.7	55.8
Eritrea	40.1	25.6
Eswatini	58.1	42.5
Ethiopia	28.6	15.6
Gambia	44.3	23.5
Ghana	32.5	24.1
India	38.3	26.4
Indonesia	43.9	20.3
Jordan	74.6	66.5
Kenya	49.6	18.9
Kiribati	44.5	11.9
Kyrgyzstan	51.8	35.6
Laos	53.0	35.2
Lesotho	57.3	50.3
Moldova	57.9	35.8
Morocco	43.8	27.6
Myanmar	59.8	37.2
Namibia	68.4	58.5
Niger	11.9	5.9
Russian Federation	75.8	66.0
Rwanda	12.5	4.3
Samoa	29.6	20.4

(continued)

Country	Diagnosis scenario target (%)	Treatment scenario target (%)
Sao Tome and Principe	42.9	24.1
Solomon Islands	54.4	20.7
South Africa	57.6	53.5
Sri Lanka	58.3	41.3
St. Vincent & the Grenadines	65.7	51.6
Sudan	48.9	44.0
Tanzania	26.2	15.7
Timor Leste	53.5	29.6
Togo	36.6	17.9
Uganda	49.8	15.6
Vanuatu	21.9	3.4
Zambia	58.9	28.1

Supplementary Table 9. Sensitivity analysis: education group targets by scenario

Scenario	Reference Country	Reference Education Category	Target
Diagnosis	Russian Federation	Some high school	77.0%
Treatment	Russian Federation	Some high school	68.8%

Results

Supplementary Table 10. Mean (95% confidence/uncertainty interval) 10-year CVD risk by country and wealth quintile in Baseline, Diagnosis, and Treatment scenarios

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Baseline	20.9 (18.5,23.4)	21.7 (16.9,26.4)	22.5 (19.8,25.2)	21.9 (19.1,24.7)	23.7 (20.6,26.7)
Afghanistan	Diagnosis scenario	20.3 (18.0,22.6)	20.4 (16.0,24.9)	21.4 (18.8,24.1)	21.6 (18.8,24.5)	23.2 (20.2,26.3)
Afghanistan	Treatment scenario	20.4 (18.1,22.8)	20.5 (16.1,25.0)	20.1 (17.4,22.8)	20.9 (18.0,23.7)	23.7 (20.6,26.7)
Albania	Baseline	4.7 (4.2,5.3)	4.9 (4.4,5.5)	5.4 (4.8,6.0)	5.3 (4.7,6.0)	5.3 (4.7,6.0)
Albania	Diagnosis scenario	4.5 (3.9,5.0)	4.6 (4.1,5.1)	5.0 (4.4,5.6)	4.9 (4.3,5.5)	4.9 (4.3,5.6)
Albania	Treatment scenario	3.9 (3.4,4.4)	4.1 (3.6,4.6)	4.5 (3.9,5.0)	4.5 (4.0,5.1)	4.7 (4.0,5.3)
Algeria	Baseline	8.4 (7.8,9.0)	8.9 (8.1,9.6)	9.1 (8.4,9.8)	8.2 (7.5,8.8)	8.7 (8.1,9.4)
Algeria	Diagnosis scenario	8.0 (7.4,8.6)	8.4 (7.7,9.1)	8.6 (7.9,9.3)	7.8 (7.2,8.4)	8.3 (7.7,8.9)
Algeria	Treatment scenario	7.6 (7.0,8.2)	7.9 (7.2,8.6)	8.3 (7.6,8.9)	7.5 (6.9,8.1)	8.0 (7.4,8.6)
Azerbaijan	Baseline	15.9 (14.0,17.7)	16.8 (13.3,20.4)	16.3 (14.4,18.3)	15.2 (13.4,17.1)	13.4 (10.7,16.0)
Azerbaijan	Diagnosis scenario	15.3 (13.5,17.1)	16.1 (12.5,19.8)	15.7 (13.8,17.7)	15.1 (13.2,16.9)	12.9 (10.3,15.6)
Azerbaijan	Treatment scenario	14.7 (12.9,16.4)	15.7 (12.1,19.3)	15.3 (13.4,17.2)	14.1 (12.4,15.9)	12.4 (9.9,14.9)
Benin	Baseline	15.1 (12.4,17.8)	14.1 (12.0,16.2)	12.4 (10.7,14.0)	13.6 (11.8,15.4)	13.8 (12.1,15.5)
Benin	Diagnosis scenario	13.0 (10.7,16.3)	12.8 (10.7,14.9)	10.2 (8.9,11.7)	12.0 (10.3,13.8)	12.9 (11.2,14.5)
Benin	Treatment scenario	12.3 (10.2,15.7)	11.4 (9.7,13.3)	10.2 (8.8,11.6)	11.4 (9.8,13.1)	11.7 (10.1,13.2)
Bhutan	Baseline	12.5 (11.6,13.5)	12.0 (10.9,13.1)	12.5 (11.3,13.7)	11.7 (10.4,13.0)	12.0 (10.6,13.4)
Bhutan	Diagnosis scenario	12.0 (11.0,12.9)	11.5 (10.4,12.6)	11.7 (10.6,12.9)	11.5 (10.1,12.8)	11.5 (10.1,13.0)
Bhutan	Treatment scenario	11.0 (10.0,12.0)	10.6 (9.5,11.7)	10.7 (9.7,11.9)	10.4 (9.1,11.7)	10.5 (9.2,11.9)
Botswana	Baseline	10.9 (9.2,12.6)	9.2 (7.1,11.3)	9.0 (6.6,11.3)	9.5 (6.4,12.6)	7.8 (5.9,9.8)
Botswana	Diagnosis scenario	10.5 (8.7,12.3)	8.8 (6.7,10.9)	8.8 (6.5,11.1)	9.3 (6.1,12.4)	7.5 (5.6,9.4)
Botswana	Treatment scenario	9.7 (8.1,11.5)	8.6 (6.5,10.8)	8.3 (6.2,10.6)	8.4 (5.6,11.4)	7.1 (5.4,8.9)
Brazil	Baseline	10.9 (10.5,11.3)	10.4 (9.8,10.9)	9.9 (9.4,10.4)	8.9 (8.5,9.2)	8.8 (8.4,9.2)
Brazil	Diagnosis scenario	10.5 (10.1,10.9)	10.1 (9.6,10.6)	9.7 (9.2,10.2)	8.7 (8.3,9.0)	8.6 (8.2,9.0)
Brazil	Treatment scenario	10.5 (10.1,10.9)	10.1 (9.6,10.6)	9.7 (9.2,10.3)	8.7 (8.4,9.1)	8.7 (8.3,9.1)
Cambodia	Baseline	15.7 (13.8,17.5)	16.7 (15.1,18.4)	16.5 (14.6,18.4)	18.2 (16.5,19.9)	16.4 (14.7,18.2)
Cambodia	Diagnosis scenario	14.3 (12.5,16.1)	15.2 (13.6,16.9)	15.3 (13.5,17.1)	17.3 (15.6,19.0)	15.7 (14.0,17.5)
Cambodia	Treatment scenario	13.3 (11.7,15.1)	14.7 (13.0,16.3)	14.3 (12.7,16.1)	16.0 (14.3,17.7)	15.0 (13.3,16.7)
China	Baseline	23.9 (22.1,25.6)	19.6 (18.2,21.1)	19.8 (18.0,21.6)	18.9 (17.3,20.4)	19.1 (17.4,20.7)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
China	Diagnosis scenario	22.1 (20.5,23.8)	18.3 (17.0,19.7)	18.3 (16.6,20.0)	17.8 (16.3,19.3)	18.1 (16.4,19.7)
China	Treatment scenario	21.9 (20.2,23.6)	18.1 (16.8,19.5)	18.2 (16.5,19.9)	17.7 (16.1,19.2)	18.1 (16.4,19.7)
Ecuador	Baseline	8.2 (7.0,9.5)	7.6 (6.9,8.2)	7.1 (6.0,8.2)	6.9 (6.0,7.9)	7.9 (7.0,8.8)
Ecuador	Diagnosis scenario	7.7 (6.6,8.9)	7.3 (6.6,7.9)	6.9 (5.9,8.0)	6.8 (5.8,7.8)	7.6 (6.7,8.5)
Ecuador	Treatment scenario	7.4 (6.3,8.6)	7.1 (6.5,7.8)	6.7 (5.7,7.7)	6.6 (5.6,7.6)	7.6 (6.7,8.5)
Eritrea	Baseline	18.7 (16.6,20.9)	18.0 (13.7,22.3)	15.5 (13.3,17.7)	16.2 (13.6,18.7)	17.4 (14.2,20.6)
Eritrea	Diagnosis scenario	17.4 (15.3,19.5)	16.1 (12.0,20.3)	14.1 (12.0,16.2)	15.1 (12.7,17.6)	16.2 (13.3,19.2)
Eritrea	Treatment scenario	15.9 (13.9,17.9)	15.5 (11.6,19.5)	13.5 (11.5,15.6)	14.3 (11.9,16.6)	15.1 (12.3,17.8)
Eswatini	Baseline	14.2 (11.7,16.8)	16.6 (12.6,20.7)	14.8 (9.7,19.9)	14.0 (10.8,17.2)	11.7 (7.9,15.6)
Eswatini	Diagnosis scenario	13.5 (11.0,16.1)	15.9 (12.0,19.9)	14.4 (9.3,19.5)	13.5 (10.4,16.8)	11.3 (7.6,15.0)
Eswatini	Treatment scenario	12.7 (10.3,15.1)	14.8 (11.1,18.8)	13.1 (8.9,17.9)	13.1 (10.0,16.4)	10.8 (7.3,14.5)
Ethiopia	Baseline	10.7 (8.9,12.5)	10.9 (8.7,13.2)	11.5 (9.8,13.2)	8.6 (6.8,10.4)	9.4 (7.8,11.0)
Ethiopia	Diagnosis scenario	10.1 (8.3,11.9)	10.2 (8.0,12.4)	10.6 (8.8,12.3)	8.1 (6.4,9.8)	8.7 (7.1,10.3)
Ethiopia	Treatment scenario	8.7 (7.2,10.4)	9.4 (7.2,11.6)	9.5 (7.9,11.2)	7.1 (5.6,8.6)	8.0 (6.5,9.5)
Gambia	Baseline	12.3 (10.7,13.8)	11.8 (9.8,13.8)	12.0 (10.2,13.9)	10.0 (8.7,11.4)	12.9 (11.2,14.7)
Gambia	Diagnosis scenario	11.1 (9.5,12.6)	10.8 (8.8,12.9)	11.0 (9.2,12.9)	9.3 (7.8,10.7)	12.4 (10.6,14.2)
Gambia	Treatment scenario	10.2 (8.8,11.6)	10.0 (8.2,11.9)	10.1 (8.5,11.7)	8.6 (7.4,9.9)	11.2 (9.4,13.0)
Ghana	Baseline	15.0 (12.7,17.2)	15.9 (13.5,18.3)	13.1 (11.6,14.6)	14.6 (12.6,16.7)	13.6 (11.7,15.5)
Ghana	Diagnosis scenario	13.4 (11.3,15.5)	13.7 (11.5,15.8)	11.5 (10.1,12.9)	13.4 (11.5,15.3)	12.4 (10.6,14.1)
Ghana	Treatment scenario	12.4 (10.4,14.3)	13.2 (11.2,15.3)	11.0 (9.7,12.3)	12.9 (11.0,14.8)	11.9 (10.2,13.7)
India	Baseline	14.3 (13.8,14.8)	13.8 (13.4,14.3)	13.9 (13.5,14.3)	13.8 (13.4,14.2)	12.9 (12.5,13.2)
India	Diagnosis scenario	12.8 (12.3,13.3)	12.6 (12.2,13.0)	12.8 (12.4,13.2)	12.7 (12.3,13.1)	12.0 (11.6,12.3)
India	Treatment scenario	12.0 (11.6,12.5)	11.7 (11.4,12.1)	12.0 (11.6,12.3)	12.0 (11.6,12.4)	11.4 (11.1,11.7)
Indonesia	Baseline	27.6 (25.9,29.2)	25.3 (24.4,26.3)	25.7 (24.8,26.6)	23.3 (22.7,23.9)	21.9 (20.9,23.0)
Indonesia	Diagnosis scenario	26.6 (25.0,28.3)	24.3 (23.2,25.3)	24.7 (23.8,25.7)	22.4 (21.8,23.0)	21.0 (19.9,22.1)
Indonesia	Treatment scenario	22.5 (21.0,23.9)	20.9 (19.9,21.9)	21.4 (20.4,22.3)	19.6 (19.0,20.2)	18.8 (17.9,19.7)
Jordan	Baseline	10.8 (9.7,11.8)	10.1 (8.8,11.3)	9.9 (8.9,10.8)	9.4 (7.7,11.0)	10.8 (9.4,12.2)
Jordan	Diagnosis scenario	10.5 (9.5,11.5)	10.0 (8.7,11.3)	9.8 (8.9,10.8)	9.0 (7.4,10.6)	10.5 (9.1,11.9)
Jordan	Treatment scenario	10.4 (9.3,11.4)	10.1 (8.8,11.3)	9.7 (8.8,10.7)	9.0 (7.4,10.6)	10.4 (9.1,11.8)
Kenya	Baseline	7.4 (6.3,8.4)	7.1 (6.1,8.1)	7.4 (6.6,8.3)	6.1 (5.3,6.8)	6.7 (4.7,8.6)
Kenya	Diagnosis scenario	6.9 (5.9,7.9)	6.7 (5.8,7.7)	7.0 (6.1,7.9)	5.8 (5.0,6.5)	6.5 (4.6,8.4)
Kenya	Treatment scenario	5.9 (5.0,6.8)	5.8 (5.0,6.7)	6.2 (5.4,7.0)	5.0 (4.3,5.8)	5.6 (4.0,7.2)
Kiribati	Baseline	9.3 (6.8,11.8)	13.0 (10.5,15.4)	11.7 (9.5,13.9)	12.8 (9.3,16.2)	15.7 (8.4,23.1)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Kiribati	Diagnosis scenario	8.8 (6.3,11.3)	11.9 (9.1,14.8)	11.5 (9.1,13.8)	12.3 (8.7,16.1)	15.4 (7.9,23.0)
Kiribati	Treatment scenario	7.8 (5.5,10.1)	10.7 (8.2,13.8)	9.8 (7.6,12.3)	10.6 (7.4,14.2)	12.8 (6.6,19.8)
Kyrgyzstan	Baseline	18.6 (16.3,20.8)	21.3 (18.8,23.8)	19.4 (17.1,21.8)	17.5 (15.2,19.9)	17.7 (15.3,20.1)
Kyrgyzstan	Diagnosis scenario	17.5 (15.3,19.7)	20.5 (18.0,23.0)	18.8 (16.5,21.2)	16.9 (14.5,19.3)	17.1 (14.7,19.5)
Kyrgyzstan	Treatment scenario	16.4 (14.3,18.6)	19.6 (17.2,22.0)	16.8 (14.7,19.1)	15.5 (13.2,17.8)	15.6 (13.4,17.8)
Laos	Baseline	18.7 (14.7,22.8)	19.9 (17.0,22.7)	17.6 (14.9,20.3)	18.0 (14.8,21.1)	17.4 (13.9,20.9)
Laos	Diagnosis scenario	16.9 (12.9,20.9)	18.3 (15.4,21.5)	16.6 (13.8,19.4)	17.4 (14.1,20.6)	16.1 (12.9,19.5)
Laos	Treatment scenario	15.7 (12.0,19.6)	17.7 (14.8,21.0)	14.9 (12.6,17.5)	16.6 (13.3,19.9)	15.2 (12.2,18.4)
Lesotho	Baseline	8.0 (6.4,9.6)	8.0 (6.3,9.7)	9.4 (7.6,11.2)	7.8 (5.8,9.7)	7.8 (6.4,9.1)
Lesotho	Diagnosis scenario	7.2 (5.8,8.7)	7.3 (5.7,9.0)	8.3 (6.7,10.1)	7.3 (5.5,9.1)	7.4 (6.1,8.8)
Lesotho	Treatment scenario	7.2 (5.7,8.7)	7.2 (5.6,8.8)	8.1 (6.5,9.8)	7.3 (5.5,9.2)	7.4 (6.1,8.7)
Moldova	Baseline	19.6 (18.3,21.0)	21.3 (19.7,22.8)	19.3 (17.7,20.9)	17.5 (15.5,19.5)	16.9 (15.3,18.6)
Moldova	Diagnosis scenario	19.0 (17.6,20.4)	20.8 (19.2,22.3)	18.8 (17.2,20.4)	16.8 (14.9,18.8)	16.4 (14.8,18.0)
Moldova	Treatment scenario	17.4 (16.1,18.7)	19.2 (17.7,20.7)	17.6 (16.0,19.2)	15.9 (14.0,17.8)	15.3 (13.7,16.8)
Morocco	Baseline	12.0 (11.2,12.9)	12.1 (10.4,13.9)	11.7 (10.2,13.2)	12.5 (10.6,14.5)	11.8 (10.6,12.9)
Morocco	Diagnosis scenario	11.3 (10.4,12.1)	11.4 (9.7,13.1)	11.2 (9.7,12.7)	11.9 (10.0,13.8)	11.1 (10.0,12.2)
Morocco	Treatment scenario	10.8 (10.0,11.6)	10.8 (9.2,12.5)	10.5 (9.1,11.9)	11.0 (9.2,12.9)	10.6 (9.5,11.7)
Myanmar	Baseline	14.7 (12.9,16.6)	13.8 (12.8,14.8)	12.3 (11.4,13.2)	12.5 (11.3,13.6)	11.7 (10.2,13.3)
Myanmar	Diagnosis scenario	14.1 (12.3,16.1)	13.2 (12.3,14.2)	11.9 (10.8,12.9)	12.0 (10.8,13.1)	11.4 (9.8,13.0)
Myanmar	Treatment scenario	12.2 (10.9,13.7)	12.0 (11.1,13.2)	10.8 (9.8,11.8)	11.1 (9.9,12.2)	10.6 (9.1,12.1)
Namibia	Baseline	7.6 (6.6,8.5)	7.5 (6.7,8.2)	8.2 (7.2,9.3)	8.4 (7.1,9.7)	8.4 (7.1,9.6)
Namibia	Diagnosis scenario	6.8 (5.9,7.7)	6.9 (6.2,7.7)	7.7 (6.8,8.7)	7.8 (6.6,9.0)	8.2 (7.0,9.5)
Namibia	Treatment scenario	6.7 (5.8,7.5)	6.8 (6.1,7.5)	7.7 (6.8,8.7)	7.8 (6.6,9.0)	8.2 (6.9,9.5)
Niger	Baseline	9.9 (8.6,11.2)	10.0 (8.7,11.2)	9.5 (8.1,10.8)	10.4 (9.0,11.7)	10.4 (8.8,12.0)
Niger	Diagnosis scenario	8.4 (7.2,9.6)	10.0 (8.7,11.2)	8.7 (7.4,10.0)	9.5 (8.2,10.8)	9.3 (7.8,10.8)
Niger	Treatment scenario	7.9 (6.7,9.0)	7.6 (6.6,8.7)	7.3 (6.2,8.4)	8.1 (7.0,9.3)	8.3 (6.9,9.7)
Russian Federation	Baseline	34.6 (30.6,38.6)	32.9 (28.8,37.0)	32.9 (28.7,37.0)	22.1 (14.2,30.0)	26.9 (20.9,32.9)
Russian Federation	Diagnosis scenario	33.7 (29.8,37.7)	32.9 (28.8,37.0)	32.8 (28.6,36.9)	21.3 (13.3,29.2)	26.8 (20.8,32.8)
Russian Federation	Treatment scenario	32.4 (28.5,36.4)	32.0 (27.8,36.3)	32.6 (28.4,36.7)	21.3 (13.4,29.2)	26.8 (20.8,32.9)
Rwanda	Baseline	10.6 (9.1,12.1)	8.8 (7.4,10.3)	8.0 (6.7,9.2)	9.1 (7.7,10.5)	8.7 (7.5,9.8)
Rwanda	Diagnosis scenario	9.7 (8.2,11.1)	7.7 (6.4,9.1)	7.6 (6.3,8.9)	9.0 (7.6,10.4)	8.1 (7.0,9.3)
Rwanda	Treatment scenario	8.5 (7.2,9.9)	7.0 (5.8,8.3)	6.3 (5.3,7.4)	7.2 (6.1,8.4)	6.8 (5.9,7.9)
Samoa	Baseline	14.0 (12.3,15.8)	11.8 (10.2,13.4)	11.3 (9.0,13.6)	8.5 (6.6,10.5)	12.0 (10.2,13.7)
Samoa	Diagnosis scenario	11.8 (10.3,13.7)	9.1 (7.6,10.9)	10.0 (7.8,12.4)	7.9 (5.9,9.9)	10.7 (8.7,12.6)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Samoa	Treatment scenario	11.8 (10.2,13.7)	9.6 (7.9,11.4)	9.5 (7.5,11.8)	7.0 (5.1,9.0)	10.2 (8.3,12.0)
Sao Tome and Principe	Baseline	9.6 (8.9,10.4)	9.1 (8.4,9.8)	7.8 (7.1,8.5)	8.7 (8.0,9.4)	9.0 (8.5,9.6)
Sao Tome and Principe	Diagnosis scenario	9.0 (8.1,9.9)	8.6 (7.8,9.4)	7.1 (6.4,7.8)	8.4 (7.6,9.1)	8.4 (7.7,9.1)
Sao Tome and Principe	Treatment scenario	8.1 (7.3,8.9)	7.5 (6.8,8.3)	6.5 (5.9,7.2)	7.5 (6.7,8.3)	7.8 (7.1,8.4)
Solomon Islands	Baseline	15.5 (12.0,18.9)	14.8 (11.6,17.9)	12.5 (10.1,14.9)	12.8 (10.2,15.4)	14.6 (12.4,16.7)
Solomon Islands	Diagnosis scenario	15.0 (11.6,18.5)	14.2 (11.1,17.4)	12.0 (9.6,14.3)	12.6 (10.0,15.2)	14.2 (12.1,16.3)
Solomon Islands	Treatment scenario	12.5 (9.7,15.6)	12.0 (9.4,14.7)	10.3 (8.3,12.4)	10.4 (8.3,12.7)	12.5 (10.5,14.4)
South Africa	Baseline	18.0 (16.1,19.9)	18.5 (16.9,20.2)	18.2 (16.2,20.3)	19.3 (17.3,21.4)	20.5 (18.9,22.2)
South Africa	Diagnosis scenario	16.4 (14.5,18.2)	17.0 (15.4,18.5)	17.2 (15.3,19.2)	18.5 (16.5,20.6)	19.6 (18.0,21.3)
South Africa	Treatment scenario	16.3 (14.5,18.1)	17.0 (15.5,18.6)	17.4 (15.5,19.4)	18.6 (16.5,20.7)	19.8 (18.2,21.5)
Sri Lanka	Baseline	17.8 (16.5,19.1)	17.8 (16.8,18.9)	15.9 (14.5,17.2)	15.8 (14.6,17.1)	16.0 (14.5,17.5)
Sri Lanka	Diagnosis scenario	16.8 (15.5,18.0)	16.5 (15.5,17.5)	14.6 (13.3,16.0)	15.0 (13.7,16.3)	15.5 (14.0,17.0)
Sri Lanka	Treatment scenario	16.1 (14.9,17.4)	15.8 (14.8,16.8)	14.2 (12.9,15.6)	14.6 (13.4,15.8)	14.8 (13.3,16.3)
St. Vincent & the Grenadines	Baseline	17.5 (15.7,19.2)	16.0 (13.3,18.8)	13.5 (11.4,15.5)	13.7 (12.3,15.2)	12.6 (11.4,13.8)
St. Vincent & the Grenadines	Diagnosis scenario	17.1 (15.4,18.9)	15.5 (12.7,18.3)	12.9 (10.9,15.0)	13.1 (11.6,14.6)	12.3 (11.1,13.5)
St. Vincent & the Grenadines	Treatment scenario	16.7 (14.9,18.5)	14.5 (11.9,17.3)	12.3 (10.3,14.4)	12.5 (11.0,14.1)	12.1 (10.8,13.3)
Sudan	Baseline	19.7 (18.2,21.2)	20.3 (19.1,21.4)	19.0 (17.9,20.2)	20.1 (18.2,22.0)	23.9 (21.1,26.6)
Sudan	Diagnosis scenario	17.3 (15.8,18.9)	18.1 (17.0,19.2)	17.5 (16.4,18.7)	18.4 (16.6,20.4)	22.3 (19.6,25.3)
Sudan	Treatment scenario	16.6 (15.1,18.1)	17.5 (16.4,18.6)	16.5 (15.5,17.6)	17.6 (15.8,19.4)	22.3 (19.5,25.4)
Tanzania	Baseline	8.3 (7.3,9.2)	7.7 (6.8,8.5)	8.1 (7.2,8.9)	7.6 (6.8,8.4)	10.8 (6.1,15.6)
Tanzania	Diagnosis scenario	7.2 (6.3,8.2)	6.8 (6.0,7.7)	7.4 (6.5,8.3)	7.3 (6.5,8.1)	10.2 (5.9,15.0)
Tanzania	Treatment scenario	6.7 (5.9,7.5)	6.3 (5.5,7.1)	6.6 (5.7,7.5)	6.0 (5.3,6.7)	8.4 (5.1,12.6)
Timor Leste	Baseline	21.4 (16.6,26.2)	23.3 (20.4,26.3)	20.6 (17.3,24.0)	16.6 (13.6,19.5)	15.3 (12.4,18.2)
Timor Leste	Diagnosis scenario	20.2 (15.5,24.9)	21.3 (18.5,24.1)	19.0 (15.7,22.3)	15.1 (12.2,18.0)	14.9 (12.0,17.8)
Timor Leste	Treatment scenario	17.3 (13.3,21.5)	19.6 (17.0,22.2)	17.7 (14.7,20.9)	14.3 (11.6,17.1)	13.7 (10.8,16.5)
Togo	Baseline	12.0 (9.2,14.9)	10.3 (7.5,13.0)	12.2 (9.5,14.9)	10.5 (9.0,12.0)	10.4 (8.5,12.3)
Togo	Diagnosis scenario	11.4 (8.5,14.2)	9.7 (7.1,12.4)	11.4 (8.8,14.0)	10.1 (8.6,11.6)	9.8 (8.0,11.7)
Togo	Treatment scenario	10.0 (7.4,12.7)	8.3 (6.2,10.8)	10.1 (7.7,12.5)	8.5 (7.1,9.9)	8.9 (7.2,10.6)
Uganda	Baseline	10.5 (7.6,13.5)	11.1 (8.9,13.2)	9.3 (7.5,11.2)	7.7 (6.3,9.2)	11.0 (8.1,13.9)
Uganda	Diagnosis scenario	9.2 (6.6,12.0)	10.5 (8.4,12.6)	8.7 (6.9,10.5)	7.2 (5.8,8.7)	10.8 (7.9,13.7)
Uganda	Treatment scenario	8.7 (6.3,11.4)	9.0 (7.2,11.0)	7.9 (6.2,9.6)	6.4 (5.1,7.7)	9.0 (6.7,11.6)
Vanuatu	Baseline	10.6 (9.7,11.6)	9.7 (8.7,10.7)	11.4 (10.1,12.8)	10.6 (9.4,11.8)	12.3 (10.8,13.9)
Vanuatu	Diagnosis scenario	10.0 (9.0,10.9)	9.6 (8.6,10.6)	11.2 (9.9,12.5)	10.5 (9.2,11.7)	11.9 (10.4,13.4)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Vanuatu	Treatment scenario	8.5 (7.7,9.3)	7.8 (7.0,8.6)	9.2 (8.0,10.3)	8.3 (7.3,9.4)	9.8 (8.6,11.1)
Zambia	Baseline	7.9 (6.4,9.4)	8.4 (6.7,10.1)	6.6 (5.4,7.9)	7.9 (6.1,9.7)	8.2 (6.1,10.3)
Zambia	Diagnosis scenario	7.5 (6.0,9.0)	7.8 (6.2,9.5)	6.3 (5.0,7.5)	7.7 (5.9,9.6)	8.1 (6.0,10.2)
Zambia	Treatment scenario	6.7 (5.3,8.1)	7.2 (5.6,8.8)	5.5 (4.5,6.6)	6.5 (5.0,8.2)	7.3 (5.3,9.4)

Note. 95% confidence intervals are presented for the Baseline scenario. 95% uncertainty intervals are presented for the Diagnosis and Treatment scenario values.

Supplementary Table 11. Absolute (percentage point) difference in mean 10-year cardiovascular disease risk comparing the bottom (Q1) and top (Q5) wealth quintiles by country and modelled scenario, either Baseline, Diagnosis or Treatment scenario

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Afghanistan	Baseline	-2.7
Afghanistan	Diagnosis scenario	-3.0
Afghanistan	Treatment scenario	-3.3
Albania	Baseline	-0.6
Albania	Diagnosis scenario	-0.5
Albania	Treatment scenario	-0.8
Algeria	Baseline	-0.3
Algeria	Diagnosis scenario	-0.3
Algeria	Treatment scenario	-0.4
Azerbaijan	Baseline	2.5
Azerbaijan	Diagnosis scenario	2.4
Azerbaijan	Treatment scenario	2.3
Benin	Baseline	1.3
Benin	Diagnosis scenario	0.1
Benin	Treatment scenario	0.6
Bhutan	Baseline	0.6
Bhutan	Diagnosis scenario	0.5
Bhutan	Treatment scenario	0.5
Botswana	Baseline	3.1
Botswana	Diagnosis scenario	3.0
Botswana	Treatment scenario	2.6
Brazil	Baseline	2.1
Brazil	Diagnosis scenario	1.9
Brazil	Treatment scenario	1.8
Cambodia	Baseline	-0.8
Cambodia	Diagnosis scenario	-1.4
Cambodia	Treatment scenario	-1.6
China	Baseline	4.8
China	Diagnosis scenario	4.1
China	Treatment scenario	3.9
Ecuador	Baseline	0.3

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Ecuador	Diagnosis scenario	0.1
Ecuador	Treatment scenario	-0.2
Eritrea	Baseline	1.4
Eritrea	Diagnosis scenario	1.2
Eritrea	Treatment scenario	0.8
Eswatini	Baseline	2.5
Eswatini	Diagnosis scenario	2.3
Eswatini	Treatment scenario	1.9
Ethiopia	Baseline	1.3
Ethiopia	Diagnosis scenario	1.3
Ethiopia	Treatment scenario	0.8
Gambia	Baseline	-0.7
Gambia	Diagnosis scenario	-1.3
Gambia	Treatment scenario	-0.9
Ghana	Baseline	1.4
Ghana	Diagnosis scenario	1.1
Ghana	Treatment scenario	0.4
India	Baseline	1.4
India	Diagnosis scenario	0.9
India	Treatment scenario	0.6
Indonesia	Baseline	5.6
Indonesia	Diagnosis scenario	5.7
Indonesia	Treatment scenario	3.7
Jordan	Baseline	-0.0
Jordan	Diagnosis scenario	0.0
Jordan	Treatment scenario	-0.0
Kenya	Baseline	0.7
Kenya	Diagnosis scenario	0.4
Kenya	Treatment scenario	0.3
Kiribati	Baseline	-6.5
Kiribati	Diagnosis scenario	-6.5
Kiribati	Treatment scenario	-5.0
Kyrgyzstan	Baseline	0.9
Kyrgyzstan	Diagnosis scenario	0.4

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Kyrgyzstan	Treatment scenario	0.8
Laos	Baseline	1.4
Laos	Diagnosis scenario	0.8
Laos	Treatment scenario	0.6
Lesotho	Baseline	0.2
Lesotho	Diagnosis scenario	-0.2
Lesotho	Treatment scenario	-0.2
Moldova	Baseline	2.7
Moldova	Diagnosis scenario	2.6
Moldova	Treatment scenario	2.1
Morocco	Baseline	0.3
Morocco	Diagnosis scenario	0.2
Morocco	Treatment scenario	0.2
Myanmar	Baseline	3.0
Myanmar	Diagnosis scenario	2.8
Myanmar	Treatment scenario	1.6
Namibia	Baseline	-0.8
Namibia	Diagnosis scenario	-1.5
Namibia	Treatment scenario	-1.5
Niger	Baseline	-0.5
Niger	Diagnosis scenario	-0.9
Niger	Treatment scenario	-0.4
Russian Federation	Baseline	7.7
Russian Federation	Diagnosis scenario	7.0
Russian Federation	Treatment scenario	5.6
Rwanda	Baseline	2.0
Rwanda	Diagnosis scenario	1.6
Rwanda	Treatment scenario	1.7
Samoa	Baseline	2.1
Samoa	Diagnosis scenario	1.1
Samoa	Treatment scenario	1.6
Sao Tome and Principe	Baseline	0.6
Sao Tome and Principe	Diagnosis scenario	0.6

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Sao Tome and Principe	Treatment scenario	0.3
Solomon Islands	Baseline	0.9
Solomon Islands	Diagnosis scenario	0.8
Solomon Islands	Treatment scenario	0.1
South Africa	Baseline	-2.5
South Africa	Diagnosis scenario	-3.3
South Africa	Treatment scenario	-3.5
Sri Lanka	Baseline	1.8
Sri Lanka	Diagnosis scenario	1.3
Sri Lanka	Treatment scenario	1.3
St. Vincent & the Grenadines	Baseline	4.9
St. Vincent & the Grenadines	Diagnosis scenario	4.8
St. Vincent & the Grenadines	Treatment scenario	4.6
Sudan	Baseline	-4.1
Sudan	Diagnosis scenario	-5.0
Sudan	Treatment scenario	-5.7
Tanzania	Baseline	-2.6
Tanzania	Diagnosis scenario	-3.0
Tanzania	Treatment scenario	-1.7
Timor Leste	Baseline	6.1
Timor Leste	Diagnosis scenario	5.3
Timor Leste	Treatment scenario	3.7
Togo	Baseline	1.7
Togo	Diagnosis scenario	1.6
Togo	Treatment scenario	1.1
Uganda	Baseline	-0.5
Uganda	Diagnosis scenario	-1.6
Uganda	Treatment scenario	-0.3
Vanuatu	Baseline	-1.7
Vanuatu	Diagnosis scenario	-1.9
Vanuatu	Treatment scenario	-1.3
Zambia	Baseline	-0.3
Zambia	Diagnosis scenario	-0.6

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Zambia	Treatment scenario	-0.6

Supplementary Table 12. Mean difference (95% uncertainty interval) in CVD cases per 1,000 people living with hypertension compared to baseline by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	6.8 (0.3,16.5)	12.9 (1.7,31.0)	10.6 (2.0,22.9)	2.6 (-0.1,6.6)	4.6 (-0.2,12.0)
Afghanistan	Treatment scenario	5.4 (0.1,14.1)	11.8 (1.5,28.9)	24.1 (10.3,39.2)	10.4 (3.1,19.9)	0.0 (0.0,0.0)
Albania	Diagnosis scenario	2.8 (1.4,4.4)	3.8 (2.2,5.7)	3.9 (2.2,5.7)	4.1 (2.5,6.0)	4.3 (2.6,6.2)
Albania	Treatment scenario	8.5 (6.3,10.7)	8.2 (6.2,10.3)	9.3 (6.8,11.9)	8.1 (5.9,10.5)	6.8 (4.8,8.9)
Algeria	Diagnosis scenario	4.2 (2.9,5.8)	4.7 (3.2,6.4)	5.3 (3.4,7.3)	3.7 (2.4,5.3)	4.4 (2.7,6.2)
Algeria	Treatment scenario	8.2 (6.4,10.0)	10.1 (7.6,12.7)	8.6 (6.3,10.9)	6.9 (5.1,8.8)	7.6 (5.5,9.8)
Azerbaijan	Diagnosis scenario	5.8 (2.7,9.5)	7.5 (1.9,15.4)	6.3 (2.6,11.8)	1.3 (-0.2,4.2)	4.3 (0.2,11.8)
Azerbaijan	Treatment scenario	11.9 (7.2,17.4)	11.7 (4.4,20.9)	10.7 (5.7,17.0)	11.1 (5.8,17.1)	10.0 (3.5,18.9)
Benin	Diagnosis scenario	21.4 (6.9,45.0)	13.6 (8.2,20.2)	21.2 (14.4,28.9)	15.8 (9.7,22.7)	9.5 (5.3,14.3)
Benin	Treatment scenario	28.1 (11.0,49.4)	26.8 (19.1,35.2)	22.0 (15.2,29.7)	22.1 (15.3,29.4)	21.5 (15.6,27.7)
Bhutan	Diagnosis scenario	5.6 (2.9,9.0)	5.0 (2.7,7.6)	7.6 (3.4,12.7)	2.3 (0.4,4.8)	4.7 (1.5,8.9)
Bhutan	Treatment scenario	15.2 (11.2,19.5)	14.2 (10.2,18.4)	17.4 (11.7,23.6)	12.9 (7.5,19.2)	14.3 (9.2,19.9)
Botswana	Diagnosis scenario	3.9 (0.1,13.9)	4.1 (1.1,8.3)	2.0 (-0.1,9.8)	2.3 (0.1,6.6)	3.4 (0.1,9.3)
Botswana	Treatment scenario	11.7 (4.2,22.2)	5.7 (2.2,10.1)	6.4 (1.6,14.7)	10.9 (3.6,21.0)	7.2 (2.4,13.8)
Brazil	Diagnosis scenario	4.0 (3.2,4.9)	3.0 (2.0,4.5)	2.0 (1.3,2.8)	1.7 (1.1,2.4)	1.8 (1.2,2.7)
Brazil	Treatment scenario	3.7 (2.8,4.6)	2.8 (1.9,4.3)	1.5 (0.9,2.9)	1.2 (0.7,1.8)	1.1 (0.5,2.1)
Cambodia	Diagnosis scenario	13.8 (7.6,22.2)	15.1 (9.3,21.1)	12.3 (6.2,19.4)	9.0 (3.9,16.3)	7.0 (2.7,12.0)
Cambodia	Treatment scenario	23.3 (15.6,32.2)	20.6 (14.1,27.4)	22.0 (14.1,30.6)	22.3 (14.5,31.2)	14.9 (8.5,21.9)
China	Diagnosis scenario	17.2 (13.5,21.1)	12.8 (10.0,15.9)	14.8 (11.9,18.0)	10.7 (8.0,13.7)	9.9 (7.4,12.6)
China	Treatment scenario	19.5 (15.6,23.5)	15.0 (11.8,18.4)	15.9 (12.8,19.2)	11.9 (9.0,14.9)	10.0 (7.3,12.8)
Ecuador	Diagnosis scenario	5.2 (1.8,10.8)	2.9 (1.4,4.6)	1.9 (0.1,5.3)	1.2 (-0.0,3.0)	3.1 (1.0,5.6)
Ecuador	Treatment scenario	8.1 (4.1,13.9)	4.5 (2.6,6.7)	4.0 (1.2,8.1)	3.2 (1.1,5.8)	2.6 (0.6,5.3)
Eritrea	Diagnosis scenario	13.5 (9.0,18.5)	18.7 (6.8,32.4)	14.0 (8.8,20.0)	10.5 (5.4,17.1)	11.7 (5.6,19.4)
Eritrea	Treatment scenario	28.5 (22.0,35.4)	25.5 (11.6,40.7)	19.4 (13.6,25.7)	18.9 (12.4,26.1)	23.2 (15.0,32.7)
Eswatini	Diagnosis scenario	7.2 (2.2,14.2)	7.9 (0.7,21.8)	4.2 (0.4,10.2)	4.8 (0.0,15.5)	4.9 (-0.8,17.4)
Eswatini	Treatment scenario	15.7 (8.7,23.8)	18.4 (7.4,32.6)	17.1 (3.0,41.7)	8.9 (2.1,20.2)	9.4 (0.8,23.5)
Ethiopia	Diagnosis scenario	6.4 (2.4,12.5)	7.6 (2.3,14.7)	9.3 (3.8,15.8)	5.3 (1.7,10.4)	6.8 (2.6,11.9)
Ethiopia	Treatment scenario	19.5 (12.4,27.6)	15.4 (8.5,23.2)	20.0 (12.6,27.7)	15.4 (9.4,22.0)	14.4 (9.1,20.0)
Gambia	Diagnosis scenario	12.3 (7.3,17.8)	9.8 (4.7,15.8)	10.1 (4.8,17.2)	7.4 (3.1,12.8)	5.6 (1.8,10.5)
Gambia	Treatment scenario	20.8 (14.3,27.6)	17.9 (10.6,25.7)	19.7 (11.9,28.8)	13.8 (7.8,20.6)	17.9 (11.2,25.3)
Ghana	Diagnosis scenario	15.4 (11.0,20.1)	22.2 (16.8,27.5)	15.7 (11.7,19.8)	12.7 (8.8,16.8)	12.2 (8.5,16.3)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Ghana	Treatment scenario	26.2 (20.6,31.7)	26.8 (20.9,32.5)	20.7 (16.3,25.1)	17.3 (12.9,21.8)	16.4 (12.2,20.9)
India	Diagnosis scenario	14.8 (13.1,16.8)	12.6 (11.1,14.2)	10.7 (9.2,12.3)	10.8 (9.3,12.4)	9.2 (8.1,10.3)
India	Treatment scenario	22.9 (20.9,25.0)	21.0 (19.2,22.8)	19.1 (17.3,21.0)	18.0 (16.3,19.7)	14.6 (13.3,16.0)
Indonesia	Diagnosis scenario	9.1 (6.8,11.7)	10.5 (8.2,13.2)	9.5 (7.2,12.0)	8.8 (6.8,10.9)	9.3 (7.1,11.7)
Indonesia	Treatment scenario	50.8 (45.8,56.4)	44.1 (40.1,48.0)	43.1 (39.4,47.1)	36.6 (32.7,40.7)	31.4 (27.6,35.1)
Jordan	Diagnosis scenario	2.5 (0.2,5.7)	0.7 (-0.0,2.0)	0.1 (-0.1,0.7)	3.3 (0.8,6.4)	3.1 (1.2,5.3)
Jordan	Treatment scenario	4.0 (1.2,7.5)	0.0 (0.0,0.0)	1.2 (-0.0,3.4)	3.5 (1.0,6.7)	3.9 (1.1,9.3)
Kenya	Diagnosis scenario	4.8 (2.0,8.8)	4.1 (1.6,7.9)	4.9 (1.9,9.4)	2.8 (0.8,5.8)	1.5 (0.2,3.4)
Kenya	Treatment scenario	15.0 (10.4,20.1)	13.4 (9.3,17.9)	12.6 (8.0,17.5)	10.4 (6.9,14.0)	10.7 (5.8,16.4)
Kiribati	Diagnosis scenario	4.4 (-0.2,12.3)	10.9 (-0.7,34.7)	1.7 (-0.6,10.7)	4.4 (-1.5,20.4)	3.7 (-1.5,24.7)
Kiribati	Treatment scenario	14.7 (6.0,22.7)	22.4 (4.3,43.1)	19.2 (4.0,33.2)	22.1 (6.1,39.3)	29.7 (2.4,65.6)
Kyrgyzstan	Diagnosis scenario	11.0 (6.0,16.8)	7.8 (3.6,13.1)	5.8 (1.5,14.7)	6.2 (2.6,10.9)	6.1 (1.9,11.7)
Kyrgyzstan	Treatment scenario	21.7 (15.0,29.0)	17.4 (10.8,24.7)	26.3 (14.1,40.9)	20.3 (14.1,27.1)	21.1 (12.7,31.0)
Laos	Diagnosis scenario	18.9 (4.9,37.5)	15.9 (3.3,35.9)	9.4 (3.7,16.3)	6.1 (1.9,11.2)	13.3 (3.8,30.1)
Laos	Treatment scenario	30.2 (13.0,49.9)	21.9 (7.4,41.2)	26.6 (14.0,43.2)	14.2 (8.1,20.9)	22.4 (10.0,39.9)
Lesotho	Diagnosis scenario	8.1 (3.2,13.8)	6.2 (1.9,11.6)	10.7 (4.6,18.0)	5.1 (0.5,12.7)	3.5 (1.4,6.1)
Lesotho	Treatment scenario	8.2 (3.4,14.0)	8.2 (3.0,14.5)	12.7 (6.2,20.3)	4.7 (0.4,12.4)	4.0 (1.3,7.9)
Moldova	Diagnosis scenario	6.4 (3.7,9.6)	5.3 (2.8,8.3)	5.1 (2.6,8.4)	6.5 (2.5,11.8)	5.6 (2.7,9.4)
Moldova	Treatment scenario	22.3 (17.7,27.2)	20.5 (15.2,26.2)	17.6 (12.6,23.2)	15.8 (9.3,23.1)	16.6 (12.0,21.7)
Morocco	Diagnosis scenario	7.7 (5.9,9.7)	7.2 (3.6,11.5)	5.2 (2.7,8.1)	6.2 (2.6,10.6)	6.7 (4.2,9.4)
Morocco	Treatment scenario	12.6 (10.3,14.9)	12.8 (8.4,17.6)	12.0 (7.7,16.9)	14.8 (9.6,20.4)	11.6 (8.7,14.8)
Myanmar	Diagnosis scenario	6.0 (2.7,10.4)	6.1 (2.3,13.2)	4.0 (1.4,7.9)	5.0 (2.2,8.7)	3.5 (1.3,6.5)
Myanmar	Treatment scenario	25.6 (16.5,37.4)	17.9 (11.9,24.9)	15.2 (10.0,20.6)	13.6 (9.3,18.5)	11.6 (7.1,16.7)
Namibia	Diagnosis scenario	7.8 (5.3,10.6)	5.5 (3.8,7.4)	5.3 (2.9,8.7)	6.5 (3.5,10.3)	1.5 (0.4,2.9)
Namibia	Treatment scenario	9.1 (6.2,12.3)	7.0 (5.0,9.1)	5.1 (2.7,8.5)	6.4 (3.4,10.3)	1.9 (0.7,3.5)
Niger	Diagnosis scenario	15.2 (10.2,20.7)	0.0 (0.0,0.0)	7.7 (3.5,12.7)	9.0 (4.8,14.2)	11.4 (6.2,17.3)
Niger	Treatment scenario	20.4 (15.0,26.1)	23.4 (17.9,29.2)	22.1 (16.1,28.4)	22.6 (16.8,28.8)	21.8 (15.4,28.5)
Russian Federation	Diagnosis scenario	8.6 (2.0,19.7)	0.0 (0.0,0.0)	0.9 (-0.2,3.3)	8.6 (3.6,14.5)	0.7 (-0.1,2.1)
Russian Federation	Treatment scenario	21.8 (11.3,34.8)	8.4 (3.3,16.3)	3.1 (0.6,6.8)	8.2 (3.3,14.0)	0.3 (-0.1,1.5)
Rwanda	Diagnosis scenario	9.7 (5.1,15.4)	11.2 (6.7,16.3)	3.6 (1.0,7.4)	1.4 (-0.3,3.9)	5.6 (2.4,9.8)
Rwanda	Treatment scenario	21.0 (15.0,27.6)	18.1 (12.8,23.6)	16.2 (11.4,21.6)	18.9 (13.0,25.3)	18.2 (13.0,23.8)
Samoa	Diagnosis scenario	22.4 (12.0,34.6)	27.0 (16.5,36.1)	12.5 (3.4,24.6)	6.9 (1.4,14.4)	12.5 (4.3,21.3)
Samoa	Treatment scenario	22.4 (11.9,34.7)	22.8 (12.3,33.2)	17.5 (6.7,30.3)	15.3 (8.5,22.5)	17.9 (8.6,26.4)
Sao Tome and Principe	Diagnosis scenario	6.5 (2.9,10.7)	5.4 (2.6,8.6)	7.0 (3.8,10.9)	3.6 (1.5,6.1)	6.5 (3.4,10.0)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	15.7 (10.0,22.1)	15.8 (11.4,20.7)	12.8 (8.2,18.1)	12.3 (7.9,17.6)	12.6 (8.4,17.2)
Solomon Islands	Diagnosis scenario	4.6 (-0.0,15.2)	5.4 (0.8,11.9)	5.2 (0.6,11.3)	2.6 (-0.8,9.8)	4.0 (-0.3,9.2)
Solomon Islands	Treatment scenario	29.2 (16.3,44.8)	27.5 (16.4,39.9)	21.5 (12.9,30.9)	24.4 (14.3,36.3)	21.2 (12.3,30.4)
South Africa	Diagnosis scenario	16.7 (12.1,21.8)	15.8 (11.4,20.6)	10.0 (5.6,17.0)	8.3 (5.2,11.9)	9.2 (5.6,13.3)
South Africa	Treatment scenario	17.3 (12.6,22.5)	15.2 (10.9,19.9)	8.0 (4.1,14.8)	7.3 (4.2,11.3)	7.1 (3.9,11.0)
Sri Lanka	Diagnosis scenario	10.4 (6.8,14.5)	13.5 (9.5,17.7)	12.2 (8.2,16.6)	8.3 (4.5,12.5)	5.8 (1.8,11.0)
Sri Lanka	Treatment scenario	17.1 (12.6,21.9)	20.5 (16.0,25.4)	16.2 (11.8,20.9)	12.3 (7.6,17.4)	12.1 (6.5,18.4)
St. Vincent & the Grenadines	Diagnosis scenario	3.7 (1.3,6.6)	5.5 (0.8,15.7)	5.2 (1.1,10.4)	6.6 (2.4,11.8)	2.8 (0.9,5.0)
St. Vincent & the Grenadines	Treatment scenario	7.9 (4.2,12.0)	15.0 (6.9,26.8)	11.3 (5.2,18.1)	12.0 (6.9,17.5)	5.2 (2.7,8.1)
Sudan	Diagnosis scenario	23.7 (18.0,29.8)	22.0 (17.5,27.2)	15.4 (11.2,20.3)	16.5 (9.8,24.6)	15.6 (3.0,33.1)
Sudan	Treatment scenario	31.3 (25.2,37.4)	27.6 (22.7,33.0)	25.5 (20.3,31.2)	25.3 (17.0,34.5)	15.4 (3.3,32.8)
Tanzania	Diagnosis scenario	10.3 (6.9,14.2)	8.3 (5.1,11.9)	6.6 (3.6,10.2)	3.1 (1.2,5.6)	6.3 (0.4,24.3)
Tanzania	Treatment scenario	15.9 (11.6,20.5)	13.5 (9.7,17.4)	14.6 (10.8,18.6)	16.1 (12.2,20.2)	24.3 (7.8,50.2)
Timor Leste	Diagnosis scenario	12.2 (1.9,26.4)	20.7 (11.6,30.8)	16.2 (7.3,26.8)	14.8 (6.3,24.7)	4.5 (0.6,10.6)
Timor Leste	Treatment scenario	40.8 (23.6,59.8)	37.2 (26.2,48.7)	28.7 (17.5,41.0)	22.3 (12.1,33.5)	16.7 (8.9,25.5)
Togo	Diagnosis scenario	6.9 (2.1,13.2)	6.4 (1.2,17.6)	8.2 (2.6,15.6)	3.9 (0.4,9.0)	5.7 (1.6,11.4)
Togo	Treatment scenario	20.3 (12.2,29.3)	19.6 (10.1,32.8)	20.6 (11.8,30.3)	20.5 (12.6,28.8)	14.9 (8.7,21.9)
Uganda	Diagnosis scenario	13.8 (6.0,26.1)	5.8 (1.1,13.3)	6.7 (2.2,12.2)	5.1 (1.5,10.3)	2.0 (-0.4,10.1)
Uganda	Treatment scenario	18.1 (9.2,30.1)	20.3 (12.0,29.8)	14.7 (8.7,21.3)	13.5 (8.0,19.6)	20.1 (7.9,35.9)
Vanuatu	Diagnosis scenario	6.6 (3.9,10.3)	1.6 (0.3,3.7)	2.5 (0.3,6.0)	1.4 (0.1,3.6)	4.3 (1.8,8.1)
Vanuatu	Treatment scenario	21.3 (17.1,25.8)	19.3 (14.8,24.1)	22.9 (16.8,29.2)	22.5 (17.5,27.8)	25.1 (19.4,31.5)
Zambia	Diagnosis scenario	3.9 (1.4,7.4)	5.6 (1.3,11.4)	3.6 (1.3,6.4)	1.3 (-0.1,3.6)	1.2 (-0.1,3.1)
Zambia	Treatment scenario	11.8 (7.5,16.4)	11.9 (5.8,18.8)	11.4 (6.6,16.9)	13.3 (5.7,22.5)	8.7 (3.2,15.8)

Supplementary Table 13. Mean (95% uncertainty interval) relative decline (%) in CVD risk compared to baseline by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	2.6 (0.3,6.4)	4.3 (1.3,8.1)	4.4 (1.2,8.4)	1.2 (-0.1,3.4)	1.8 (-0.0,4.6)
Afghanistan	Treatment scenario	2.1 (0.2,5.6)	4.2 (1.3,7.8)	10.0 (5.0,15.1)	4.4 (1.4,8.1)	0.0 (0.0,0.0)
Albania	Diagnosis scenario	5.8 (3.5,8.3)	7.5 (5.1,10.0)	7.3 (5.0,9.6)	8.4 (5.7,11.2)	8.4 (5.7,11.1)
Albania	Treatment scenario	17.2 (14.1,20.2)	16.6 (13.7,19.4)	16.1 (13.4,18.8)	15.2 (12.1,18.2)	12.9 (10.0,15.8)
Algeria	Diagnosis scenario	5.5 (4.1,6.8)	6.0 (4.4,7.6)	5.9 (4.2,7.5)	4.8 (3.4,6.3)	5.0 (3.5,6.5)
Algeria	Treatment scenario	10.1 (8.5,11.8)	11.4 (9.5,13.3)	9.5 (7.5,11.5)	8.6 (6.9,10.4)	8.8 (7.1,10.6)
Azerbaijan	Diagnosis scenario	4.2 (2.5,5.9)	5.8 (2.6,9.4)	4.3 (2.2,6.6)	0.9 (0.0,2.0)	3.3 (1.2,5.5)
Azerbaijan	Treatment scenario	7.7 (5.5,10.0)	8.1 (4.6,11.9)	6.8 (4.3,9.4)	7.0 (4.6,9.6)	7.3 (4.3,10.4)
Benin	Diagnosis scenario	13.3 (5.4,24.1)	10.1 (7.0,13.5)	16.9 (13.5,20.5)	11.3 (8.1,14.5)	7.3 (4.6,10.1)
Benin	Treatment scenario	17.7 (8.4,26.8)	18.3 (14.9,21.7)	17.4 (14.0,21.0)	16.2 (12.9,19.6)	16.3 (12.8,19.7)
Bhutan	Diagnosis scenario	4.6 (2.7,6.8)	4.3 (2.3,6.4)	5.9 (3.0,9.1)	2.2 (0.5,4.2)	3.9 (1.8,6.4)
Bhutan	Treatment scenario	12.4 (9.7,15.2)	11.6 (8.8,14.5)	13.3 (9.7,17.0)	11.2 (7.6,15.0)	11.8 (8.5,15.1)
Botswana	Diagnosis scenario	3.5 (0.4,10.9)	5.2 (1.7,10.5)	2.5 (0.4,5.5)	3.4 (0.7,6.7)	3.2 (0.9,5.9)
Botswana	Treatment scenario	10.2 (4.9,17.4)	7.1 (3.2,12.5)	7.1 (3.7,10.9)	11.2 (6.7,15.9)	7.2 (3.9,10.8)
Brazil	Diagnosis scenario	3.8 (3.1,4.6)	2.7 (2.1,3.4)	2.0 (1.4,2.7)	1.8 (1.3,2.4)	2.0 (1.4,2.6)
Brazil	Treatment scenario	3.3 (2.6,4.1)	2.5 (1.9,3.3)	1.5 (1.0,2.1)	1.2 (0.8,1.7)	1.1 (0.7,1.6)
Cambodia	Diagnosis scenario	8.3 (5.4,11.2)	8.9 (5.8,12.1)	7.2 (4.1,10.4)	4.9 (2.6,7.3)	4.0 (1.8,6.4)
Cambodia	Treatment scenario	13.9 (10.7,17.2)	12.0 (8.8,15.4)	12.5 (8.8,16.2)	11.2 (8.2,14.3)	8.4 (5.3,11.6)
China	Diagnosis scenario	7.8 (6.6,9.0)	7.5 (6.4,8.7)	8.7 (7.5,9.9)	6.7 (5.6,7.9)	6.1 (5.0,7.2)
China	Treatment scenario	8.7 (7.5,10.0)	8.6 (7.3,9.8)	9.2 (8.0,10.5)	7.6 (6.4,8.8)	6.0 (4.8,7.1)
Ecuador	Diagnosis scenario	5.5 (2.8,8.5)	3.7 (2.1,5.5)	2.2 (0.5,4.3)	1.6 (0.1,3.4)	3.7 (1.4,6.5)
Ecuador	Treatment scenario	9.0 (5.8,12.4)	5.5 (3.6,7.6)	4.7 (2.2,7.5)	4.3 (1.9,7.0)	2.9 (0.9,5.5)
Eritrea	Diagnosis scenario	7.9 (5.8,10.1)	11.4 (5.9,17.0)	9.7 (6.5,13.1)	6.3 (3.9,8.8)	6.0 (3.4,8.8)
Eritrea	Treatment scenario	15.6 (13.1,18.2)	14.3 (8.7,20.0)	13.1 (9.7,16.7)	11.8 (8.8,15.0)	13.1 (9.5,16.6)
Eswatini	Diagnosis scenario	5.0 (2.2,8.5)	4.8 (1.7,9.4)	3.2 (0.8,6.2)	4.3 (0.7,9.2)	3.4 (0.6,6.8)
Eswatini	Treatment scenario	11.3 (7.5,15.3)	11.4 (7.0,16.0)	10.1 (5.4,15.3)	9.2 (3.9,14.8)	7.1 (2.9,11.8)
Ethiopia	Diagnosis scenario	6.2 (3.5,9.1)	7.6 (3.7,12.0)	8.6 (4.6,13.0)	5.9 (2.5,10.0)	8.1 (4.0,12.8)
Ethiopia	Treatment scenario	17.7 (14.0,21.2)	15.4 (10.6,20.2)	17.5 (12.8,22.2)	17.0 (12.2,21.5)	16.6 (11.7,21.3)
Gambia	Diagnosis scenario	9.8 (6.6,13.1)	8.3 (4.9,11.8)	8.6 (5.6,11.9)	8.4 (4.4,13.0)	4.5 (2.0,7.4)
Gambia	Treatment scenario	15.6 (12.0,19.2)	14.0 (9.8,18.0)	15.3 (11.7,19.0)	13.4 (8.8,18.3)	13.7 (9.6,17.9)
Ghana	Diagnosis scenario	11.0 (6.7,15.8)	14.9 (10.2,19.5)	13.0 (8.7,17.4)	9.3 (5.7,13.3)	9.8 (6.2,13.8)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Ghana	Treatment scenario	18.2 (13.5,22.4)	17.6 (12.8,22.1)	16.7 (12.3,20.9)	12.5 (8.5,16.6)	13.1 (9.2,17.1)
India	Diagnosis scenario	9.9 (9.2,10.7)	8.6 (7.9,9.3)	7.4 (6.7,8.1)	7.4 (6.7,8.1)	6.7 (6.1,7.3)
India	Treatment scenario	15.1 (14.3,15.9)	14.2 (13.4,14.9)	12.9 (12.1,13.7)	12.2 (11.4,13.0)	10.6 (9.9,11.2)
Indonesia	Diagnosis scenario	3.4 (2.7,4.1)	4.3 (3.6,5.1)	3.8 (3.1,4.6)	4.0 (3.3,4.8)	4.5 (3.6,5.3)
Indonesia	Treatment scenario	18.1 (16.9,19.3)	17.1 (16.0,18.3)	16.7 (15.5,18.0)	15.6 (14.4,16.8)	14.5 (13.4,15.6)
Jordan	Diagnosis scenario	2.0 (0.3,4.7)	0.8 (0.0,2.1)	0.1 (-0.1,0.7)	3.2 (1.2,5.5)	2.9 (1.4,4.6)
Jordan	Treatment scenario	3.3 (1.2,6.1)	0.0 (0.0,0.0)	1.3 (0.1,3.0)	3.5 (1.4,5.8)	3.1 (1.5,5.0)
Kenya	Diagnosis scenario	5.8 (3.2,8.7)	5.5 (2.8,8.6)	6.3 (3.0,10.9)	5.0 (2.0,9.4)	2.7 (0.4,6.0)
Kenya	Treatment scenario	19.1 (15.4,22.8)	17.6 (14.0,21.1)	16.1 (11.6,20.5)	17.4 (12.7,21.8)	14.2 (9.0,18.9)
Kiribati	Diagnosis scenario	4.8 (-0.3,13.8)	8.1 (-0.4,22.6)	1.6 (-0.5,9.7)	3.1 (-1.1,11.8)	2.4 (-1.0,11.9)
Kiribati	Treatment scenario	15.6 (6.2,23.7)	16.8 (3.7,31.3)	16.5 (4.1,25.8)	16.5 (6.2,25.7)	16.9 (5.1,28.5)
Kyrgyzstan	Diagnosis scenario	6.5 (4.2,8.9)	4.6 (2.7,6.6)	3.5 (1.6,5.8)	4.3 (2.3,6.4)	4.0 (1.8,6.9)
Kyrgyzstan	Treatment scenario	12.6 (9.9,15.3)	9.2 (6.7,11.7)	13.6 (9.5,18.0)	12.8 (9.9,15.7)	12.1 (8.7,15.5)
Laos	Diagnosis scenario	10.2 (4.1,17.5)	8.4 (2.7,16.0)	5.9 (2.7,9.5)	4.0 (1.6,6.6)	7.4 (3.3,12.2)
Laos	Treatment scenario	15.6 (8.9,22.8)	12.0 (5.5,19.1)	14.2 (9.6,19.1)	9.1 (5.7,12.7)	12.4 (7.6,17.4)
Lesotho	Diagnosis scenario	8.3 (4.3,12.6)	5.9 (2.9,9.0)	10.2 (5.6,15.2)	5.1 (1.8,9.1)	4.8 (2.3,7.4)
Lesotho	Treatment scenario	8.7 (4.4,13.4)	8.2 (4.6,11.9)	12.3 (7.4,17.4)	4.8 (1.5,8.7)	4.9 (2.3,7.8)
Moldova	Diagnosis scenario	3.6 (2.4,5.0)	3.0 (1.8,4.4)	3.1 (1.8,4.6)	4.2 (2.2,6.5)	3.6 (2.1,5.3)
Moldova	Treatment scenario	11.5 (9.6,13.4)	10.1 (8.0,12.3)	9.7 (7.5,12.0)	9.1 (6.4,11.9)	10.2 (8.0,12.5)
Morocco	Diagnosis scenario	7.1 (5.9,8.4)	6.7 (4.4,9.2)	5.4 (3.4,7.4)	5.5 (3.2,7.8)	6.4 (4.7,8.1)
Morocco	Treatment scenario	11.2 (9.8,12.6)	11.7 (9.1,14.4)	11.1 (8.6,13.6)	12.8 (9.9,15.7)	10.8 (8.9,12.7)
Myanmar	Diagnosis scenario	4.1 (2.2,6.2)	4.6 (2.1,8.8)	3.3 (1.3,6.4)	4.3 (2.3,6.9)	3.1 (1.4,5.3)
Myanmar	Treatment scenario	15.5 (11.9,19.5)	12.9 (9.4,17.1)	11.2 (7.8,15.2)	10.7 (8.0,13.8)	9.5 (6.4,13.3)
Namibia	Diagnosis scenario	10.8 (8.6,13.1)	7.9 (6.0,10.0)	6.3 (4.5,8.2)	6.7 (4.7,9.0)	1.8 (0.7,3.0)
Namibia	Treatment scenario	11.9 (9.6,14.2)	10.0 (7.8,12.2)	6.1 (4.2,8.1)	6.6 (4.6,8.8)	2.4 (1.1,3.9)
Niger	Diagnosis scenario	15.2 (12.0,18.5)	0.0 (0.0,0.0)	7.8 (4.8,10.7)	8.4 (5.8,11.1)	10.6 (7.5,13.8)
Niger	Treatment scenario	20.6 (17.4,23.7)	22.2 (19.2,25.2)	22.2 (18.8,25.6)	20.9 (17.9,23.9)	20.2 (16.8,23.5)
Russian Federation	Diagnosis scenario	2.8 (0.8,5.6)	0.0 (0.0,0.0)	0.3 (-0.1,1.1)	5.8 (1.3,15.5)	0.4 (-0.0,1.6)
Russian Federation	Treatment scenario	7.2 (4.0,10.8)	3.3 (1.0,7.3)	1.1 (0.2,2.2)	5.2 (1.2,14.8)	0.2 (-0.1,0.8)
Rwanda	Diagnosis scenario	9.0 (6.2,11.7)	12.3 (9.0,15.6)	4.3 (2.1,6.5)	1.5 (0.0,3.0)	6.1 (3.7,8.6)
Rwanda	Treatment scenario	19.3 (16.3,22.3)	19.5 (16.2,22.8)	19.7 (16.6,22.8)	19.5 (16.1,22.9)	19.5 (16.4,22.6)
Samoa	Diagnosis scenario	15.5 (10.0,21.1)	22.3 (15.3,27.7)	9.3 (4.0,15.1)	7.7 (2.1,13.9)	10.1 (4.9,15.8)
Samoa	Treatment scenario	15.7 (9.9,21.5)	18.8 (11.4,25.4)	13.7 (7.6,20.1)	16.9 (10.4,23.2)	14.8 (9.2,20.4)
Sao Tome and Principe	Diagnosis scenario	6.8 (4.1,9.5)	6.2 (3.9,8.6)	9.1 (6.4,11.8)	4.7 (2.3,7.1)	8.2 (5.7,10.8)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	15.1 (11.9,18.3)	16.8 (13.7,20.0)	15.8 (12.7,19.0)	14.9 (11.4,18.5)	14.2 (11.3,17.2)
Solomon Islands	Diagnosis scenario	3.0 (0.4,6.7)	3.9 (1.1,7.2)	3.5 (0.8,6.6)	1.7 (-0.3,4.5)	2.1 (-0.1,4.8)
Solomon Islands	Treatment scenario	17.7 (12.7,22.4)	17.9 (13.3,22.6)	16.4 (11.6,21.0)	17.8 (12.6,22.9)	13.4 (8.0,18.9)
South Africa	Diagnosis scenario	9.6 (7.8,11.4)	8.6 (7.0,10.1)	5.8 (4.1,7.6)	4.8 (3.4,6.3)	5.0 (3.5,6.5)
South Africa	Treatment scenario	9.9 (8.1,11.9)	8.2 (6.7,9.8)	4.5 (3.1,6.2)	4.0 (2.7,5.4)	3.8 (2.5,5.2)
Sri Lanka	Diagnosis scenario	6.0 (4.3,7.7)	7.1 (5.5,8.7)	7.6 (5.7,9.6)	5.2 (3.2,7.4)	3.3 (1.5,5.3)
Sri Lanka	Treatment scenario	9.9 (7.9,12.0)	10.8 (9.0,12.6)	10.3 (8.3,12.3)	7.5 (5.2,10.0)	7.3 (4.6,10.2)
St. Vincent & the Grenadines	Diagnosis scenario	2.3 (0.9,4.0)	3.0 (1.0,5.7)	3.6 (1.1,6.5)	4.8 (2.1,7.7)	2.2 (0.9,4.3)
St. Vincent & the Grenadines	Treatment scenario	4.8 (2.8,7.1)	8.4 (5.1,11.8)	7.7 (4.2,11.5)	8.9 (5.4,12.3)	4.3 (2.3,7.1)
Sudan	Diagnosis scenario	12.2 (9.8,14.7)	10.8 (9.3,12.5)	8.1 (6.5,9.8)	8.2 (5.6,10.9)	6.0 (1.7,10.7)
Sudan	Treatment scenario	15.8 (13.4,18.2)	13.3 (11.7,15.0)	13.0 (11.1,14.9)	12.3 (9.3,15.3)	6.2 (1.9,10.9)
Tanzania	Diagnosis scenario	12.4 (9.1,15.6)	10.3 (7.0,13.9)	8.5 (5.2,12.4)	4.2 (1.9,6.9)	4.9 (1.0,12.2)
Tanzania	Treatment scenario	18.4 (15.1,21.7)	16.3 (12.7,20.0)	18.5 (14.6,22.5)	20.2 (16.4,23.8)	20.1 (12.9,29.1)
Timor Leste	Diagnosis scenario	5.4 (2.2,8.7)	8.2 (5.5,11.0)	8.2 (4.9,11.5)	8.3 (4.8,11.8)	3.4 (1.2,5.7)
Timor Leste	Treatment scenario	18.1 (13.8,22.4)	15.3 (12.2,18.5)	14.2 (10.5,17.9)	12.5 (8.7,16.4)	11.6 (7.8,15.3)
Togo	Diagnosis scenario	6.1 (2.9,9.6)	5.7 (2.1,10.2)	6.7 (3.4,10.5)	3.9 (0.8,8.2)	5.5 (2.4,8.8)
Togo	Treatment scenario	17.7 (13.3,22.1)	18.2 (13.0,23.4)	16.2 (11.8,20.5)	18.5 (13.0,23.9)	14.1 (10.0,18.2)
Uganda	Diagnosis scenario	13.0 (8.6,17.6)	5.3 (1.9,9.6)	6.8 (3.1,11.0)	6.7 (2.8,11.9)	2.1 (-0.3,5.7)
Uganda	Treatment scenario	16.9 (12.4,21.4)	18.2 (13.2,23.0)	15.4 (10.7,20.1)	17.0 (11.9,22.1)	15.7 (9.3,23.2)
Vanuatu	Diagnosis scenario	6.2 (4.2,8.3)	1.7 (0.5,3.2)	2.1 (0.5,4.2)	1.2 (0.2,2.4)	3.4 (1.9,5.1)
Vanuatu	Treatment scenario	19.6 (17.1,22.0)	19.3 (16.5,22.2)	19.3 (15.9,22.6)	20.1 (17.3,22.9)	19.4 (16.9,21.8)
Zambia	Diagnosis scenario	5.4 (2.6,8.7)	6.5 (2.2,11.4)	6.2 (2.5,10.6)	2.0 (0.1,5.4)	2.2 (0.0,4.9)
Zambia	Treatment scenario	15.4 (11.5,19.3)	13.5 (7.5,19.8)	15.7 (10.7,20.7)	14.1 (9.0,19.4)	12.3 (6.7,18.2)

By Baseline Cascade Gap

Supplementary Table 14. Cardiovascular disease cases averted per 1,000 people living with hypertension compared to baseline across wealth quintiles, by modelled scenario (either Diagnosis or Treatment scenario) and baseline cascade gap

Baseline Cascade Gap Tercile	Scenario	Q1	Q2	Q3	Q4	Q5
Low Gap	Diagnosis scenario	7.1	6.2	6.2	4.7	6.0
Low Gap	Treatment scenario	14.4	13.5	14.1	13.5	13.9
Mid Gap	Diagnosis scenario	14.4	11.1	12.3	9.1	8.7
Mid Gap	Treatment scenario	21.2	17.0	17.6	13.8	11.7
High Gap	Diagnosis scenario	12.8	9.3	8.2	9.8	7.6
High Gap	Treatment scenario	22.1	17.1	14.7	15.0	11.9

Supplementary Table 15. Percent of total estimated cardiovascular disease cases averted compared to baseline across wealth quintiles, by modelled scenario (either Diagnosis or Treatment scenario) and baseline cascade gap

Baseline Cascade Gap Tercile	Scenario	Q1	Q2	Q3	Q4	Q5
Low Gap	Diagnosis scenario	25.3	18.8	19.5	15.3	21.1
Low Gap	Treatment scenario	22.6	17.8	19.5	19.0	21.2
Mid Gap	Diagnosis scenario	27.8	19.3	22.3	15.6	15.0
Mid Gap	Treatment scenario	28.1	20.2	21.8	16.1	13.8
High Gap	Diagnosis scenario	23.0	18.3	17.5	24.1	17.1
High Gap	Treatment scenario	23.6	20.1	18.6	21.9	15.9

By World Health Organization (WHO) Region

Supplementary Table 16. Cardiovascular disease cases averted per 1,000 people living with hypertension compared to baseline across wealth quintiles, by modelled scenario (either Diagnosis or Treatment scenario) and WHO region

WHO Region	Scenario	Q1	Q2	Q3	Q4	Q5
Africa	Diagnosis scenario	10.7	10.0	8.6	6.2	6.5
Africa	Treatment scenario	16.7	15.7	13.1	11.7	12.3
Americas	Diagnosis scenario	4.1	3.0	2.0	1.7	1.9
Americas	Treatment scenario	3.9	2.9	1.6	1.3	1.2
Eastern Mediterranean	Diagnosis scenario	11.5	12.9	9.2	8.9	9.2
Eastern Mediterranean	Treatment scenario	15.6	16.9	18.1	16.8	9.9
Europe	Diagnosis scenario	8.4	0.6	1.3	8.2	1.3
Europe	Treatment scenario	21.3	9.0	4.3	8.7	2.1
South-East Asia	Diagnosis scenario	12.8	11.8	10.2	10.1	8.9
South-East Asia	Treatment scenario	30.4	26.2	24.1	21.2	17.6
Western Pacific	Diagnosis scenario	17.2	12.8	14.8	10.7	9.9
Western Pacific	Treatment scenario	19.5	15.0	15.9	11.9	10.0

Supplementary Table 17. Percent of total estimated cardiovascular disease cases averted compared to baseline across wealth quintiles, by modelled scenario (either Diagnosis or Treatment scenario) and WHO region

WHO Region	Scenario	Q1	Q2	Q3	Q4	Q5
Africa	Diagnosis scenario	25.7	21.7	20.3	15.2	17.1
Africa	Treatment scenario	24.2	20.5	18.6	17.2	19.5
Americas	Diagnosis scenario	32.3	25.3	16.0	13.0	13.4
Americas	Treatment scenario	35.5	28.3	15.6	11.1	9.5
Eastern Mediterranean	Diagnosis scenario	22.2	22.5	18.0	18.0	19.2
Eastern Mediterranean	Treatment scenario	19.9	19.7	23.7	22.8	13.9
Europe	Diagnosis scenario	42.2	3.2	6.4	43.7	4.4
Europe	Treatment scenario	46.9	20.7	9.1	20.1	3.2
South-East Asia	Diagnosis scenario	19.9	19.9	19.4	21.8	19.0
South-East Asia	Treatment scenario	21.4	20.0	20.9	20.7	17.1
Western Pacific	Diagnosis scenario	28.8	18.7	22.6	15.3	14.6
Western Pacific	Treatment scenario	29.6	19.8	22.0	15.4	13.3

By Sensitivity Analysis

Supplementary Table 18. Performance-based targets sensitivity analysis: Mean (95% uncertainty interval) 10-year CVD risk by country and wealth quintile in Diagnosis and Treatment scenarios

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	20.3 (18.0,22.6)	20.4 (16.0,24.9)	21.4 (18.8,24.1)	21.6 (18.8,24.5)	23.2 (20.2,26.3)
Afghanistan	Treatment scenario	20.4 (18.1,22.8)	20.5 (16.1,25.0)	20.1 (17.4,22.8)	20.9 (18.0,23.7)	23.7 (20.6,26.7)
Albania	Diagnosis scenario	4.6 (4.1,5.1)	4.7 (4.2,5.3)	5.2 (4.6,5.8)	5.1 (4.5,5.8)	5.2 (4.5,5.8)
Albania	Treatment scenario	4.5 (4.0,5.0)	4.7 (4.2,5.3)	5.2 (4.6,5.8)	5.2 (4.6,5.8)	5.3 (4.6,6.0)
Algeria	Diagnosis scenario	8.2 (7.6,8.9)	8.6 (7.9,9.4)	8.9 (8.2,9.6)	8.0 (7.4,8.6)	8.6 (7.9,9.2)
Algeria	Treatment scenario	8.1 (7.5,8.7)	8.4 (7.7,9.2)	8.8 (8.2,9.5)	8.0 (7.3,8.6)	8.5 (7.9,9.1)
Azerbaijan	Diagnosis scenario	15.3 (13.5,17.1)	16.1 (12.5,19.8)	15.7 (13.8,17.7)	15.1 (13.2,16.9)	12.9 (10.3,15.6)
Azerbaijan	Treatment scenario	14.7 (12.9,16.4)	15.7 (12.1,19.3)	15.3 (13.4,17.2)	14.1 (12.4,15.9)	12.4 (9.9,14.9)
Benin	Diagnosis scenario	13.9 (11.3,17.0)	13.4 (11.3,15.5)	11.1 (9.6,12.7)	12.8 (11.0,14.6)	13.4 (11.7,15.1)
Benin	Treatment scenario	14.5 (11.8,17.5)	13.4 (11.4,15.5)	11.9 (10.3,13.5)	13.2 (11.4,15.0)	13.5 (11.8,15.1)
Bhutan	Diagnosis scenario	12.2 (11.3,13.2)	11.8 (10.7,12.9)	12.1 (10.9,13.2)	11.6 (10.3,13.0)	11.8 (10.3,13.2)
Bhutan	Treatment scenario	11.7 (10.8,12.7)	11.3 (10.2,12.4)	11.5 (10.4,12.7)	11.1 (9.8,12.5)	11.3 (9.8,12.7)
Botswana	Diagnosis scenario	10.5 (8.7,12.3)	8.8 (6.7,10.9)	8.8 (6.5,11.1)	9.3 (6.1,12.4)	7.5 (5.6,9.4)
Botswana	Treatment scenario	9.7 (8.1,11.5)	8.6 (6.5,10.8)	8.3 (6.2,10.6)	8.4 (5.6,11.4)	7.1 (5.4,8.9)
Brazil	Diagnosis scenario	10.5 (10.1,10.9)	10.1 (9.6,10.6)	9.7 (9.2,10.2)	8.7 (8.3,9.0)	8.6 (8.2,9.0)
Brazil	Treatment scenario	10.5 (10.1,10.9)	10.1 (9.6,10.6)	9.7 (9.2,10.3)	8.7 (8.4,9.1)	8.7 (8.3,9.1)
Cambodia	Diagnosis scenario	14.3 (12.5,16.1)	15.2 (13.6,16.9)	15.3 (13.5,17.1)	17.3 (15.6,19.0)	15.7 (14.0,17.5)
Cambodia	Treatment scenario	13.3 (11.7,15.1)	14.7 (13.0,16.3)	14.3 (12.7,16.1)	16.0 (14.3,17.7)	15.0 (13.3,16.7)
China	Diagnosis scenario	22.9 (21.2,24.7)	19.0 (17.6,20.4)	18.9 (17.2,20.7)	18.4 (16.8,20.0)	18.7 (17.0,20.3)
China	Treatment scenario	23.2 (21.5,25.0)	19.2 (17.8,20.6)	19.2 (17.4,21.0)	18.6 (17.1,20.2)	19.1 (17.4,20.7)
Ecuador	Diagnosis scenario	7.7 (6.6,8.9)	7.3 (6.6,7.9)	6.9 (5.9,8.0)	6.8 (5.8,7.8)	7.6 (6.7,8.5)
Ecuador	Treatment scenario	7.4 (6.3,8.6)	7.1 (6.5,7.8)	6.7 (5.7,7.7)	6.6 (5.6,7.6)	7.6 (6.7,8.5)
Eritrea	Diagnosis scenario	17.8 (15.7,20.0)	16.7 (12.5,20.9)	14.6 (12.4,16.7)	15.6 (13.1,18.1)	16.7 (13.7,19.8)
Eritrea	Treatment scenario	17.1 (15.0,19.2)	16.7 (12.6,21.0)	14.5 (12.4,16.7)	15.3 (12.8,17.8)	16.2 (13.2,19.2)
Eswatini	Diagnosis scenario	13.5 (11.0,16.0)	15.8 (12.0,19.9)	14.4 (9.3,19.5)	13.5 (10.4,16.8)	11.3 (7.6,15.0)
Eswatini	Treatment scenario	12.7 (10.3,15.1)	14.8 (11.1,18.8)	13.1 (8.9,17.9)	13.1 (10.0,16.4)	10.8 (7.3,14.5)
Ethiopia	Diagnosis scenario	10.4 (8.6,12.2)	10.6 (8.4,12.9)	11.0 (9.2,12.8)	8.4 (6.6,10.1)	9.1 (7.5,10.7)
Ethiopia	Treatment scenario	10.2 (8.4,12.0)	10.7 (8.4,13.0)	11.0 (9.2,12.7)	8.2 (6.5,10.0)	9.1 (7.5,10.7)
Gambia	Diagnosis scenario	11.8 (10.2,13.3)	11.4 (9.4,13.5)	11.6 (9.7,13.5)	9.8 (8.4,11.2)	12.9 (11.1,14.7)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Gambia	Treatment scenario	12.0 (10.5,13.6)	11.7 (9.7,13.8)	11.8 (9.9,13.7)	10.0 (8.6,11.4)	12.9 (11.1,14.7)
Ghana	Diagnosis scenario	14.0 (11.9,16.2)	14.6 (12.3,16.8)	12.2 (10.7,13.6)	14.1 (12.1,16.1)	13.0 (11.2,14.9)
Ghana	Treatment scenario	14.1 (12.0,16.3)	15.1 (12.8,17.5)	12.6 (11.1,14.0)	14.6 (12.6,16.7)	13.5 (11.6,15.3)
India	Diagnosis scenario	13.2 (12.7,13.7)	13.0 (12.6,13.4)	13.2 (12.8,13.6)	13.1 (12.7,13.5)	12.4 (12.0,12.7)
India	Treatment scenario	12.9 (12.4,13.4)	12.6 (12.2,13.0)	12.8 (12.4,13.2)	12.9 (12.5,13.3)	12.2 (11.9,12.6)
Indonesia	Diagnosis scenario	27.2 (25.5,28.9)	25.0 (24.0,26.0)	25.4 (24.5,26.4)	23.1 (22.5,23.7)	21.8 (20.7,22.8)
Indonesia	Treatment scenario	26.2 (24.6,27.9)	24.4 (23.4,25.4)	24.9 (23.9,25.9)	22.8 (22.2,23.4)	21.7 (20.6,22.7)
Jordan	Diagnosis scenario	10.5 (9.5,11.5)	10.0 (8.7,11.3)	9.8 (8.9,10.8)	9.0 (7.4,10.6)	10.5 (9.1,11.9)
Jordan	Treatment scenario	10.4 (9.3,11.4)	10.1 (8.8,11.3)	9.7 (8.8,10.7)	9.0 (7.4,10.6)	10.4 (9.1,11.8)
Kenya	Diagnosis scenario	7.0 (6.0,8.1)	6.8 (5.9,7.8)	7.1 (6.2,8.0)	5.9 (5.1,6.6)	6.6 (4.7,8.5)
Kenya	Treatment scenario	6.4 (5.5,7.4)	6.3 (5.4,7.3)	6.7 (5.9,7.6)	5.4 (4.7,6.2)	6.1 (4.3,7.9)
Kiribati	Diagnosis scenario	9.0 (6.5,11.6)	12.5 (9.7,15.2)	11.7 (9.4,14.0)	12.6 (9.1,16.3)	15.7 (8.2,23.3)
Kiribati	Treatment scenario	8.8 (6.3,11.4)	12.4 (9.5,15.1)	11.2 (8.7,13.6)	12.1 (8.5,15.8)	15.2 (7.8,22.8)
Kyrgyzstan	Diagnosis scenario	18.0 (15.7,20.2)	21.0 (18.6,23.6)	19.2 (16.8,21.6)	17.3 (14.9,19.7)	17.4 (15.0,19.8)
Kyrgyzstan	Treatment scenario	17.5 (15.3,19.8)	20.8 (18.3,23.3)	18.1 (15.8,20.5)	16.6 (14.2,18.9)	16.7 (14.4,19.1)
Laos	Diagnosis scenario	17.4 (13.4,21.5)	19.0 (16.1,22.1)	17.0 (14.3,19.8)	17.8 (14.7,21.0)	16.6 (13.3,20.1)
Laos	Treatment scenario	17.1 (13.1,21.1)	18.9 (15.9,22.1)	16.2 (13.6,19.0)	17.6 (14.4,20.8)	16.3 (13.1,19.8)
Lesotho	Diagnosis scenario	7.2 (5.8,8.7)	7.3 (5.7,9.0)	8.3 (6.7,10.1)	7.3 (5.5,9.1)	7.4 (6.1,8.8)
Lesotho	Treatment scenario	7.2 (5.7,8.7)	7.1 (5.6,8.7)	8.2 (6.5,9.9)	7.3 (5.5,9.2)	7.4 (6.1,8.7)
Moldova	Diagnosis scenario	19.4 (18.1,20.8)	21.2 (19.7,22.8)	19.3 (17.7,20.9)	17.3 (15.3,19.3)	16.8 (15.1,18.4)
Moldova	Treatment scenario	18.7 (17.3,20.1)	20.6 (19.0,22.1)	18.8 (17.2,20.4)	17.0 (15.1,19.0)	16.3 (14.7,18.0)
Morocco	Diagnosis scenario	11.6 (10.8,12.4)	11.7 (10.0,13.5)	11.4 (9.9,12.9)	12.2 (10.2,14.2)	11.4 (10.3,12.5)
Morocco	Treatment scenario	11.5 (10.6,12.3)	11.5 (9.8,13.2)	11.2 (9.7,12.6)	11.8 (9.9,13.7)	11.2 (10.1,12.3)
Myanmar	Diagnosis scenario	14.5 (12.6,16.4)	13.6 (12.7,14.6)	12.3 (11.3,13.2)	12.3 (11.1,13.5)	11.7 (10.2,13.3)
Myanmar	Treatment scenario	13.4 (11.8,15.2)	13.1 (12.1,14.2)	11.8 (10.8,12.7)	12.0 (10.8,13.1)	11.4 (9.9,13.0)
Namibia	Diagnosis scenario	6.8 (5.9,7.7)	6.9 (6.2,7.7)	7.7 (6.8,8.7)	7.8 (6.6,9.0)	8.2 (7.0,9.5)
Namibia	Treatment scenario	6.7 (5.8,7.5)	6.8 (6.1,7.5)	7.7 (6.8,8.7)	7.8 (6.6,9.0)	8.2 (6.9,9.5)
Niger	Diagnosis scenario	8.9 (7.7,10.2)	10.0 (8.7,11.2)	9.0 (7.6,10.3)	9.8 (8.5,11.2)	9.8 (8.2,11.3)
Niger	Treatment scenario	9.2 (8.0,10.5)	9.1 (7.9,10.3)	8.7 (7.4,10.0)	9.7 (8.4,11.0)	9.8 (8.2,11.4)
Russian Federation	Diagnosis scenario	33.7 (29.8,37.7)	32.9 (28.8,37.0)	32.8 (28.6,36.9)	21.3 (13.3,29.2)	26.8 (20.8,32.8)
Russian Federation	Treatment scenario	32.4 (28.6,36.4)	32.0 (27.8,36.3)	32.6 (28.4,36.7)	21.3 (13.4,29.2)	26.8 (20.8,32.9)
Rwanda	Diagnosis scenario	10.0 (8.6,11.5)	8.2 (6.8,9.6)	7.7 (6.4,9.0)	9.0 (7.6,10.5)	8.4 (7.2,9.5)
Rwanda	Treatment scenario	10.0 (8.5,11.5)	8.3 (6.9,9.7)	7.4 (6.2,8.7)	8.5 (7.1,9.9)	8.1 (7.0,9.3)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Samoa	Diagnosis scenario	12.8 (11.1,14.8)	10.1 (8.3,12.0)	10.8 (8.4,13.2)	8.2 (6.2,10.3)	11.4 (9.4,13.3)
Samoa	Treatment scenario	13.7 (11.9,15.7)	11.1 (9.3,12.9)	11.2 (8.7,13.7)	8.2 (6.1,10.3)	11.7 (9.8,13.5)
Sao Tome and Principe	Diagnosis scenario	9.4 (8.6,10.3)	8.9 (8.1,9.7)	7.5 (6.8,8.3)	8.7 (7.9,9.4)	8.8 (8.2,9.4)
Sao Tome and Principe	Treatment scenario	9.5 (8.7,10.4)	8.9 (8.1,9.6)	7.6 (6.9,8.4)	8.6 (7.9,9.4)	9.0 (8.4,9.6)
Solomon Islands	Diagnosis scenario	15.1 (11.7,18.6)	14.4 (11.3,17.6)	12.2 (9.8,14.6)	12.7 (10.0,15.3)	14.6 (12.4,16.7)
Solomon Islands	Treatment scenario	13.7 (10.6,17.0)	13.0 (10.2,16.0)	11.1 (9.0,13.4)	11.3 (8.9,13.8)	13.5 (11.4,15.6)
South Africa	Diagnosis scenario	16.4 (14.5,18.2)	17.0 (15.4,18.5)	17.2 (15.3,19.2)	18.5 (16.5,20.6)	19.6 (18.0,21.3)
South Africa	Treatment scenario	16.3 (14.5,18.2)	17.0 (15.5,18.6)	17.4 (15.5,19.4)	18.6 (16.6,20.7)	19.8 (18.2,21.5)
Sri Lanka	Diagnosis scenario	16.8 (15.5,18.0)	16.5 (15.5,17.5)	14.6 (13.3,16.0)	15.0 (13.7,16.3)	15.5 (14.0,17.0)
Sri Lanka	Treatment scenario	16.1 (14.9,17.4)	15.8 (14.8,16.8)	14.2 (12.9,15.6)	14.6 (13.4,15.8)	14.8 (13.4,16.3)
St. Vincent & the Grenadines	Diagnosis scenario	17.1 (15.4,18.9)	15.5 (12.7,18.3)	12.9 (10.9,15.0)	13.1 (11.6,14.6)	12.3 (11.1,13.5)
St. Vincent & the Grenadines	Treatment scenario	16.7 (15.0,18.5)	14.5 (11.9,17.3)	12.3 (10.3,14.4)	12.5 (11.0,14.1)	12.1 (10.8,13.3)
Sudan	Diagnosis scenario	18.0 (16.4,19.5)	18.8 (17.6,19.9)	18.1 (16.9,19.2)	19.1 (17.2,21.0)	23.3 (20.5,26.2)
Sudan	Treatment scenario	17.8 (16.3,19.4)	18.8 (17.7,20.0)	17.7 (16.6,18.9)	18.8 (17.0,20.7)	23.8 (21.0,26.7)
Tanzania	Diagnosis scenario	7.7 (6.7,8.6)	7.3 (6.4,8.1)	7.7 (6.8,8.6)	7.4 (6.6,8.2)	10.5 (5.9,15.4)
Tanzania	Treatment scenario	7.9 (6.9,8.8)	7.4 (6.6,8.3)	7.7 (6.8,8.6)	7.1 (6.3,7.9)	10.2 (5.8,15.0)
Timor Leste	Diagnosis scenario	20.6 (15.8,25.4)	21.9 (19.1,24.8)	19.6 (16.3,22.9)	15.7 (12.8,18.7)	15.2 (12.3,18.1)
Timor Leste	Treatment scenario	18.8 (14.4,23.4)	21.2 (18.4,24.1)	19.0 (15.8,22.3)	15.6 (12.7,18.5)	14.7 (11.8,17.6)
Togo	Diagnosis scenario	11.7 (8.8,14.6)	10.0 (7.3,12.7)	11.8 (9.1,14.5)	10.3 (8.8,11.9)	10.2 (8.3,12.1)
Togo	Treatment scenario	11.5 (8.7,14.4)	9.8 (7.2,12.6)	11.8 (9.1,14.5)	9.9 (8.4,11.5)	10.2 (8.3,12.1)
Uganda	Diagnosis scenario	9.7 (7.0,12.7)	10.8 (8.7,13.0)	9.0 (7.2,10.9)	7.5 (6.0,8.9)	11.0 (8.1,13.9)
Uganda	Treatment scenario	10.1 (7.2,13.1)	10.5 (8.4,12.7)	9.1 (7.2,11.0)	7.4 (6.0,8.9)	10.7 (7.8,13.6)
Vanuatu	Diagnosis scenario	10.2 (9.3,11.2)	9.6 (8.6,10.6)	11.3 (10.0,12.7)	10.5 (9.3,11.8)	12.1 (10.6,13.6)
Vanuatu	Treatment scenario	9.9 (9.0,10.9)	9.1 (8.1,10.1)	10.7 (9.4,12.0)	9.8 (8.6,11.0)	11.5 (10.0,13.0)
Zambia	Diagnosis scenario	7.7 (6.2,9.1)	8.1 (6.4,9.8)	6.4 (5.2,7.6)	7.9 (6.0,9.7)	8.2 (6.1,10.4)
Zambia	Treatment scenario	7.2 (5.8,8.7)	7.8 (6.2,9.6)	6.0 (4.9,7.2)	7.2 (5.5,9.0)	7.9 (5.7,10.0)

Supplementary Table 19. Performance-based targets sensitivity analysis: Absolute (percentage point) difference in mean 10-year cardiovascular disease risk comparing the bottom (Q1) and top (Q5) wealth quintiles by country and modelled scenario, either Baseline, Diagnosis or Treatment scenario

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Afghanistan	Baseline	-2.7
Afghanistan	Diagnosis scenario	-3.0
Afghanistan	Treatment scenario	-3.3
Albania	Baseline	-0.6
Albania	Diagnosis scenario	-0.6
Albania	Treatment scenario	-0.8
Algeria	Baseline	-0.3
Algeria	Diagnosis scenario	-0.3
Algeria	Treatment scenario	-0.4
Azerbaijan	Baseline	2.5
Azerbaijan	Diagnosis scenario	2.4
Azerbaijan	Treatment scenario	2.3
Benin	Baseline	1.3
Benin	Diagnosis scenario	0.5
Benin	Treatment scenario	1.1
Bhutan	Baseline	0.6
Bhutan	Diagnosis scenario	0.5
Bhutan	Treatment scenario	0.5
Botswana	Baseline	3.1
Botswana	Diagnosis scenario	3.0
Botswana	Treatment scenario	2.6
Brazil	Baseline	2.1
Brazil	Diagnosis scenario	1.9
Brazil	Treatment scenario	1.8
Cambodia	Baseline	-0.8
Cambodia	Diagnosis scenario	-1.4
Cambodia	Treatment scenario	-1.6
China	Baseline	4.8
China	Diagnosis scenario	4.3
China	Treatment scenario	4.2
Ecuador	Baseline	0.3

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Ecuador	Diagnosis scenario	0.1
Ecuador	Treatment scenario	-0.2
Eritrea	Baseline	1.4
Eritrea	Diagnosis scenario	1.1
Eritrea	Treatment scenario	0.9
Eswatini	Baseline	2.5
Eswatini	Diagnosis scenario	2.3
Eswatini	Treatment scenario	1.9
Ethiopia	Baseline	1.3
Ethiopia	Diagnosis scenario	1.3
Ethiopia	Treatment scenario	1.1
Gambia	Baseline	-0.7
Gambia	Diagnosis scenario	-1.1
Gambia	Treatment scenario	-0.9
Ghana	Baseline	1.4
Ghana	Diagnosis scenario	1.0
Ghana	Treatment scenario	0.7
India	Baseline	1.4
India	Diagnosis scenario	0.9
India	Treatment scenario	0.7
Indonesia	Baseline	5.6
Indonesia	Diagnosis scenario	5.5
Indonesia	Treatment scenario	4.6
Jordan	Baseline	-0.0
Jordan	Diagnosis scenario	0.0
Jordan	Treatment scenario	-0.0
Kenya	Baseline	0.7
Kenya	Diagnosis scenario	0.4
Kenya	Treatment scenario	0.3
Kiribati	Baseline	-6.5
Kiribati	Diagnosis scenario	-6.7
Kiribati	Treatment scenario	-6.4
Kyrgyzstan	Baseline	0.9
Kyrgyzstan	Diagnosis scenario	0.5

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Kyrgyzstan	Treatment scenario	0.8
Laos	Baseline	1.4
Laos	Diagnosis scenario	0.8
Laos	Treatment scenario	0.7
Lesotho	Baseline	0.2
Lesotho	Diagnosis scenario	-0.2
Lesotho	Treatment scenario	-0.2
Moldova	Baseline	2.7
Moldova	Diagnosis scenario	2.7
Moldova	Treatment scenario	2.4
Morocco	Baseline	0.3
Morocco	Diagnosis scenario	0.2
Morocco	Treatment scenario	0.2
Myanmar	Baseline	3.0
Myanmar	Diagnosis scenario	2.7
Myanmar	Treatment scenario	2.0
Namibia	Baseline	-0.8
Namibia	Diagnosis scenario	-1.4
Namibia	Treatment scenario	-1.5
Niger	Baseline	-0.5
Niger	Diagnosis scenario	-0.8
Niger	Treatment scenario	-0.6
Russian Federation	Baseline	7.7
Russian Federation	Diagnosis scenario	6.9
Russian Federation	Treatment scenario	5.6
Rwanda	Baseline	2.0
Rwanda	Diagnosis scenario	1.7
Rwanda	Treatment scenario	1.9
Samoa	Baseline	2.1
Samoa	Diagnosis scenario	1.4
Samoa	Treatment scenario	2.1
Sao Tome and Principe	Baseline	0.6
Sao Tome and Principe	Diagnosis scenario	0.6

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Sao Tome and Principe	Treatment scenario	0.5
Solomon Islands	Baseline	0.9
Solomon Islands	Diagnosis scenario	0.6
Solomon Islands	Treatment scenario	0.2
South Africa	Baseline	-2.5
South Africa	Diagnosis scenario	-3.3
South Africa	Treatment scenario	-3.5
Sri Lanka	Baseline	1.8
Sri Lanka	Diagnosis scenario	1.3
Sri Lanka	Treatment scenario	1.3
St. Vincent & the Grenadines	Baseline	4.9
St. Vincent & the Grenadines	Diagnosis scenario	4.8
St. Vincent & the Grenadines	Treatment scenario	4.6
Sudan	Baseline	-4.1
Sudan	Diagnosis scenario	-5.3
Sudan	Treatment scenario	-6.0
Tanzania	Baseline	-2.6
Tanzania	Diagnosis scenario	-2.9
Tanzania	Treatment scenario	-2.3
Timor Leste	Baseline	6.1
Timor Leste	Diagnosis scenario	5.4
Timor Leste	Treatment scenario	4.1
Togo	Baseline	1.7
Togo	Diagnosis scenario	1.5
Togo	Treatment scenario	1.3
Uganda	Baseline	-0.5
Uganda	Diagnosis scenario	-1.3
Uganda	Treatment scenario	-0.6
Vanuatu	Baseline	-1.7
Vanuatu	Diagnosis scenario	-1.9
Vanuatu	Treatment scenario	-1.6
Zambia	Baseline	-0.3
Zambia	Diagnosis scenario	-0.6

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Zambia	Treatment scenario	-0.6

Supplementary Table 20. Performance-based targets sensitivity analysis: Mean difference (95% uncertainty interval) in CVD cases per 1,000 people living with hypertension compared to baseline by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	6.8 (0.3,16.5)	12.9 (1.7,31.0)	10.6 (2.0,22.9)	2.6 (-0.1,6.6)	4.6 (-0.2,12.0)
Afghanistan	Treatment scenario	5.4 (0.1,14.1)	11.8 (1.5,28.9)	24.1 (10.3,39.2)	10.4 (3.1,19.9)	0.0 (0.0,0.0)
Albania	Diagnosis scenario	1.6 (0.5,2.9)	2.1 (0.9,3.7)	1.9 (0.8,3.4)	2.0 (0.8,3.4)	1.9 (0.7,3.3)
Albania	Treatment scenario	2.5 (1.1,4.2)	2.2 (1.0,3.8)	2.2 (0.8,4.0)	1.4 (0.4,2.8)	0.6 (-0.0,1.5)
Algeria	Diagnosis scenario	1.8 (0.9,2.8)	2.5 (1.3,3.7)	2.3 (1.1,3.8)	1.4 (0.5,2.5)	1.5 (0.6,2.8)
Algeria	Treatment scenario	3.0 (1.8,4.3)	4.3 (2.6,6.2)	2.8 (1.4,4.4)	1.9 (0.9,3.2)	2.2 (1.1,3.7)
Azerbaijan	Diagnosis scenario	5.8 (2.7,9.5)	7.5 (1.9,15.4)	6.3 (2.6,11.8)	1.3 (-0.2,4.2)	4.3 (0.2,11.8)
Azerbaijan	Treatment scenario	11.9 (7.2,17.4)	11.7 (4.4,20.9)	10.7 (5.7,17.0)	11.1 (5.8,17.1)	10.0 (3.5,18.9)
Benin	Diagnosis scenario	12.3 (2.5,37.9)	7.5 (3.5,13.0)	12.4 (7.0,19.2)	8.1 (3.6,13.9)	4.2 (1.6,7.7)
Benin	Treatment scenario	6.0 (0.6,29.3)	6.8 (2.6,13.2)	5.1 (1.8,9.7)	4.0 (1.1,8.5)	3.6 (1.1,7.1)
Bhutan	Diagnosis scenario	3.0 (1.1,5.7)	2.5 (0.9,4.5)	4.4 (1.3,8.6)	0.5 (-0.3,1.9)	2.1 (0.1,5.3)
Bhutan	Treatment scenario	7.9 (4.8,11.6)	6.9 (3.9,10.3)	9.4 (4.8,14.9)	6.0 (2.2,11.4)	7.1 (3.3,11.9)
Botswana	Diagnosis scenario	3.9 (0.1,13.9)	4.1 (1.1,8.3)	2.0 (-0.1,9.8)	2.3 (0.1,6.6)	3.4 (0.1,9.3)
Botswana	Treatment scenario	11.7 (4.2,22.2)	5.7 (2.2,10.1)	6.4 (1.6,14.7)	10.9 (3.6,21.0)	7.2 (2.4,13.8)
Brazil	Diagnosis scenario	4.0 (3.2,4.9)	3.0 (2.0,4.5)	2.0 (1.3,2.8)	1.7 (1.1,2.4)	1.8 (1.2,2.7)
Brazil	Treatment scenario	3.7 (2.8,4.6)	2.8 (1.9,4.3)	1.5 (0.9,2.9)	1.2 (0.7,1.8)	1.1 (0.5,2.1)
Cambodia	Diagnosis scenario	13.8 (7.6,22.2)	15.1 (9.3,21.1)	12.3 (6.2,19.4)	9.0 (3.9,16.3)	7.0 (2.7,12.0)
Cambodia	Treatment scenario	23.3 (15.6,32.2)	20.6 (14.1,27.4)	22.0 (14.1,30.6)	22.3 (14.5,31.2)	14.9 (8.5,21.9)
China	Diagnosis scenario	9.2 (6.4,12.2)	6.6 (4.4,9.0)	8.6 (6.2,11.1)	4.9 (2.9,7.0)	3.7 (2.2,5.5)
China	Treatment scenario	6.3 (4.0,8.8)	4.2 (2.4,6.4)	5.6 (3.6,7.8)	2.3 (1.0,3.9)	0.0 (0.0,0.0)
Ecuador	Diagnosis scenario	5.2 (1.8,10.8)	2.9 (1.4,4.6)	1.9 (0.1,5.3)	1.2 (-0.0,3.0)	3.1 (1.0,5.6)
Ecuador	Treatment scenario	8.2 (4.1,13.9)	4.5 (2.6,6.7)	4.1 (1.2,8.1)	3.2 (1.1,5.8)	2.6 (0.6,5.3)
Eritrea	Diagnosis scenario	9.0 (5.2,13.2)	13.6 (3.2,26.4)	9.1 (4.8,14.6)	5.4 (1.8,11.0)	6.5 (2.2,12.6)
Eritrea	Treatment scenario	16.3 (11.0,22.3)	12.9 (2.5,26.0)	9.7 (5.3,15.1)	8.7 (4.1,14.7)	11.6 (5.8,18.9)
Eswatini	Diagnosis scenario	7.2 (2.2,14.2)	8.0 (0.7,22.0)	4.2 (0.3,10.2)	4.8 (0.0,15.5)	4.7 (-0.9,17.1)
Eswatini	Treatment scenario	15.6 (8.7,23.8)	18.5 (7.5,32.7)	17.0 (3.1,41.6)	8.9 (2.1,20.1)	9.5 (0.9,23.6)
Ethiopia	Diagnosis scenario	3.2 (0.6,8.0)	3.2 (0.1,9.1)	5.1 (1.1,10.6)	2.5 (0.2,6.5)	3.2 (0.5,7.2)
Ethiopia	Treatment scenario	5.1 (1.5,11.0)	2.3 (-0.1,7.3)	5.2 (1.1,11.1)	3.6 (0.6,8.1)	2.9 (0.4,6.7)
Gambia	Diagnosis scenario	5.3 (1.9,9.6)	4.0 (0.8,8.3)	4.3 (0.9,10.2)	2.5 (0.2,6.2)	0.8 (-0.4,3.3)
Gambia	Treatment scenario	2.5 (0.1,6.1)	1.0 (-0.5,4.0)	2.2 (-0.1,6.6)	0.0 (0.0,0.0)	0.4 (-0.4,2.4)
Ghana	Diagnosis scenario	9.4 (5.9,13.3)	13.5 (9.2,18.2)	9.0 (5.9,12.5)	5.0 (2.7,8.0)	5.6 (3.0,8.9)
Ghana	Treatment scenario	8.4 (5.1,12.2)	7.6 (4.4,11.5)	5.0 (2.7,7.9)	0.0 (0.0,0.0)	1.3 (0.3,3.3)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario	10.9 (9.3,12.6)	8.9 (7.5,10.3)	7.0 (5.7,8.4)	6.8 (5.6,8.2)	5.2 (4.3,6.2)
India	Treatment scenario	13.9 (12.2,15.9)	12.3 (10.7,13.9)	10.4 (8.9,12.0)	9.4 (8.0,10.9)	6.6 (5.6,7.7)
Indonesia	Diagnosis scenario	3.4 (2.0,5.0)	3.5 (2.1,5.2)	2.4 (1.3,3.8)	1.8 (0.9,2.9)	1.7 (0.8,2.9)
Indonesia	Treatment scenario	13.1 (10.2,16.5)	9.2 (6.9,11.7)	8.1 (5.9,10.4)	5.0 (3.4,6.8)	2.6 (1.4,4.0)
Jordan	Diagnosis scenario	2.5 (0.2,5.7)	0.7 (-0.0,2.0)	0.1 (-0.1,0.7)	3.3 (0.8,6.4)	3.1 (1.2,5.3)
Jordan	Treatment scenario	3.9 (1.1,7.5)	0.0 (0.0,0.0)	1.2 (-0.0,3.5)	3.5 (1.0,6.6)	3.9 (1.1,9.3)
Kenya	Diagnosis scenario	3.6 (1.2,7.3)	2.9 (0.8,6.4)	3.0 (0.7,7.0)	1.8 (0.3,4.4)	0.6 (-0.1,1.8)
Kenya	Treatment scenario	9.6 (5.7,14.4)	8.3 (4.8,12.6)	7.2 (3.5,12.0)	6.3 (3.2,9.8)	5.8 (2.2,10.5)
Kiribati	Diagnosis scenario	2.2 (-0.7,8.9)	5.0 (-1.3,27.0)	0.0 (0.0,0.0)	1.5 (-0.8,13.3)	0.0 (0.0,0.0)
Kiribati	Treatment scenario	4.2 (-0.2,11.9)	6.1 (-1.2,29.3)	5.0 (-0.8,20.9)	7.2 (-1.2,24.4)	5.4 (-2.5,32.6)
Kyrgyzstan	Diagnosis scenario	6.1 (2.4,10.9)	2.6 (0.3,6.3)	2.3 (0.1,8.8)	2.5 (0.4,6.0)	2.8 (0.1,7.1)
Kyrgyzstan	Treatment scenario	10.4 (5.5,16.2)	5.1 (1.6,9.9)	13.4 (5.0,26.9)	9.5 (4.9,15.0)	9.9 (3.8,18.5)
Laos	Diagnosis scenario	12.9 (1.6,30.2)	8.7 (0.0,28.0)	5.2 (1.0,10.9)	1.4 (-0.4,4.3)	8.0 (1.1,23.0)
Laos	Treatment scenario	16.7 (3.4,34.8)	9.6 (0.5,29.2)	13.4 (4.6,29.1)	4.0 (0.7,8.4)	10.6 (2.5,26.2)
Lesotho	Diagnosis scenario	8.1 (3.2,13.8)	6.2 (1.9,11.6)	10.7 (4.6,18.0)	5.1 (0.5,12.7)	3.5 (1.4,6.1)
Lesotho	Treatment scenario	8.2 (3.3,13.8)	8.2 (3.0,14.5)	12.6 (6.1,20.1)	4.6 (0.4,12.0)	4.0 (1.3,8.0)
Moldova	Diagnosis scenario	1.9 (0.5,4.0)	0.6 (-0.1,1.9)	0.5 (-0.1,1.9)	1.9 (-0.0,5.3)	1.6 (0.2,4.0)
Moldova	Treatment scenario	9.3 (6.1,13.1)	7.0 (3.7,10.9)	5.4 (2.6,9.3)	4.5 (1.1,9.4)	6.1 (3.1,9.9)
Morocco	Diagnosis scenario	4.3 (2.9,5.9)	4.1 (1.4,7.6)	2.6 (0.9,4.9)	3.4 (0.8,6.9)	3.6 (1.8,5.8)
Morocco	Treatment scenario	5.6 (4.0,7.5)	6.1 (2.9,10.1)	5.2 (2.2,9.1)	7.5 (3.4,12.3)	5.1 (3.0,7.6)
Myanmar	Diagnosis scenario	2.8 (0.7,6.3)	2.0 (0.3,7.3)	0.6 (-0.1,2.3)	1.5 (0.2,3.8)	0.0 (0.0,0.0)
Myanmar	Treatment scenario	13.6 (7.0,23.1)	7.6 (3.5,13.8)	5.5 (2.2,9.7)	4.8 (2.1,8.5)	3.0 (0.8,6.2)
Namibia	Diagnosis scenario	7.8 (5.3,10.6)	5.5 (3.7,7.4)	5.2 (2.9,8.7)	6.5 (3.5,10.3)	1.5 (0.4,2.9)
Namibia	Treatment scenario	9.1 (6.2,12.3)	7.0 (5.0,9.1)	5.1 (2.7,8.4)	6.4 (3.4,10.2)	1.9 (0.7,3.6)
Niger	Diagnosis scenario	9.5 (5.4,14.4)	0.0 (0.0,0.0)	4.9 (1.6,9.2)	5.5 (2.3,9.8)	6.8 (2.7,11.9)
Niger	Treatment scenario	6.5 (3.0,10.9)	8.4 (4.4,13.0)	7.7 (3.6,12.7)	7.3 (3.5,12.0)	6.4 (2.5,11.4)
Russian Federation	Diagnosis scenario	8.9 (2.0,20.2)	0.0 (0.0,0.0)	0.9 (-0.2,3.3)	8.6 (3.6,14.5)	0.8 (-0.1,2.2)
Russian Federation	Treatment scenario	21.5 (11.3,34.3)	8.5 (3.3,16.3)	3.1 (0.6,6.7)	8.2 (3.3,14.1)	0.3 (-0.1,1.5)
Rwanda	Diagnosis scenario	5.9 (2.3,11.0)	6.8 (3.1,11.2)	2.3 (0.4,5.3)	0.7 (-0.4,2.6)	3.2 (0.8,6.7)
Rwanda	Treatment scenario	6.6 (2.8,11.5)	5.7 (2.3,9.9)	5.5 (2.3,9.8)	6.4 (2.4,11.4)	5.8 (2.4,10.1)
Samoa	Diagnosis scenario	12.2 (3.8,24.0)	17.5 (7.5,28.5)	5.1 (-0.4,15.2)	3.2 (-0.4,9.3)	5.7 (0.4,13.5)
Samoa	Treatment scenario	3.2 (-0.5,10.5)	7.8 (1.1,18.4)	0.8 (-0.7,4.8)	3.2 (-0.2,9.1)	2.9 (-0.6,9.2)
Sao Tome and Principe	Diagnosis scenario	2.1 (0.2,5.4)	2.2 (0.5,4.8)	3.1 (1.0,6.0)	0.6 (-0.2,1.9)	2.1 (0.5,4.2)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	1.0 (-0.2,3.9)	2.7 (0.7,5.7)	1.8 (0.1,4.3)	1.0 (-0.2,2.9)	0.0 (0.0,0.0)
Solomon Islands	Diagnosis scenario	3.2 (-0.5,13.0)	3.4 (-0.1,8.7)	2.9 (-0.4,7.8)	1.6 (-0.8,6.8)	0.0 (0.0,0.0)
Solomon Islands	Treatment scenario	17.7 (7.3,32.6)	17.6 (8.3,28.9)	13.4 (6.1,21.9)	15.5 (6.9,27.1)	11.0 (4.0,18.8)
South Africa	Diagnosis scenario	16.7 (12.2,21.8)	15.9 (11.4,20.7)	10.0 (5.5,17.1)	8.3 (5.2,11.9)	9.1 (5.5,13.1)
South Africa	Treatment scenario	17.3 (12.6,22.3)	15.2 (10.9,19.9)	8.0 (4.2,14.7)	7.3 (4.2,11.3)	7.1 (4.0,11.0)
Sri Lanka	Diagnosis scenario	10.5 (6.8,14.6)	13.4 (9.6,17.6)	12.1 (8.1,16.6)	8.4 (4.5,12.6)	5.8 (1.8,10.9)
Sri Lanka	Treatment scenario	17.1 (12.6,21.8)	20.6 (16.0,25.4)	16.2 (11.7,20.9)	12.3 (7.6,17.4)	12.1 (6.5,18.3)
St. Vincent & the Grenadines	Diagnosis scenario	3.7 (1.2,6.8)	5.4 (0.8,15.5)	5.2 (1.1,10.5)	6.6 (2.4,11.7)	2.8 (1.0,5.1)
St. Vincent & the Grenadines	Treatment scenario	7.8 (4.3,11.9)	15.1 (7.0,26.8)	11.4 (5.1,18.1)	12.1 (7.0,17.6)	5.2 (2.7,8.1)
Sudan	Diagnosis scenario	17.4 (12.2,23.1)	14.7 (10.8,19.6)	9.7 (6.4,14.3)	10.1 (4.9,17.1)	5.6 (-0.8,20.8)
Sudan	Treatment scenario	18.9 (13.5,24.8)	14.5 (10.6,19.3)	13.1 (9.1,17.9)	12.8 (6.4,20.9)	0.0 (0.0,0.0)
Tanzania	Diagnosis scenario	5.8 (3.1,9.2)	4.0 (1.8,6.9)	3.6 (1.4,6.7)	1.6 (0.3,3.5)	2.9 (-0.0,17.3)
Tanzania	Treatment scenario	3.8 (1.6,7.0)	2.1 (0.6,4.5)	3.7 (1.5,6.6)	5.2 (2.6,8.4)	6.7 (0.6,24.9)
Timor Leste	Diagnosis scenario	8.1 (0.0,20.1)	13.8 (6.1,22.5)	10.1 (3.0,19.1)	8.1 (1.8,16.2)	1.1 (-0.6,5.0)
Timor Leste	Treatment scenario	25.7 (11.1,43.2)	20.8 (11.9,30.8)	15.7 (6.9,26.3)	9.8 (2.8,18.5)	6.4 (1.5,13.0)
Togo	Diagnosis scenario	3.4 (0.3,8.2)	3.2 (-0.0,12.5)	3.5 (0.2,8.9)	1.7 (-0.4,5.4)	1.7 (-0.2,5.7)
Togo	Treatment scenario	5.1 (1.0,10.8)	4.8 (0.7,15.4)	3.8 (0.2,9.5)	5.6 (1.0,12.2)	1.8 (-0.2,5.6)
Uganda	Diagnosis scenario	7.9 (2.3,19.8)	2.4 (-0.2,7.8)	3.0 (0.1,7.2)	2.6 (0.2,7.0)	0.0 (0.0,0.0)
Uganda	Treatment scenario	4.5 (0.7,14.9)	5.2 (0.9,12.4)	2.6 (0.0,6.5)	3.2 (0.5,7.7)	3.3 (-0.7,13.1)
Vanuatu	Diagnosis scenario	4.0 (1.9,7.1)	0.9 (-0.0,2.5)	1.2 (-0.2,3.9)	0.6 (-0.2,2.2)	2.3 (0.6,5.1)
Vanuatu	Treatment scenario	7.1 (4.3,11.0)	6.4 (3.4,10.1)	7.8 (3.5,13.1)	7.7 (4.3,11.7)	8.1 (4.6,12.8)
Zambia	Diagnosis scenario	2.4 (0.5,5.3)	3.0 (0.0,7.9)	2.3 (0.5,4.8)	0.2 (-0.2,1.4)	0.0 (0.0,0.0)
Zambia	Treatment scenario	6.5 (3.1,10.6)	5.6 (1.2,11.6)	6.2 (2.4,11.0)	6.4 (1.3,14.4)	3.6 (0.4,9.6)

Supplementary Table 21. Performance-based targets sensitivity analysis: Mean (95% uncertainty interval) relative decline (%) in CVD risk compared to baseline by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	2.6 (0.3,6.4)	4.3 (1.3,8.1)	4.4 (1.2,8.4)	1.2 (-0.1,3.4)	1.8 (-0.0,4.6)
Afghanistan	Treatment scenario	2.1 (0.2,5.6)	4.2 (1.3,7.8)	10.0 (5.0,15.1)	4.4 (1.4,8.1)	0.0 (0.0,0.0)
Albania	Diagnosis scenario	5.8 (3.5,8.3)	7.5 (5.1,10.0)	7.3 (5.0,9.6)	8.4 (5.7,11.2)	8.4 (5.7,11.1)
Albania	Treatment scenario	17.2 (14.1,20.2)	16.6 (13.7,19.4)	16.1 (13.4,18.8)	15.2 (12.1,18.2)	12.9 (10.0,15.8)
Algeria	Diagnosis scenario	5.5 (4.1,6.8)	6.0 (4.4,7.6)	5.9 (4.2,7.5)	4.8 (3.4,6.3)	5.0 (3.5,6.5)
Algeria	Treatment scenario	10.1 (8.5,11.8)	11.4 (9.5,13.3)	9.5 (7.5,11.5)	8.6 (6.9,10.4)	8.8 (7.1,10.6)
Azerbaijan	Diagnosis scenario	4.2 (2.5,5.9)	5.8 (2.6,9.4)	4.3 (2.2,6.6)	0.9 (0.0,2.0)	3.3 (1.2,5.5)
Azerbaijan	Treatment scenario	7.7 (5.5,10.0)	8.1 (4.6,11.9)	6.8 (4.3,9.4)	7.0 (4.6,9.6)	7.3 (4.3,10.4)
Benin	Diagnosis scenario	13.3 (5.4,24.1)	10.1 (7.0,13.5)	16.9 (13.5,20.5)	11.3 (8.1,14.5)	7.3 (4.6,10.1)
Benin	Treatment scenario	17.7 (8.4,26.8)	18.3 (14.9,21.7)	17.4 (14.0,21.0)	16.2 (12.9,19.6)	16.3 (12.8,19.7)
Bhutan	Diagnosis scenario	4.6 (2.7,6.8)	4.3 (2.3,6.4)	5.9 (3.0,9.1)	2.2 (0.5,4.2)	3.9 (1.8,6.4)
Bhutan	Treatment scenario	12.4 (9.7,15.2)	11.6 (8.8,14.5)	13.3 (9.7,17.0)	11.2 (7.6,15.0)	11.8 (8.5,15.1)
Botswana	Diagnosis scenario	3.5 (0.4,10.9)	5.2 (1.7,10.5)	2.5 (0.4,5.5)	3.4 (0.7,6.7)	3.2 (0.9,5.9)
Botswana	Treatment scenario	10.2 (4.9,17.4)	7.1 (3.2,12.5)	7.1 (3.7,10.9)	11.2 (6.7,15.9)	7.2 (3.9,10.8)
Brazil	Diagnosis scenario	3.8 (3.1,4.6)	2.7 (2.1,3.4)	2.0 (1.4,2.7)	1.8 (1.3,2.4)	2.0 (1.4,2.6)
Brazil	Treatment scenario	3.3 (2.6,4.1)	2.5 (1.9,3.3)	1.5 (1.0,2.1)	1.2 (0.8,1.7)	1.1 (0.7,1.6)
Cambodia	Diagnosis scenario	8.3 (5.4,11.2)	8.9 (5.8,12.1)	7.2 (4.1,10.4)	4.9 (2.6,7.3)	4.0 (1.8,6.4)
Cambodia	Treatment scenario	13.9 (10.7,17.2)	12.0 (8.8,15.4)	12.5 (8.8,16.2)	11.2 (8.2,14.3)	8.4 (5.3,11.6)
China	Diagnosis scenario	7.8 (6.6,9.0)	7.5 (6.4,8.7)	8.7 (7.5,9.9)	6.7 (5.6,7.9)	6.1 (5.0,7.2)
China	Treatment scenario	8.7 (7.5,10.0)	8.6 (7.3,9.8)	9.2 (8.0,10.5)	7.6 (6.4,8.8)	6.0 (4.8,7.1)
Ecuador	Diagnosis scenario	5.5 (2.8,8.5)	3.7 (2.1,5.5)	2.2 (0.5,4.3)	1.6 (0.1,3.4)	3.7 (1.4,6.5)
Ecuador	Treatment scenario	9.0 (5.8,12.4)	5.5 (3.6,7.6)	4.7 (2.2,7.5)	4.3 (1.9,7.0)	2.9 (0.9,5.5)
Eritrea	Diagnosis scenario	7.9 (5.8,10.1)	11.4 (5.9,17.0)	9.7 (6.5,13.1)	6.3 (3.9,8.8)	6.0 (3.4,8.8)
Eritrea	Treatment scenario	15.6 (13.1,18.2)	14.3 (8.7,20.0)	13.1 (9.7,16.7)	11.8 (8.8,15.0)	13.1 (9.5,16.6)
Eswatini	Diagnosis scenario	5.0 (2.2,8.5)	4.8 (1.7,9.4)	3.2 (0.8,6.2)	4.3 (0.7,9.2)	3.4 (0.6,6.8)
Eswatini	Treatment scenario	11.3 (7.5,15.3)	11.4 (7.0,16.0)	10.1 (5.4,15.3)	9.2 (3.9,14.8)	7.1 (2.9,11.8)
Ethiopia	Diagnosis scenario	6.2 (3.5,9.1)	7.6 (3.7,12.0)	8.6 (4.6,13.0)	5.9 (2.5,10.0)	8.1 (4.0,12.8)
Ethiopia	Treatment scenario	17.7 (14.0,21.2)	15.4 (10.6,20.2)	17.5 (12.8,22.2)	17.0 (12.2,21.5)	16.6 (11.7,21.3)
Gambia	Diagnosis scenario	9.8 (6.6,13.1)	8.3 (4.9,11.8)	8.6 (5.6,11.9)	8.4 (4.4,13.0)	4.5 (2.0,7.4)
Gambia	Treatment scenario	15.6 (12.0,19.2)	14.0 (9.8,18.0)	15.3 (11.7,19.0)	13.4 (8.8,18.3)	13.7 (9.6,17.9)
Ghana	Diagnosis scenario	11.0 (6.7,15.8)	14.9 (10.2,19.5)	13.0 (8.7,17.4)	9.3 (5.7,13.3)	9.8 (6.2,13.8)
Ghana	Treatment scenario	18.2 (13.5,22.4)	17.6 (12.8,22.1)	16.7 (12.3,20.9)	12.5 (8.5,16.6)	13.1 (9.2,17.1)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario	9.9 (9.2,10.7)	8.6 (7.9,9.3)	7.4 (6.7,8.1)	7.4 (6.7,8.1)	6.7 (6.1,7.3)
India	Treatment scenario	15.1 (14.3,15.9)	14.2 (13.4,14.9)	12.9 (12.1,13.7)	12.2 (11.4,13.0)	10.6 (9.9,11.2)
Indonesia	Diagnosis scenario	3.4 (2.7,4.1)	4.3 (3.6,5.1)	3.8 (3.1,4.6)	4.0 (3.3,4.8)	4.5 (3.6,5.3)
Indonesia	Treatment scenario	18.1 (16.9,19.3)	17.1 (16.0,18.3)	16.7 (15.5,18.0)	15.6 (14.4,16.8)	14.5 (13.4,15.6)
Jordan	Diagnosis scenario	2.0 (0.3,4.7)	0.8 (0.0,2.1)	0.1 (-0.1,0.7)	3.2 (1.2,5.5)	2.9 (1.4,4.6)
Jordan	Treatment scenario	3.3 (1.2,6.1)	0.0 (0.0,0.0)	1.3 (0.1,3.0)	3.5 (1.4,5.8)	3.1 (1.5,5.0)
Kenya	Diagnosis scenario	5.8 (3.2,8.7)	5.5 (2.8,8.6)	6.3 (3.0,10.9)	5.0 (2.0,9.4)	2.7 (0.4,6.0)
Kenya	Treatment scenario	19.1 (15.4,22.8)	17.6 (14.0,21.1)	16.1 (11.6,20.5)	17.4 (12.7,21.8)	14.2 (9.0,18.9)
Kiribati	Diagnosis scenario	4.8 (-0.3,13.8)	8.1 (-0.4,22.6)	1.6 (-0.5,9.7)	3.1 (-1.1,11.8)	2.4 (-1.0,11.9)
Kiribati	Treatment scenario	15.6 (6.2,23.7)	16.8 (3.7,31.3)	16.5 (4.1,25.8)	16.5 (6.2,25.7)	16.9 (5.1,28.5)
Kyrgyzstan	Diagnosis scenario	6.5 (4.2,8.9)	4.6 (2.7,6.6)	3.5 (1.6,5.8)	4.3 (2.3,6.4)	4.0 (1.8,6.9)
Kyrgyzstan	Treatment scenario	12.6 (9.9,15.3)	9.2 (6.7,11.7)	13.6 (9.5,18.0)	12.8 (9.9,15.7)	12.1 (8.7,15.5)
Laos	Diagnosis scenario	10.2 (4.1,17.5)	8.4 (2.7,16.0)	5.9 (2.7,9.5)	4.0 (1.6,6.6)	7.4 (3.3,12.2)
Laos	Treatment scenario	15.6 (8.9,22.8)	12.0 (5.5,19.1)	14.2 (9.6,19.1)	9.1 (5.7,12.7)	12.4 (7.6,17.4)
Lesotho	Diagnosis scenario	8.3 (4.3,12.6)	5.9 (2.9,9.0)	10.2 (5.6,15.2)	5.1 (1.8,9.1)	4.8 (2.3,7.4)
Lesotho	Treatment scenario	8.7 (4.4,13.4)	8.2 (4.6,11.9)	12.3 (7.4,17.4)	4.8 (1.5,8.7)	4.9 (2.3,7.8)
Moldova	Diagnosis scenario	3.6 (2.4,5.0)	3.0 (1.8,4.4)	3.1 (1.8,4.6)	4.2 (2.2,6.5)	3.6 (2.1,5.3)
Moldova	Treatment scenario	11.5 (9.6,13.4)	10.1 (8.0,12.3)	9.7 (7.5,12.0)	9.1 (6.4,11.9)	10.2 (8.0,12.5)
Morocco	Diagnosis scenario	7.1 (5.9,8.4)	6.7 (4.4,9.2)	5.4 (3.4,7.4)	5.5 (3.2,7.8)	6.4 (4.7,8.1)
Morocco	Treatment scenario	11.2 (9.8,12.6)	11.7 (9.1,14.4)	11.1 (8.6,13.6)	12.8 (9.9,15.7)	10.8 (8.9,12.7)
Myanmar	Diagnosis scenario	4.1 (2.2,6.2)	4.6 (2.1,8.8)	3.3 (1.3,6.4)	4.3 (2.3,6.9)	3.1 (1.4,5.3)
Myanmar	Treatment scenario	15.5 (11.9,19.5)	12.9 (9.4,17.1)	11.2 (7.8,15.2)	10.7 (8.0,13.8)	9.5 (6.4,13.3)
Namibia	Diagnosis scenario	10.8 (8.6,13.1)	7.9 (6.0,10.0)	6.3 (4.5,8.2)	6.7 (4.7,9.0)	1.8 (0.7,3.0)
Namibia	Treatment scenario	11.9 (9.6,14.2)	10.0 (7.8,12.2)	6.1 (4.2,8.1)	6.6 (4.6,8.8)	2.4 (1.1,3.9)
Niger	Diagnosis scenario	15.2 (12.0,18.5)	0.0 (0.0,0.0)	7.8 (4.8,10.7)	8.4 (5.8,11.1)	10.6 (7.5,13.8)
Niger	Treatment scenario	20.6 (17.4,23.7)	22.2 (19.2,25.2)	22.2 (18.8,25.6)	20.9 (17.9,23.9)	20.2 (16.8,23.5)
Russian Federation	Diagnosis scenario	2.8 (0.8,5.6)	0.0 (0.0,0.0)	0.3 (-0.1,1.1)	5.8 (1.3,15.5)	0.4 (-0.0,1.6)
Russian Federation	Treatment scenario	7.2 (4.0,10.8)	3.3 (1.0,7.3)	1.1 (0.2,2.2)	5.2 (1.2,14.8)	0.2 (-0.1,0.8)
Rwanda	Diagnosis scenario	9.0 (6.2,11.7)	12.3 (9.0,15.6)	4.3 (2.1,6.5)	1.5 (0.0,3.0)	6.1 (3.7,8.6)
Rwanda	Treatment scenario	19.3 (16.3,22.3)	19.5 (16.2,22.8)	19.7 (16.6,22.8)	19.5 (16.1,22.9)	19.5 (16.4,22.6)
Samoa	Diagnosis scenario	15.5 (10.0,21.1)	22.3 (15.3,27.7)	9.3 (4.0,15.1)	7.7 (2.1,13.9)	10.1 (4.9,15.8)
Samoa	Treatment scenario	15.7 (9.9,21.5)	18.8 (11.4,25.4)	13.7 (7.6,20.1)	16.9 (10.4,23.2)	14.8 (9.2,20.4)
Sao Tome and Principe	Diagnosis scenario	6.8 (4.1,9.5)	6.2 (3.9,8.6)	9.1 (6.4,11.8)	4.7 (2.3,7.1)	8.2 (5.7,10.8)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	15.1 (11.9,18.3)	16.8 (13.7,20.0)	15.8 (12.7,19.0)	14.9 (11.4,18.5)	14.2 (11.3,17.2)
Solomon Islands	Diagnosis scenario	3.0 (0.4,6.7)	3.9 (1.1,7.2)	3.5 (0.8,6.6)	1.7 (-0.3,4.5)	2.1 (-0.1,4.8)
Solomon Islands	Treatment scenario	17.7 (12.7,22.4)	17.9 (13.3,22.6)	16.4 (11.6,21.0)	17.8 (12.6,22.9)	13.4 (8.0,18.9)
South Africa	Diagnosis scenario	9.6 (7.8,11.4)	8.6 (7.0,10.1)	5.8 (4.1,7.6)	4.8 (3.4,6.3)	5.0 (3.5,6.5)
South Africa	Treatment scenario	9.9 (8.1,11.9)	8.2 (6.7,9.8)	4.5 (3.1,6.2)	4.0 (2.7,5.4)	3.8 (2.5,5.2)
Sri Lanka	Diagnosis scenario	6.0 (4.3,7.7)	7.1 (5.5,8.7)	7.6 (5.7,9.6)	5.2 (3.2,7.4)	3.3 (1.5,5.3)
Sri Lanka	Treatment scenario	9.9 (7.9,12.0)	10.8 (9.0,12.6)	10.3 (8.3,12.3)	7.5 (5.2,10.0)	7.3 (4.6,10.2)
St. Vincent & the Grenadines	Diagnosis scenario	2.3 (0.9,4.0)	3.0 (1.0,5.7)	3.6 (1.1,6.5)	4.8 (2.1,7.7)	2.2 (0.9,4.3)
St. Vincent & the Grenadines	Treatment scenario	4.8 (2.8,7.1)	8.4 (5.1,11.8)	7.7 (4.2,11.5)	8.9 (5.4,12.3)	4.3 (2.3,7.1)
Sudan	Diagnosis scenario	12.2 (9.8,14.7)	10.8 (9.3,12.5)	8.1 (6.5,9.8)	8.2 (5.6,10.9)	6.0 (1.7,10.7)
Sudan	Treatment scenario	15.8 (13.4,18.2)	13.3 (11.7,15.0)	13.0 (11.1,14.9)	12.3 (9.3,15.3)	6.2 (1.9,10.9)
Tanzania	Diagnosis scenario	12.4 (9.1,15.6)	10.3 (7.0,13.9)	8.5 (5.2,12.4)	4.2 (1.9,6.9)	4.9 (1.0,12.2)
Tanzania	Treatment scenario	18.4 (15.1,21.7)	16.3 (12.7,20.0)	18.5 (14.6,22.5)	20.2 (16.4,23.8)	20.1 (12.9,29.1)
Timor Leste	Diagnosis scenario	5.4 (2.2,8.7)	8.2 (5.5,11.0)	8.2 (4.9,11.5)	8.3 (4.8,11.8)	3.4 (1.2,5.7)
Timor Leste	Treatment scenario	18.1 (13.8,22.4)	15.3 (12.2,18.5)	14.2 (10.5,17.9)	12.5 (8.7,16.4)	11.6 (7.8,15.3)
Togo	Diagnosis scenario	6.1 (2.9,9.6)	5.7 (2.1,10.2)	6.7 (3.4,10.5)	3.9 (0.8,8.2)	5.5 (2.4,8.8)
Togo	Treatment scenario	17.7 (13.3,22.1)	18.2 (13.0,23.4)	16.2 (11.8,20.5)	18.5 (13.0,23.9)	14.1 (10.0,18.2)
Uganda	Diagnosis scenario	13.0 (8.6,17.6)	5.3 (1.9,9.6)	6.8 (3.1,11.0)	6.7 (2.8,11.9)	2.1 (-0.3,5.7)
Uganda	Treatment scenario	16.9 (12.4,21.4)	18.2 (13.2,23.0)	15.4 (10.7,20.1)	17.0 (11.9,22.1)	15.7 (9.3,23.2)
Vanuatu	Diagnosis scenario	6.2 (4.2,8.3)	1.7 (0.5,3.2)	2.1 (0.5,4.2)	1.2 (0.2,2.4)	3.4 (1.9,5.1)
Vanuatu	Treatment scenario	19.6 (17.1,22.0)	19.3 (16.5,22.2)	19.3 (15.9,22.6)	20.1 (17.3,22.9)	19.4 (16.9,21.8)
Zambia	Diagnosis scenario	5.4 (2.6,8.7)	6.5 (2.2,11.4)	6.2 (2.5,10.6)	2.0 (0.1,5.4)	2.2 (0.0,4.9)
Zambia	Treatment scenario	15.4 (11.5,19.3)	13.5 (7.5,19.8)	15.7 (10.7,20.7)	14.1 (9.0,19.4)	12.3 (6.7,18.2)

Supplementary Table 22. Relative increase targets sensitivity analysis: Mean (95% uncertainty interval) 10-year CVD risk by country and wealth quintile in Diagnosis and Treatment scenarios

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	18.9 (17.1,20.7)	19.5 (15.5,23.7)	21.5 (18.9,24.2)	20.5 (17.6,23.4)	21.5 (18.6,24.5)
Afghanistan	Treatment scenario	18.9 (17.0,20.9)	19.6 (15.5,24.0)	21.4 (18.7,24.2)	20.2 (17.4,23.0)	21.3 (18.4,24.3)
Albania	Diagnosis scenario	4.7 (4.2,5.2)	4.9 (4.4,5.4)	5.3 (4.7,5.9)	5.2 (4.6,5.9)	5.2 (4.5,5.9)
Albania	Treatment scenario	4.7 (4.2,5.2)	4.9 (4.4,5.4)	5.3 (4.7,5.9)	5.2 (4.6,5.9)	5.2 (4.5,5.9)
Algeria	Diagnosis scenario	8.1 (7.5,8.7)	8.6 (7.8,9.3)	8.7 (8.0,9.4)	7.8 (7.2,8.4)	8.3 (7.7,8.9)
Algeria	Treatment scenario	8.0 (7.4,8.7)	8.5 (7.8,9.3)	8.7 (8.0,9.4)	7.8 (7.2,8.4)	8.3 (7.7,8.9)
Azerbaijan	Diagnosis scenario	15.1 (13.3,16.9)	16.2 (12.5,19.8)	15.5 (13.6,17.4)	14.5 (12.7,16.3)	12.7 (10.2,15.3)
Azerbaijan	Treatment scenario	15.0 (13.2,16.8)	16.0 (12.4,19.6)	15.4 (13.5,17.3)	14.3 (12.6,16.1)	12.7 (10.1,15.3)
Benin	Diagnosis scenario	14.8 (12.1,17.6)	13.9 (11.8,16.0)	12.2 (10.6,13.8)	13.3 (11.5,15.2)	13.5 (11.9,15.2)
Benin	Treatment scenario	14.8 (12.1,17.6)	13.9 (11.9,16.0)	12.2 (10.5,13.8)	13.3 (11.5,15.2)	13.5 (11.8,15.2)
Bhutan	Diagnosis scenario	12.2 (11.2,13.2)	11.7 (10.6,12.8)	12.2 (11.0,13.4)	11.4 (10.0,12.7)	11.7 (10.2,13.1)
Bhutan	Treatment scenario	12.2 (11.2,13.2)	11.6 (10.6,12.8)	12.2 (11.0,13.4)	11.3 (10.0,12.7)	11.6 (10.2,13.1)
Botswana	Diagnosis scenario	10.3 (8.5,12.1)	8.7 (6.6,10.8)	8.5 (6.3,10.7)	9.2 (6.0,12.3)	7.1 (5.4,8.9)
Botswana	Treatment scenario	10.3 (8.5,12.0)	8.7 (6.6,10.8)	8.4 (6.2,10.7)	9.0 (6.1,12.1)	7.2 (5.4,9.0)
Brazil	Diagnosis scenario	10.1 (9.7,10.5)	9.5 (9.0,9.9)	9.1 (8.6,9.6)	8.1 (7.8,8.4)	8.0 (7.7,8.4)
Brazil	Treatment scenario	10.0 (9.6,10.4)	9.5 (9.0,9.9)	9.0 (8.5,9.5)	8.0 (7.7,8.3)	8.0 (7.6,8.3)
Cambodia	Diagnosis scenario	15.2 (13.3,17.0)	16.1 (14.4,17.7)	15.9 (14.1,17.8)	17.4 (15.7,19.1)	15.4 (13.7,17.2)
Cambodia	Treatment scenario	15.2 (13.3,17.0)	16.0 (14.4,17.7)	15.9 (14.0,17.8)	17.3 (15.6,19.0)	15.4 (13.6,17.1)
China	Diagnosis scenario	22.9 (21.1,24.6)	18.8 (17.4,20.2)	19.0 (17.3,20.8)	18.0 (16.5,19.6)	18.1 (16.5,19.7)
China	Treatment scenario	22.9 (21.1,24.6)	18.8 (17.4,20.2)	19.0 (17.3,20.8)	18.0 (16.5,19.6)	18.0 (16.4,19.7)
Ecuador	Diagnosis scenario	7.8 (6.6,9.0)	7.1 (6.4,7.7)	6.5 (5.6,7.5)	6.4 (5.5,7.4)	7.3 (6.4,8.2)
Ecuador	Treatment scenario	7.8 (6.6,9.0)	7.0 (6.4,7.6)	6.5 (5.5,7.5)	6.4 (5.4,7.4)	7.2 (6.4,8.1)
Eritrea	Diagnosis scenario	18.4 (16.2,20.5)	17.6 (13.3,21.9)	15.0 (12.8,17.2)	15.6 (13.1,18.1)	16.8 (13.7,19.9)
Eritrea	Treatment scenario	18.3 (16.2,20.5)	17.6 (13.3,21.9)	15.0 (12.8,17.2)	15.6 (13.1,18.1)	16.8 (13.7,19.9)
Eswatini	Diagnosis scenario	13.7 (11.2,16.2)	16.0 (12.1,20.1)	14.2 (9.1,19.2)	13.4 (10.3,16.7)	10.9 (7.4,14.5)
Eswatini	Treatment scenario	13.7 (11.1,16.2)	16.0 (12.0,20.1)	13.9 (9.2,18.9)	13.5 (10.3,16.7)	10.9 (7.3,14.7)
Ethiopia	Diagnosis scenario	10.6 (8.7,12.4)	10.7 (8.5,13.0)	11.4 (9.6,13.1)	8.5 (6.7,10.3)	9.2 (7.7,10.8)
Ethiopia	Treatment scenario	10.6 (8.7,12.4)	10.7 (8.4,13.0)	11.4 (9.6,13.1)	8.5 (6.7,10.3)	9.2 (7.6,10.8)
Gambia	Diagnosis scenario	12.0 (10.4,13.5)	11.5 (9.5,13.5)	11.7 (9.8,13.6)	9.7 (8.3,11.1)	12.6 (10.8,14.4)
Gambia	Treatment scenario	11.9 (10.4,13.5)	11.4 (9.4,13.5)	11.7 (9.8,13.6)	9.6 (8.3,11.0)	12.5 (10.7,14.3)
Ghana	Diagnosis scenario	14.9 (12.7,17.2)	15.8 (13.4,18.1)	12.9 (11.4,14.4)	14.2 (12.2,16.2)	13.3 (11.4,15.1)
Ghana	Treatment scenario	14.9 (12.6,17.2)	15.8 (13.4,18.1)	12.9 (11.4,14.4)	14.2 (12.2,16.2)	13.2 (11.4,15.1)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario	14.1 (13.6,14.6)	13.6 (13.2,14.0)	13.5 (13.1,13.9)	13.4 (13.0,13.8)	12.4 (12.1,12.8)
India	Treatment scenario	14.1 (13.6,14.6)	13.6 (13.2,14.0)	13.5 (13.1,13.9)	13.4 (13.0,13.8)	12.4 (12.1,12.7)
Indonesia	Diagnosis scenario	27.2 (25.5,28.9)	24.9 (23.8,25.9)	25.1 (24.2,26.1)	22.7 (22.1,23.3)	21.3 (20.2,22.4)
Indonesia	Treatment scenario	27.2 (25.5,28.8)	24.8 (23.8,25.8)	25.1 (24.1,26.1)	22.6 (22.0,23.3)	21.3 (20.2,22.3)
Jordan	Diagnosis scenario	9.9 (9.0,10.9)	9.5 (8.2,10.8)	9.4 (8.4,10.4)	8.7 (7.1,10.2)	10.0 (8.7,11.4)
Jordan	Treatment scenario	10.0 (9.0,11.0)	9.4 (8.1,10.7)	9.1 (8.2,10.0)	8.7 (7.1,10.3)	9.9 (8.7,11.2)
Kenya	Diagnosis scenario	7.3 (6.3,8.4)	7.1 (6.1,8.1)	7.3 (6.4,8.2)	6.0 (5.2,6.7)	6.5 (4.6,8.4)
Kenya	Treatment scenario	7.3 (6.3,8.4)	7.1 (6.1,8.0)	7.3 (6.4,8.2)	6.0 (5.2,6.7)	6.4 (4.6,8.3)
Kiribati	Diagnosis scenario	9.2 (6.6,11.7)	12.8 (10.1,15.4)	11.6 (9.3,13.9)	12.8 (9.2,16.3)	15.5 (8.0,23.1)
Kiribati	Treatment scenario	9.2 (6.6,11.7)	12.8 (10.2,15.4)	11.6 (9.3,13.9)	12.8 (9.2,16.3)	15.6 (8.1,23.2)
Kyrgyzstan	Diagnosis scenario	18.0 (15.8,20.2)	20.4 (17.9,22.9)	18.9 (16.6,21.3)	17.0 (14.6,19.4)	17.2 (14.8,19.6)
Kyrgyzstan	Treatment scenario	18.0 (15.7,20.2)	20.3 (17.9,22.8)	18.8 (16.5,21.2)	17.0 (14.6,19.3)	17.1 (14.8,19.5)
Laos	Diagnosis scenario	18.5 (14.4,22.6)	19.3 (16.3,22.4)	17.2 (14.4,19.9)	17.3 (14.0,20.5)	16.8 (13.4,20.4)
Laos	Treatment scenario	18.3 (14.2,22.4)	19.2 (16.2,22.3)	17.0 (14.3,19.8)	17.2 (13.9,20.4)	16.8 (13.4,20.4)
Lesotho	Diagnosis scenario	7.5 (6.0,9.0)	7.4 (5.8,9.0)	8.9 (7.2,10.7)	7.1 (5.4,8.8)	7.2 (5.9,8.6)
Lesotho	Treatment scenario	7.5 (5.9,9.0)	7.4 (5.8,9.0)	8.9 (7.2,10.7)	7.1 (5.4,8.9)	7.2 (5.9,8.5)
Moldova	Diagnosis scenario	18.9 (17.5,20.3)	20.5 (18.9,22.0)	18.5 (16.9,20.1)	16.7 (14.8,18.7)	16.3 (14.7,17.9)
Moldova	Treatment scenario	18.8 (17.5,20.2)	20.3 (18.7,21.8)	18.4 (16.8,20.0)	16.6 (14.7,18.5)	16.2 (14.6,17.8)
Morocco	Diagnosis scenario	11.6 (10.8,12.5)	11.8 (10.0,13.5)	11.3 (9.8,12.8)	12.2 (10.3,14.2)	11.4 (10.3,12.5)
Morocco	Treatment scenario	11.6 (10.8,12.5)	11.8 (10.0,13.5)	11.3 (9.8,12.7)	12.2 (10.2,14.2)	11.4 (10.3,12.5)
Myanmar	Diagnosis scenario	14.3 (12.4,16.2)	13.2 (12.3,14.3)	11.7 (10.6,12.8)	11.9 (10.7,13.0)	11.1 (9.5,12.6)
Myanmar	Treatment scenario	14.2 (12.5,16.1)	13.2 (12.2,14.3)	11.6 (10.6,12.6)	11.8 (10.6,13.0)	11.0 (9.5,12.5)
Namibia	Diagnosis scenario	7.3 (6.4,8.2)	7.2 (6.4,7.9)	7.7 (6.7,8.7)	7.7 (6.5,9.0)	7.7 (6.5,9.0)
Namibia	Treatment scenario	7.2 (6.3,8.2)	7.1 (6.4,7.9)	7.7 (6.7,8.7)	7.7 (6.5,9.0)	7.7 (6.5,9.0)
Niger	Diagnosis scenario	9.9 (8.6,11.2)	10.0 (8.7,11.2)	9.5 (8.1,10.8)	10.4 (9.0,11.7)	10.4 (8.7,12.0)
Niger	Treatment scenario	9.8 (8.5,11.1)	10.0 (8.7,11.2)	9.5 (8.1,10.8)	10.4 (9.0,11.7)	10.4 (8.7,12.0)
Russian Federation	Diagnosis scenario	33.1 (29.2,36.9)	31.7 (27.6,35.9)	31.4 (27.3,35.5)	21.2 (13.3,29.1)	25.8 (19.6,32.0)
Russian Federation	Treatment scenario	33.0 (29.1,37.0)	31.1 (26.7,35.5)	30.5 (26.3,34.7)	21.2 (13.3,29.0)	25.1 (18.8,31.5)
Rwanda	Diagnosis scenario	10.6 (9.1,12.1)	8.8 (7.4,10.3)	8.0 (6.7,9.2)	9.1 (7.7,10.5)	8.6 (7.5,9.8)
Rwanda	Treatment scenario	10.6 (9.1,12.1)	8.8 (7.3,10.2)	7.9 (6.7,9.2)	9.1 (7.7,10.5)	8.6 (7.4,9.8)
Samoa	Diagnosis scenario	13.7 (11.9,15.7)	11.8 (10.1,13.6)	10.9 (8.5,13.4)	8.5 (6.4,10.6)	11.7 (9.8,13.6)
Samoa	Treatment scenario	13.7 (11.9,15.7)	11.8 (10.1,13.6)	10.9 (8.5,13.4)	8.4 (6.3,10.5)	11.7 (9.8,13.6)
Sao Tome and Principe	Diagnosis scenario	9.3 (8.5,10.2)	9.0 (8.2,9.7)	7.6 (6.9,8.4)	8.5 (7.7,9.2)	8.7 (8.1,9.4)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	9.3 (8.5,10.2)	8.9 (8.1,9.7)	7.6 (6.8,8.4)	8.5 (7.7,9.2)	8.7 (8.1,9.3)
Solomon Islands	Diagnosis scenario	15.3 (11.8,18.8)	14.7 (11.5,17.9)	12.3 (9.9,14.7)	12.7 (10.1,15.4)	14.1 (12.0,16.2)
Solomon Islands	Treatment scenario	15.3 (11.8,18.8)	14.7 (11.5,17.9)	12.3 (9.9,14.7)	12.7 (10.1,15.4)	14.1 (12.0,16.3)
South Africa	Diagnosis scenario	17.2 (15.3,19.1)	17.5 (15.9,19.1)	16.9 (15.1,18.9)	18.0 (16.0,20.0)	19.2 (17.5,20.8)
South Africa	Treatment scenario	17.2 (15.3,19.1)	17.5 (15.9,19.1)	16.9 (15.0,18.8)	17.9 (15.9,19.9)	19.1 (17.5,20.7)
Sri Lanka	Diagnosis scenario	17.1 (15.8,18.3)	17.1 (16.0,18.1)	15.2 (13.8,16.6)	15.0 (13.7,16.3)	15.1 (13.6,16.5)
Sri Lanka	Treatment scenario	17.1 (15.8,18.3)	17.1 (16.0,18.1)	15.2 (13.9,16.6)	14.9 (13.7,16.2)	15.1 (13.6,16.6)
St. Vincent & the Grenadines	Diagnosis scenario	16.4 (14.8,18.0)	14.9 (12.3,17.7)	12.7 (10.6,14.7)	13.0 (11.5,14.5)	11.7 (10.5,12.9)
St. Vincent & the Grenadines	Treatment scenario	16.3 (14.6,18.0)	14.9 (12.2,17.7)	12.6 (10.6,14.7)	13.0 (11.5,14.6)	11.7 (10.4,12.9)
Sudan	Diagnosis scenario	19.4 (17.9,21.0)	19.7 (18.5,20.8)	18.5 (17.4,19.7)	19.5 (17.6,21.4)	22.4 (19.7,25.4)
Sudan	Treatment scenario	19.4 (17.9,21.0)	19.7 (18.5,20.8)	18.5 (17.3,19.6)	19.5 (17.6,21.4)	22.3 (19.5,25.4)
Tanzania	Diagnosis scenario	8.1 (7.2,9.1)	7.5 (6.6,8.3)	8.0 (7.1,8.8)	7.5 (6.7,8.4)	10.7 (6.0,15.5)
Tanzania	Treatment scenario	8.1 (7.2,9.1)	7.4 (6.6,8.3)	7.9 (7.1,8.8)	7.5 (6.7,8.4)	10.7 (6.0,15.5)
Timor Leste	Diagnosis scenario	21.3 (16.4,26.1)	22.9 (19.9,25.8)	20.1 (16.8,23.5)	15.9 (13.0,18.9)	14.8 (11.9,17.7)
Timor Leste	Treatment scenario	21.3 (16.4,26.1)	22.8 (19.9,25.8)	20.1 (16.8,23.5)	15.9 (13.0,18.9)	14.7 (11.8,17.6)
Togo	Diagnosis scenario	11.9 (9.0,14.8)	10.2 (7.4,12.9)	11.9 (9.3,14.6)	10.4 (8.9,11.9)	10.1 (8.3,12.0)
Togo	Treatment scenario	11.9 (9.0,14.8)	10.2 (7.4,12.9)	11.9 (9.2,14.6)	10.4 (8.9,11.9)	10.1 (8.2,12.0)
Uganda	Diagnosis scenario	10.4 (7.5,13.4)	10.9 (8.8,13.1)	9.2 (7.3,11.1)	7.6 (6.2,9.1)	10.8 (7.9,13.7)
Uganda	Treatment scenario	10.4 (7.5,13.4)	10.9 (8.8,13.1)	9.2 (7.3,11.1)	7.6 (6.2,9.1)	10.8 (7.9,13.7)
Vanuatu	Diagnosis scenario	10.6 (9.6,11.5)	9.7 (8.7,10.7)	11.4 (10.1,12.8)	10.6 (9.3,11.8)	12.3 (10.7,13.8)
Vanuatu	Treatment scenario	10.6 (9.6,11.5)	9.7 (8.7,10.7)	11.4 (10.1,12.8)	10.6 (9.3,11.8)	12.2 (10.7,13.8)
Zambia	Diagnosis scenario	7.7 (6.3,9.2)	8.1 (6.4,9.9)	6.5 (5.3,7.8)	7.7 (5.8,9.5)	8.0 (5.8,10.1)
Zambia	Treatment scenario	7.7 (6.2,9.2)	8.1 (6.4,9.9)	6.5 (5.3,7.7)	7.6 (5.8,9.4)	7.9 (5.8,10.1)

Supplementary Table 23. Relative increase targets sensitivity analysis: Absolute (percentage point) difference in mean 10-year cardiovascular disease risk comparing the bottom (Q1) and top (Q5) wealth quintiles by country and modelled scenario, either Baseline, Diagnosis or Treatment scenario

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Afghanistan	Baseline	-2.7
Afghanistan	Diagnosis scenario	-2.7
Afghanistan	Treatment scenario	-2.4
Albania	Baseline	-0.6
Albania	Diagnosis scenario	-0.5
Albania	Treatment scenario	-0.5
Algeria	Baseline	-0.3
Algeria	Diagnosis scenario	-0.2
Algeria	Treatment scenario	-0.3
Azerbaijan	Baseline	2.5
Azerbaijan	Diagnosis scenario	2.4
Azerbaijan	Treatment scenario	2.3
Benin	Baseline	1.3
Benin	Diagnosis scenario	1.3
Benin	Treatment scenario	1.3
Bhutan	Baseline	0.6
Bhutan	Diagnosis scenario	0.5
Bhutan	Treatment scenario	0.6
Botswana	Baseline	3.1
Botswana	Diagnosis scenario	3.1
Botswana	Treatment scenario	3.1
Brazil	Baseline	2.1
Brazil	Diagnosis scenario	2.0
Brazil	Treatment scenario	2.1
Cambodia	Baseline	-0.8
Cambodia	Diagnosis scenario	-0.3
Cambodia	Treatment scenario	-0.2
China	Baseline	4.8
China	Diagnosis scenario	4.8
China	Treatment scenario	4.8
Ecuador	Baseline	0.3

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Ecuador	Diagnosis scenario	0.5
Ecuador	Treatment scenario	0.5
Eritrea	Baseline	1.4
Eritrea	Diagnosis scenario	1.5
Eritrea	Treatment scenario	1.5
Eswatini	Baseline	2.5
Eswatini	Diagnosis scenario	2.8
Eswatini	Treatment scenario	2.7
Ethiopia	Baseline	1.3
Ethiopia	Diagnosis scenario	1.3
Ethiopia	Treatment scenario	1.3
Gambia	Baseline	-0.7
Gambia	Diagnosis scenario	-0.6
Gambia	Treatment scenario	-0.6
Ghana	Baseline	1.4
Ghana	Diagnosis scenario	1.6
Ghana	Treatment scenario	1.7
India	Baseline	1.4
India	Diagnosis scenario	1.7
India	Treatment scenario	1.7
Indonesia	Baseline	5.6
Indonesia	Diagnosis scenario	5.9
Indonesia	Treatment scenario	5.9
Jordan	Baseline	-0.0
Jordan	Diagnosis scenario	-0.1
Jordan	Treatment scenario	0.1
Kenya	Baseline	0.7
Kenya	Diagnosis scenario	0.8
Kenya	Treatment scenario	0.9
Kiribati	Baseline	-6.5
Kiribati	Diagnosis scenario	-6.3
Kiribati	Treatment scenario	-6.4
Kyrgyzstan	Baseline	0.9
Kyrgyzstan	Diagnosis scenario	0.8

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Kyrgyzstan	Treatment scenario	0.8
Laos	Baseline	1.4
Laos	Diagnosis scenario	1.6
Laos	Treatment scenario	1.5
Lesotho	Baseline	0.2
Lesotho	Diagnosis scenario	0.3
Lesotho	Treatment scenario	0.3
Moldova	Baseline	2.7
Moldova	Diagnosis scenario	2.6
Moldova	Treatment scenario	2.6
Morocco	Baseline	0.3
Morocco	Diagnosis scenario	0.2
Morocco	Treatment scenario	0.2
Myanmar	Baseline	3.0
Myanmar	Diagnosis scenario	3.2
Myanmar	Treatment scenario	3.2
Namibia	Baseline	-0.8
Namibia	Diagnosis scenario	-0.5
Namibia	Treatment scenario	-0.5
Niger	Baseline	-0.5
Niger	Diagnosis scenario	-0.5
Niger	Treatment scenario	-0.5
Russian Federation	Baseline	7.7
Russian Federation	Diagnosis scenario	7.2
Russian Federation	Treatment scenario	7.9
Rwanda	Baseline	2.0
Rwanda	Diagnosis scenario	1.9
Rwanda	Treatment scenario	2.0
Samoa	Baseline	2.1
Samoa	Diagnosis scenario	2.0
Samoa	Treatment scenario	2.0
Sao Tome and Principe	Baseline	0.6
Sao Tome and Principe	Diagnosis scenario	0.6

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Sao Tome and Principe	Treatment scenario	0.6
Solomon Islands	Baseline	0.9
Solomon Islands	Diagnosis scenario	1.2
Solomon Islands	Treatment scenario	1.2
South Africa	Baseline	-2.5
South Africa	Diagnosis scenario	-1.9
South Africa	Treatment scenario	-1.9
Sri Lanka	Baseline	1.8
Sri Lanka	Diagnosis scenario	2.0
Sri Lanka	Treatment scenario	2.0
St. Vincent & the Grenadines	Baseline	4.9
St. Vincent & the Grenadines	Diagnosis scenario	4.7
St. Vincent & the Grenadines	Treatment scenario	4.6
Sudan	Baseline	-4.1
Sudan	Diagnosis scenario	-3.0
Sudan	Treatment scenario	-2.9
Tanzania	Baseline	-2.6
Tanzania	Diagnosis scenario	-2.5
Tanzania	Treatment scenario	-2.6
Timor Leste	Baseline	6.1
Timor Leste	Diagnosis scenario	6.4
Timor Leste	Treatment scenario	6.6
Togo	Baseline	1.7
Togo	Diagnosis scenario	1.8
Togo	Treatment scenario	1.8
Uganda	Baseline	-0.5
Uganda	Diagnosis scenario	-0.4
Uganda	Treatment scenario	-0.3
Vanuatu	Baseline	-1.7
Vanuatu	Diagnosis scenario	-1.7
Vanuatu	Treatment scenario	-1.7
Zambia	Baseline	-0.3
Zambia	Diagnosis scenario	-0.3

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Zambia	Treatment scenario	-0.2

Supplementary Table 24. Relative increase targets sensitivity analysis: Mean difference (95% uncertainty interval) in CVD cases per 1,000 people living with hypertension compared to baseline by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	20.8 (9.3,32.5)	21.9 (6.3,41.6)	9.8 (1.7,21.3)	13.6 (7.1,20.3)	21.4 (8.5,34.4)
Afghanistan	Treatment scenario	20.4 (8.8,32.4)	20.1 (5.9,39.5)	10.7 (1.7,24.2)	16.7 (7.7,27.1)	23.2 (9.8,36.7)
Albania	Diagnosis scenario	0.4 (-0.1,1.2)	0.5 (-0.0,1.4)	0.8 (0.1,1.9)	1.0 (0.2,2.1)	1.3 (0.4,2.5)
Albania	Treatment scenario	0.5 (-0.1,1.4)	0.5 (-0.0,1.4)	0.9 (0.1,2.3)	1.1 (0.2,2.4)	1.4 (0.4,2.6)
Algeria	Diagnosis scenario	3.5 (2.2,4.8)	3.0 (1.7,4.3)	4.2 (2.6,6.1)	3.7 (2.4,5.3)	4.1 (2.5,6.0)
Algeria	Treatment scenario	3.7 (2.4,5.2)	3.5 (2.0,5.4)	4.3 (2.6,6.2)	3.9 (2.5,5.6)	4.2 (2.6,6.0)
Azerbaijan	Diagnosis scenario	7.7 (4.1,11.9)	7.0 (1.6,14.8)	8.5 (4.1,14.3)	7.4 (3.2,12.2)	6.7 (1.2,15.0)
Azerbaijan	Treatment scenario	8.8 (4.8,13.7)	8.4 (2.3,17.2)	9.2 (4.5,15.2)	8.8 (4.0,14.3)	6.8 (1.6,14.6)
Benin	Diagnosis scenario	3.0 (-0.1,21.5)	1.9 (0.1,5.2)	1.7 (0.0,4.8)	2.8 (0.4,6.7)	3.0 (0.8,5.9)
Benin	Treatment scenario	3.0 (0.1,18.8)	2.0 (0.1,6.1)	2.0 (0.1,5.1)	2.7 (0.4,6.5)	3.2 (0.8,6.5)
Bhutan	Diagnosis scenario	3.3 (1.3,6.1)	3.4 (1.5,5.6)	2.8 (0.4,6.3)	3.1 (0.9,5.9)	3.2 (0.6,6.8)
Bhutan	Treatment scenario	3.2 (1.3,5.9)	3.7 (1.5,6.5)	3.0 (0.4,6.6)	3.5 (0.8,8.1)	3.5 (0.9,7.3)
Botswana	Diagnosis scenario	6.3 (1.1,16.5)	5.1 (1.7,9.5)	5.1 (0.5,13.4)	3.3 (0.5,8.0)	6.9 (1.6,13.8)
Botswana	Treatment scenario	6.3 (1.2,16.3)	5.3 (2.0,9.7)	5.6 (1.3,13.9)	4.8 (0.3,14.2)	6.3 (1.9,12.8)
Brazil	Diagnosis scenario	8.0 (6.9,9.1)	9.0 (7.3,10.8)	7.9 (6.8,9.0)	7.5 (6.4,8.6)	7.5 (6.4,8.7)
Brazil	Treatment scenario	8.5 (7.3,9.7)	9.0 (7.3,11.0)	9.1 (7.5,10.9)	8.6 (7.4,9.9)	8.4 (6.9,9.9)
Cambodia	Diagnosis scenario	5.1 (1.4,11.5)	6.8 (2.7,11.6)	5.9 (1.6,11.5)	8.2 (3.3,15.4)	10.0 (4.8,15.7)
Cambodia	Treatment scenario	4.9 (1.3,11.1)	7.1 (2.8,12.1)	6.5 (1.9,12.6)	9.2 (4.0,16.5)	10.9 (5.4,17.2)
China	Diagnosis scenario	9.8 (6.9,12.9)	8.2 (5.8,10.9)	7.4 (5.2,9.8)	8.4 (5.9,11.1)	9.7 (7.2,12.4)
China	Treatment scenario	9.9 (7.1,13.0)	8.6 (6.0,11.4)	7.6 (5.3,10.1)	8.5 (6.0,11.2)	10.1 (7.4,12.9)
Ecuador	Diagnosis scenario	4.8 (1.6,10.3)	5.1 (3.2,7.1)	5.9 (2.3,10.1)	5.0 (2.4,7.7)	5.9 (3.2,8.9)
Ecuador	Treatment scenario	4.6 (1.6,9.9)	5.5 (3.5,7.9)	6.0 (2.5,10.3)	5.2 (2.6,8.1)	6.5 (3.4,9.9)
Eritrea	Diagnosis scenario	3.6 (1.3,6.5)	4.0 (-1.2,12.7)	4.6 (1.5,8.9)	5.8 (2.0,11.4)	5.5 (1.7,11.1)
Eritrea	Treatment scenario	4.0 (1.5,7.6)	4.3 (-1.3,13.5)	4.5 (1.5,8.7)	5.8 (2.1,11.2)	5.6 (1.8,11.0)
Eswatini	Diagnosis scenario	5.7 (1.4,12.4)	6.0 (-0.0,19.1)	6.3 (1.4,12.9)	5.9 (0.3,16.9)	8.4 (0.0,22.1)
Eswatini	Treatment scenario	5.8 (1.7,12.3)	6.2 (0.4,18.7)	9.2 (0.4,32.4)	5.3 (0.6,15.9)	8.1 (0.3,21.7)
Ethiopia	Diagnosis scenario	1.2 (-0.1,4.6)	1.9 (-0.2,6.8)	1.0 (-0.4,4.2)	1.2 (-0.2,3.9)	1.5 (-0.2,4.5)
Ethiopia	Treatment scenario	1.3 (-0.2,4.9)	2.1 (-0.1,7.1)	1.4 (-0.4,5.1)	1.2 (-0.2,4.2)	1.7 (-0.1,4.8)
Gambia	Diagnosis scenario	3.3 (0.7,6.9)	3.2 (0.3,7.4)	3.2 (0.4,8.6)	2.8 (0.3,6.8)	3.6 (0.6,7.8)
Gambia	Treatment scenario	3.6 (0.7,7.7)	3.9 (0.5,9.0)	3.4 (0.4,8.7)	3.7 (0.6,8.0)	4.4 (0.9,9.5)
Ghana	Diagnosis scenario	0.7 (-0.0,2.2)	1.4 (0.3,3.5)	1.8 (0.6,3.7)	4.7 (2.5,7.7)	3.4 (1.5,6.1)
Ghana	Treatment scenario	0.7 (-0.0,2.2)	1.5 (0.3,3.5)	1.8 (0.6,3.8)	4.8 (2.6,7.6)	3.5 (1.5,6.4)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario	2.0 (1.3,3.0)	2.6 (1.8,3.5)	3.4 (2.5,4.5)	3.9 (3.0,5.1)	4.6 (3.8,5.6)
India	Treatment scenario	2.0 (1.3,3.0)	2.6 (1.8,3.5)	3.5 (2.6,4.6)	4.0 (3.0,5.1)	4.8 (3.9,5.7)
Indonesia	Diagnosis scenario	3.8 (2.3,5.5)	4.9 (3.2,6.8)	5.4 (3.7,7.4)	5.7 (4.1,7.4)	6.4 (4.5,8.4)
Indonesia	Treatment scenario	4.1 (2.4,6.1)	5.3 (3.5,7.4)	5.8 (4.0,7.8)	6.4 (4.5,8.5)	6.8 (4.8,8.9)
Jordan	Diagnosis scenario	8.1 (4.3,12.1)	5.4 (3.3,7.5)	4.5 (2.4,6.7)	6.9 (3.5,10.6)	7.4 (4.7,10.2)
Jordan	Treatment scenario	8.1 (4.3,12.1)	6.9 (4.6,9.1)	7.7 (4.3,11.3)	6.9 (3.5,10.6)	8.9 (4.6,14.9)
Kenya	Diagnosis scenario	0.5 (-0.2,2.0)	0.7 (-0.1,2.3)	1.7 (0.1,5.0)	0.9 (-0.1,2.9)	1.4 (0.1,3.1)
Kenya	Treatment scenario	0.5 (-0.2,2.0)	0.9 (-0.1,2.8)	1.9 (0.2,5.2)	0.9 (-0.1,2.9)	2.1 (0.2,5.4)
Kiribati	Diagnosis scenario	0.7 (-0.7,4.1)	2.0 (-1.0,19.1)	0.5 (-0.3,5.5)	0.0 (0.0,0.0)	2.4 (-0.9,20.0)
Kiribati	Treatment scenario	0.7 (-0.7,3.9)	1.4 (-0.9,9.5)	0.8 (-0.3,9.1)	0.0 (0.0,0.0)	1.9 (-0.8,20.1)
Kyrgyzstan	Diagnosis scenario	5.9 (2.2,10.5)	8.7 (4.2,14.2)	5.1 (1.1,14.0)	5.1 (1.9,9.6)	4.9 (1.1,10.0)
Kyrgyzstan	Treatment scenario	6.3 (2.5,11.3)	9.8 (4.8,16.0)	5.9 (1.0,16.8)	5.6 (2.2,10.2)	5.8 (1.4,13.0)
Laos	Diagnosis scenario	2.8 (-1.5,13.0)	5.9 (-0.9,24.2)	4.0 (0.4,9.2)	6.9 (2.5,12.3)	5.4 (-0.0,19.2)
Laos	Treatment scenario	4.7 (-1.6,17.4)	6.7 (-0.4,24.4)	5.3 (0.3,17.2)	8.1 (3.3,13.7)	6.0 (0.4,18.9)
Lesotho	Diagnosis scenario	5.2 (1.3,10.3)	6.1 (1.7,11.5)	4.9 (0.7,10.9)	7.1 (1.4,15.2)	5.4 (2.9,8.3)
Lesotho	Treatment scenario	5.3 (1.4,10.4)	5.8 (1.4,11.5)	4.8 (0.8,10.6)	7.0 (1.5,15.0)	6.1 (2.8,10.5)
Moldova	Diagnosis scenario	7.3 (4.5,10.8)	8.1 (5.1,11.7)	8.3 (5.1,12.1)	7.7 (3.3,13.2)	6.7 (3.6,10.7)
Moldova	Treatment scenario	8.2 (5.2,11.9)	10.1 (6.2,14.6)	9.5 (5.7,14.2)	9.1 (4.1,15.5)	7.2 (3.9,11.3)
Morocco	Diagnosis scenario	3.9 (2.6,5.4)	3.3 (0.9,6.6)	3.4 (1.4,6.0)	3.1 (0.6,6.7)	3.6 (1.8,5.8)
Morocco	Treatment scenario	4.1 (2.7,5.7)	3.4 (1.0,6.6)	4.2 (1.6,7.8)	3.3 (0.7,6.9)	3.8 (2.0,6.1)
Myanmar	Diagnosis scenario	4.5 (1.7,8.4)	6.0 (2.3,13.1)	6.0 (2.7,10.5)	5.7 (2.8,9.6)	6.7 (3.6,10.2)
Myanmar	Treatment scenario	5.2 (1.7,11.2)	6.4 (2.8,12.4)	6.9 (3.2,11.6)	6.3 (3.2,10.3)	7.3 (3.6,11.7)
Namibia	Diagnosis scenario	2.8 (1.3,4.8)	3.3 (1.9,5.0)	5.6 (3.1,9.0)	6.6 (3.6,10.5)	6.5 (4.2,8.8)
Namibia	Treatment scenario	3.2 (1.4,5.4)	3.5 (2.0,5.1)	5.7 (3.2,9.2)	6.6 (3.6,10.5)	6.8 (4.4,9.3)
Niger	Diagnosis scenario	0.3 (-0.3,1.5)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.3 (-0.3,1.6)	0.7 (-0.4,2.9)
Niger	Treatment scenario	0.6 (-0.3,2.3)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.3 (-0.3,1.6)	0.7 (-0.4,2.7)
Russian Federation	Diagnosis scenario	15.5 (6.1,27.9)	11.4 (6.2,17.0)	14.9 (9.9,19.9)	9.2 (4.0,15.0)	10.3 (5.2,15.5)
Russian Federation	Treatment scenario	15.7 (6.7,27.9)	17.8 (10.6,25.9)	23.6 (16.8,30.6)	9.7 (4.3,15.8)	17.3 (9.6,25.0)
Rwanda	Diagnosis scenario	0.6 (-0.3,2.3)	0.3 (-0.3,1.6)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.3 (-0.3,1.5)
Rwanda	Treatment scenario	0.6 (-0.3,2.2)	0.6 (-0.3,2.3)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.5 (-0.3,2.2)
Samoa	Diagnosis scenario	3.2 (-0.5,10.9)	0.0 (0.0,0.0)	3.3 (-0.8,11.6)	0.7 (-0.6,3.7)	2.2 (-0.7,8.1)
Samoa	Treatment scenario	3.2 (-0.5,10.7)	0.0 (0.0,0.0)	3.8 (-0.6,12.6)	1.3 (-0.6,5.3)	2.2 (-0.7,8.1)
Sao Tome and Principe	Diagnosis scenario	3.0 (0.6,6.5)	1.7 (0.2,3.9)	1.7 (0.2,3.8)	2.4 (0.6,4.6)	2.9 (1.0,5.4)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	3.3 (0.6,8.0)	2.2 (0.3,5.0)	2.1 (0.3,4.7)	2.5 (0.6,5.2)	3.4 (1.2,6.2)
Solomon Islands	Diagnosis scenario	1.7 (-0.8,9.5)	0.7 (-0.6,3.5)	1.5 (-0.7,5.3)	0.9 (-0.8,4.7)	4.9 (0.2,10.5)
Solomon Islands	Treatment scenario	1.7 (-0.8,7.2)	0.8 (-0.7,4.1)	1.5 (-0.8,5.2)	0.9 (-0.8,4.3)	4.6 (0.0,10.4)
South Africa	Diagnosis scenario	8.2 (4.9,12.3)	10.0 (6.4,14.1)	12.9 (7.7,20.1)	13.2 (9.5,17.2)	13.8 (9.5,18.4)
South Africa	Treatment scenario	8.3 (5.0,12.3)	10.1 (6.5,14.2)	13.3 (8.2,20.5)	14.2 (9.9,18.9)	14.2 (9.8,18.8)
Sri Lanka	Diagnosis scenario	7.3 (4.3,10.9)	7.7 (4.6,11.3)	6.4 (3.4,10.0)	8.4 (4.6,12.6)	9.9 (4.7,15.8)
Sri Lanka	Treatment scenario	7.5 (4.4,11.1)	7.7 (4.6,11.3)	6.4 (3.4,10.0)	8.8 (4.7,13.5)	9.5 (4.5,15.5)
St. Vincent & the Grenadines	Diagnosis scenario	11.1 (7.1,15.3)	10.9 (3.9,22.0)	8.1 (2.9,14.3)	7.4 (3.0,12.5)	8.9 (6.2,11.5)
St. Vincent & the Grenadines	Treatment scenario	11.9 (7.6,16.7)	11.5 (4.5,22.6)	8.4 (3.0,14.7)	7.0 (2.9,11.9)	9.1 (5.9,12.4)
Sudan	Diagnosis scenario	2.7 (0.7,5.5)	5.8 (3.3,9.4)	5.5 (3.0,9.3)	6.2 (2.1,12.4)	14.3 (2.3,31.7)
Sudan	Treatment scenario	2.9 (0.8,5.9)	6.0 (3.5,9.5)	5.7 (3.1,9.5)	6.1 (1.9,12.6)	15.5 (3.3,32.8)
Tanzania	Diagnosis scenario	1.4 (0.3,3.4)	2.0 (0.5,4.4)	1.0 (-0.0,2.9)	0.4 (-0.1,1.5)	1.7 (-0.1,14.2)
Tanzania	Treatment scenario	1.5 (0.2,3.8)	2.0 (0.5,4.4)	1.2 (0.0,3.1)	0.4 (-0.1,1.6)	1.5 (-0.1,13.0)
Timor Leste	Diagnosis scenario	1.4 (-1.4,7.6)	4.6 (0.3,10.3)	5.1 (0.2,12.3)	6.5 (0.9,14.2)	5.1 (0.8,11.4)
Timor Leste	Treatment scenario	1.4 (-1.3,7.2)	5.2 (0.7,11.1)	5.2 (0.3,12.4)	6.5 (0.8,14.1)	6.4 (1.5,13.0)
Togo	Diagnosis scenario	1.3 (-0.4,4.6)	1.4 (-0.4,7.0)	2.4 (-0.3,7.2)	0.9 (-0.5,4.0)	2.3 (-0.0,6.7)
Togo	Treatment scenario	1.4 (-0.4,4.8)	1.3 (-0.4,5.5)	2.5 (-0.2,7.4)	1.1 (-0.6,4.7)	2.6 (0.0,6.8)
Uganda	Diagnosis scenario	1.4 (-0.3,6.9)	1.2 (-0.4,5.5)	1.8 (-0.3,5.4)	0.9 (-0.3,3.8)	2.1 (-0.4,10.5)
Uganda	Treatment scenario	1.3 (-0.2,4.9)	1.3 (-0.5,5.4)	1.9 (-0.2,5.3)	0.9 (-0.3,3.6)	2.5 (-0.8,11.5)
Vanuatu	Diagnosis scenario	0.3 (-0.1,1.1)	0.2 (-0.2,1.0)	0.0 (0.0,0.0)	0.2 (-0.2,1.1)	0.5 (-0.1,2.1)
Vanuatu	Treatment scenario	0.3 (-0.2,1.2)	0.2 (-0.2,1.1)	0.3 (-0.3,1.7)	0.2 (-0.2,1.1)	0.7 (-0.1,2.4)
Zambia	Diagnosis scenario	1.6 (0.1,4.1)	2.5 (-0.2,7.0)	1.3 (-0.0,3.3)	2.1 (0.2,4.8)	2.2 (0.4,4.5)
Zambia	Treatment scenario	1.9 (0.2,4.6)	2.5 (-0.2,7.2)	1.6 (-0.1,4.8)	3.1 (-0.2,9.7)	2.9 (0.1,8.6)

Supplementary Table 25. Relative increase targets sensitivity analysis: Mean (95% uncertainty interval) relative decline (%) in CVD risk compared to baseline by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	2.6 (0.3,6.4)	4.3 (1.3,8.1)	4.4 (1.2,8.4)	1.2 (-0.1,3.4)	1.8 (-0.0,4.6)
Afghanistan	Treatment scenario	2.1 (0.2,5.6)	4.2 (1.3,7.8)	10.0 (5.0,15.1)	4.4 (1.4,8.1)	0.0 (0.0,0.0)
Albania	Diagnosis scenario	5.8 (3.5,8.3)	7.5 (5.1,10.0)	7.3 (5.0,9.6)	8.4 (5.7,11.2)	8.4 (5.7,11.1)
Albania	Treatment scenario	17.2 (14.1,20.2)	16.6 (13.7,19.4)	16.1 (13.4,18.8)	15.2 (12.1,18.2)	12.9 (10.0,15.8)
Algeria	Diagnosis scenario	5.5 (4.1,6.8)	6.0 (4.4,7.6)	5.9 (4.2,7.5)	4.8 (3.4,6.3)	5.0 (3.5,6.5)
Algeria	Treatment scenario	10.1 (8.5,11.8)	11.4 (9.5,13.3)	9.5 (7.5,11.5)	8.6 (6.9,10.4)	8.8 (7.1,10.6)
Azerbaijan	Diagnosis scenario	4.2 (2.5,5.9)	5.8 (2.6,9.4)	4.3 (2.2,6.6)	0.9 (0.0,2.0)	3.3 (1.2,5.5)
Azerbaijan	Treatment scenario	7.7 (5.5,10.0)	8.1 (4.6,11.9)	6.8 (4.3,9.4)	7.0 (4.6,9.6)	7.3 (4.3,10.4)
Benin	Diagnosis scenario	13.3 (5.4,24.1)	10.1 (7.0,13.5)	16.9 (13.5,20.5)	11.3 (8.1,14.5)	7.3 (4.6,10.1)
Benin	Treatment scenario	17.7 (8.4,26.8)	18.3 (14.9,21.7)	17.4 (14.0,21.0)	16.2 (12.9,19.6)	16.3 (12.8,19.7)
Bhutan	Diagnosis scenario	4.6 (2.7,6.8)	4.3 (2.3,6.4)	5.9 (3.0,9.1)	2.2 (0.5,4.2)	3.9 (1.8,6.4)
Bhutan	Treatment scenario	12.4 (9.7,15.2)	11.6 (8.8,14.5)	13.3 (9.7,17.0)	11.2 (7.6,15.0)	11.8 (8.5,15.1)
Botswana	Diagnosis scenario	3.5 (0.4,10.9)	5.2 (1.7,10.5)	2.5 (0.4,5.5)	3.4 (0.7,6.7)	3.2 (0.9,5.9)
Botswana	Treatment scenario	10.2 (4.9,17.4)	7.1 (3.2,12.5)	7.1 (3.7,10.9)	11.2 (6.7,15.9)	7.2 (3.9,10.8)
Brazil	Diagnosis scenario	3.8 (3.1,4.6)	2.7 (2.1,3.4)	2.0 (1.4,2.7)	1.8 (1.3,2.4)	2.0 (1.4,2.6)
Brazil	Treatment scenario	3.3 (2.6,4.1)	2.5 (1.9,3.3)	1.5 (1.0,2.1)	1.2 (0.8,1.7)	1.1 (0.7,1.6)
Cambodia	Diagnosis scenario	8.3 (5.4,11.2)	8.9 (5.8,12.1)	7.2 (4.1,10.4)	4.9 (2.6,7.3)	4.0 (1.8,6.4)
Cambodia	Treatment scenario	13.9 (10.7,17.2)	12.0 (8.8,15.4)	12.5 (8.8,16.2)	11.2 (8.2,14.3)	8.4 (5.3,11.6)
China	Diagnosis scenario	7.8 (6.6,9.0)	7.5 (6.4,8.7)	8.7 (7.5,9.9)	6.7 (5.6,7.9)	6.1 (5.0,7.2)
China	Treatment scenario	8.7 (7.5,10.0)	8.6 (7.3,9.8)	9.2 (8.0,10.5)	7.6 (6.4,8.8)	6.0 (4.8,7.1)
Ecuador	Diagnosis scenario	5.5 (2.8,8.5)	3.7 (2.1,5.5)	2.2 (0.5,4.3)	1.6 (0.1,3.4)	3.7 (1.4,6.5)
Ecuador	Treatment scenario	9.0 (5.8,12.4)	5.5 (3.6,7.6)	4.7 (2.2,7.5)	4.3 (1.9,7.0)	2.9 (0.9,5.5)
Eritrea	Diagnosis scenario	7.9 (5.8,10.1)	11.4 (5.9,17.0)	9.7 (6.5,13.1)	6.3 (3.9,8.8)	6.0 (3.4,8.8)
Eritrea	Treatment scenario	15.6 (13.1,18.2)	14.3 (8.7,20.0)	13.1 (9.7,16.7)	11.8 (8.8,15.0)	13.1 (9.5,16.6)
Eswatini	Diagnosis scenario	5.0 (2.2,8.5)	4.8 (1.7,9.4)	3.2 (0.8,6.2)	4.3 (0.7,9.2)	3.4 (0.6,6.8)
Eswatini	Treatment scenario	11.3 (7.5,15.3)	11.4 (7.0,16.0)	10.1 (5.4,15.3)	9.2 (3.9,14.8)	7.1 (2.9,11.8)
Ethiopia	Diagnosis scenario	6.2 (3.5,9.1)	7.6 (3.7,12.0)	8.6 (4.6,13.0)	5.9 (2.5,10.0)	8.1 (4.0,12.8)
Ethiopia	Treatment scenario	17.7 (14.0,21.2)	15.4 (10.6,20.2)	17.5 (12.8,22.2)	17.0 (12.2,21.5)	16.6 (11.7,21.3)
Gambia	Diagnosis scenario	9.8 (6.6,13.1)	8.3 (4.9,11.8)	8.6 (5.6,11.9)	8.4 (4.4,13.0)	4.5 (2.0,7.4)
Gambia	Treatment scenario	15.6 (12.0,19.2)	14.0 (9.8,18.0)	15.3 (11.7,19.0)	13.4 (8.8,18.3)	13.7 (9.6,17.9)
Ghana	Diagnosis scenario	11.0 (6.7,15.8)	14.9 (10.2,19.5)	13.0 (8.7,17.4)	9.3 (5.7,13.3)	9.8 (6.2,13.8)
Ghana	Treatment scenario	18.2 (13.5,22.4)	17.6 (12.8,22.1)	16.7 (12.3,20.9)	12.5 (8.5,16.6)	13.1 (9.2,17.1)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario	9.9 (9.2,10.7)	8.6 (7.9,9.3)	7.4 (6.7,8.1)	7.4 (6.7,8.1)	6.7 (6.1,7.3)
India	Treatment scenario	15.1 (14.3,15.9)	14.2 (13.4,14.9)	12.9 (12.1,13.7)	12.2 (11.4,13.0)	10.6 (9.9,11.2)
Indonesia	Diagnosis scenario	3.4 (2.7,4.1)	4.3 (3.6,5.1)	3.8 (3.1,4.6)	4.0 (3.3,4.8)	4.5 (3.6,5.3)
Indonesia	Treatment scenario	18.1 (16.9,19.3)	17.1 (16.0,18.3)	16.7 (15.5,18.0)	15.6 (14.4,16.8)	14.5 (13.4,15.6)
Jordan	Diagnosis scenario	2.0 (0.3,4.7)	0.8 (0.0,2.1)	0.1 (-0.1,0.7)	3.2 (1.2,5.5)	2.9 (1.4,4.6)
Jordan	Treatment scenario	3.3 (1.2,6.1)	0.0 (0.0,0.0)	1.3 (0.1,3.0)	3.5 (1.4,5.8)	3.1 (1.5,5.0)
Kenya	Diagnosis scenario	5.8 (3.2,8.7)	5.5 (2.8,8.6)	6.3 (3.0,10.9)	5.0 (2.0,9.4)	2.7 (0.4,6.0)
Kenya	Treatment scenario	19.1 (15.4,22.8)	17.6 (14.0,21.1)	16.1 (11.6,20.5)	17.4 (12.7,21.8)	14.2 (9.0,18.9)
Kiribati	Diagnosis scenario	4.8 (-0.3,13.8)	8.1 (-0.4,22.6)	1.6 (-0.5,9.7)	3.1 (-1.1,11.8)	2.4 (-1.0,11.9)
Kiribati	Treatment scenario	15.6 (6.2,23.7)	16.8 (3.7,31.3)	16.5 (4.1,25.8)	16.5 (6.2,25.7)	16.9 (5.1,28.5)
Kyrgyzstan	Diagnosis scenario	6.5 (4.2,8.9)	4.6 (2.7,6.6)	3.5 (1.6,5.8)	4.3 (2.3,6.4)	4.0 (1.8,6.9)
Kyrgyzstan	Treatment scenario	12.6 (9.9,15.3)	9.2 (6.7,11.7)	13.6 (9.5,18.0)	12.8 (9.9,15.7)	12.1 (8.7,15.5)
Laos	Diagnosis scenario	10.2 (4.1,17.5)	8.4 (2.7,16.0)	5.9 (2.7,9.5)	4.0 (1.6,6.6)	7.4 (3.3,12.2)
Laos	Treatment scenario	15.6 (8.9,22.8)	12.0 (5.5,19.1)	14.2 (9.6,19.1)	9.1 (5.7,12.7)	12.4 (7.6,17.4)
Lesotho	Diagnosis scenario	8.3 (4.3,12.6)	5.9 (2.9,9.0)	10.2 (5.6,15.2)	5.1 (1.8,9.1)	4.8 (2.3,7.4)
Lesotho	Treatment scenario	8.7 (4.4,13.4)	8.2 (4.6,11.9)	12.3 (7.4,17.4)	4.8 (1.5,8.7)	4.9 (2.3,7.8)
Moldova	Diagnosis scenario	3.6 (2.4,5.0)	3.0 (1.8,4.4)	3.1 (1.8,4.6)	4.2 (2.2,6.5)	3.6 (2.1,5.3)
Moldova	Treatment scenario	11.5 (9.6,13.4)	10.1 (8.0,12.3)	9.7 (7.5,12.0)	9.1 (6.4,11.9)	10.2 (8.0,12.5)
Morocco	Diagnosis scenario	7.1 (5.9,8.4)	6.7 (4.4,9.2)	5.4 (3.4,7.4)	5.5 (3.2,7.8)	6.4 (4.7,8.1)
Morocco	Treatment scenario	11.2 (9.8,12.6)	11.7 (9.1,14.4)	11.1 (8.6,13.6)	12.8 (9.9,15.7)	10.8 (8.9,12.7)
Myanmar	Diagnosis scenario	4.1 (2.2,6.2)	4.6 (2.1,8.8)	3.3 (1.3,6.4)	4.3 (2.3,6.9)	3.1 (1.4,5.3)
Myanmar	Treatment scenario	15.5 (11.9,19.5)	12.9 (9.4,17.1)	11.2 (7.8,15.2)	10.7 (8.0,13.8)	9.5 (6.4,13.3)
Namibia	Diagnosis scenario	10.8 (8.6,13.1)	7.9 (6.0,10.0)	6.3 (4.5,8.2)	6.7 (4.7,9.0)	1.8 (0.7,3.0)
Namibia	Treatment scenario	11.9 (9.6,14.2)	10.0 (7.8,12.2)	6.1 (4.2,8.1)	6.6 (4.6,8.8)	2.4 (1.1,3.9)
Niger	Diagnosis scenario	15.2 (12.0,18.5)	0.0 (0.0,0.0)	7.8 (4.8,10.7)	8.4 (5.8,11.1)	10.6 (7.5,13.8)
Niger	Treatment scenario	20.6 (17.4,23.7)	22.2 (19.2,25.2)	22.2 (18.8,25.6)	20.9 (17.9,23.9)	20.2 (16.8,23.5)
Russian Federation	Diagnosis scenario	2.8 (0.8,5.6)	0.0 (0.0,0.0)	0.3 (-0.1,1.1)	5.8 (1.3,15.5)	0.4 (-0.0,1.6)
Russian Federation	Treatment scenario	7.2 (4.0,10.8)	3.3 (1.0,7.3)	1.1 (0.2,2.2)	5.2 (1.2,14.8)	0.2 (-0.1,0.8)
Rwanda	Diagnosis scenario	9.0 (6.2,11.7)	12.3 (9.0,15.6)	4.3 (2.1,6.5)	1.5 (0.0,3.0)	6.1 (3.7,8.6)
Rwanda	Treatment scenario	19.3 (16.3,22.3)	19.5 (16.2,22.8)	19.7 (16.6,22.8)	19.5 (16.1,22.9)	19.5 (16.4,22.6)
Samoa	Diagnosis scenario	15.5 (10.0,21.1)	22.3 (15.3,27.7)	9.3 (4.0,15.1)	7.7 (2.1,13.9)	10.1 (4.9,15.8)
Samoa	Treatment scenario	15.7 (9.9,21.5)	18.8 (11.4,25.4)	13.7 (7.6,20.1)	16.9 (10.4,23.2)	14.8 (9.2,20.4)
Sao Tome and Principe	Diagnosis scenario	6.8 (4.1,9.5)	6.2 (3.9,8.6)	9.1 (6.4,11.8)	4.7 (2.3,7.1)	8.2 (5.7,10.8)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	15.1 (11.9,18.3)	16.8 (13.7,20.0)	15.8 (12.7,19.0)	14.9 (11.4,18.5)	14.2 (11.3,17.2)
Solomon Islands	Diagnosis scenario	3.0 (0.4,6.7)	3.9 (1.1,7.2)	3.5 (0.8,6.6)	1.7 (-0.3,4.5)	2.1 (-0.1,4.8)
Solomon Islands	Treatment scenario	17.7 (12.7,22.4)	17.9 (13.3,22.6)	16.4 (11.6,21.0)	17.8 (12.6,22.9)	13.4 (8.0,18.9)
South Africa	Diagnosis scenario	9.6 (7.8,11.4)	8.6 (7.0,10.1)	5.8 (4.1,7.6)	4.8 (3.4,6.3)	5.0 (3.5,6.5)
South Africa	Treatment scenario	9.9 (8.1,11.9)	8.2 (6.7,9.8)	4.5 (3.1,6.2)	4.0 (2.7,5.4)	3.8 (2.5,5.2)
Sri Lanka	Diagnosis scenario	6.0 (4.3,7.7)	7.1 (5.5,8.7)	7.6 (5.7,9.6)	5.2 (3.2,7.4)	3.3 (1.5,5.3)
Sri Lanka	Treatment scenario	9.9 (7.9,12.0)	10.8 (9.0,12.6)	10.3 (8.3,12.3)	7.5 (5.2,10.0)	7.3 (4.6,10.2)
St. Vincent & the Grenadines	Diagnosis scenario	2.3 (0.9,4.0)	3.0 (1.0,5.7)	3.6 (1.1,6.5)	4.8 (2.1,7.7)	2.2 (0.9,4.3)
St. Vincent & the Grenadines	Treatment scenario	4.8 (2.8,7.1)	8.4 (5.1,11.8)	7.7 (4.2,11.5)	8.9 (5.4,12.3)	4.3 (2.3,7.1)
Sudan	Diagnosis scenario	12.2 (9.8,14.7)	10.8 (9.3,12.5)	8.1 (6.5,9.8)	8.2 (5.6,10.9)	6.0 (1.7,10.7)
Sudan	Treatment scenario	15.8 (13.4,18.2)	13.3 (11.7,15.0)	13.0 (11.1,14.9)	12.3 (9.3,15.3)	6.2 (1.9,10.9)
Tanzania	Diagnosis scenario	12.4 (9.1,15.6)	10.3 (7.0,13.9)	8.5 (5.2,12.4)	4.2 (1.9,6.9)	4.9 (1.0,12.2)
Tanzania	Treatment scenario	18.4 (15.1,21.7)	16.3 (12.7,20.0)	18.5 (14.6,22.5)	20.2 (16.4,23.8)	20.1 (12.9,29.1)
Timor Leste	Diagnosis scenario	5.4 (2.2,8.7)	8.2 (5.5,11.0)	8.2 (4.9,11.5)	8.3 (4.8,11.8)	3.4 (1.2,5.7)
Timor Leste	Treatment scenario	18.1 (13.8,22.4)	15.3 (12.2,18.5)	14.2 (10.5,17.9)	12.5 (8.7,16.4)	11.6 (7.8,15.3)
Togo	Diagnosis scenario	6.1 (2.9,9.6)	5.7 (2.1,10.2)	6.7 (3.4,10.5)	3.9 (0.8,8.2)	5.5 (2.4,8.8)
Togo	Treatment scenario	17.7 (13.3,22.1)	18.2 (13.0,23.4)	16.2 (11.8,20.5)	18.5 (13.0,23.9)	14.1 (10.0,18.2)
Uganda	Diagnosis scenario	13.0 (8.6,17.6)	5.3 (1.9,9.6)	6.8 (3.1,11.0)	6.7 (2.8,11.9)	2.1 (-0.3,5.7)
Uganda	Treatment scenario	16.9 (12.4,21.4)	18.2 (13.2,23.0)	15.4 (10.7,20.1)	17.0 (11.9,22.1)	15.7 (9.3,23.2)
Vanuatu	Diagnosis scenario	6.2 (4.2,8.3)	1.7 (0.5,3.2)	2.1 (0.5,4.2)	1.2 (0.2,2.4)	3.4 (1.9,5.1)
Vanuatu	Treatment scenario	19.6 (17.1,22.0)	19.3 (16.5,22.2)	19.3 (15.9,22.6)	20.1 (17.3,22.9)	19.4 (16.9,21.8)
Zambia	Diagnosis scenario	5.4 (2.6,8.7)	6.5 (2.2,11.4)	6.2 (2.5,10.6)	2.0 (0.1,5.4)	2.2 (0.0,4.9)
Zambia	Treatment scenario	15.4 (11.5,19.3)	13.5 (7.5,19.8)	15.7 (10.7,20.7)	14.1 (9.0,19.4)	12.3 (6.7,18.2)

Supplementary Table 26. Within-country targets sensitivity analysis: Mean (95% uncertainty interval) 10-year CVD risk by country and wealth quintile in Diagnosis and Treatment scenarios

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	20.7 (18.3,23.1)	20.9 (16.3,25.5)	21.8 (19.1,24.5)	21.9 (19.1,24.7)	23.7 (20.6,26.7)
Afghanistan	Treatment scenario	20.4 (18.1,22.8)	20.5 (16.1,25.0)	20.1 (17.4,22.8)	20.9 (18.0,23.7)	23.7 (20.6,26.7)
Albania	Diagnosis scenario	4.7 (4.2,5.2)	4.9 (4.3,5.4)	5.3 (4.7,6.0)	5.3 (4.7,5.9)	5.3 (4.7,6.0)
Albania	Treatment scenario	4.6 (4.0,5.1)	4.8 (4.3,5.3)	5.2 (4.6,5.9)	5.3 (4.6,5.9)	5.3 (4.7,6.0)
Algeria	Diagnosis scenario	8.4 (7.8,9.0)	8.8 (8.0,9.5)	9.0 (8.4,9.7)	8.2 (7.5,8.8)	8.7 (8.1,9.4)
Algeria	Treatment scenario	8.3 (7.7,8.9)	8.7 (7.9,9.4)	9.1 (8.4,9.7)	8.2 (7.5,8.8)	8.7 (8.1,9.4)
Azerbaijan	Diagnosis scenario	15.5 (13.7,17.3)	16.3 (12.7,20.0)	15.9 (13.9,17.8)	15.2 (13.4,17.1)	13.1 (10.5,15.7)
Azerbaijan	Treatment scenario	15.8 (13.9,17.6)	16.7 (13.1,20.4)	16.3 (14.4,18.3)	15.2 (13.3,17.1)	13.2 (10.6,15.9)
Benin	Diagnosis scenario	14.7 (12.0,17.6)	13.9 (11.8,16.0)	11.8 (10.2,13.4)	13.4 (11.6,15.2)	13.8 (12.1,15.5)
Benin	Treatment scenario	15.0 (12.3,17.8)	13.9 (11.8,16.0)	12.2 (10.6,13.8)	13.6 (11.8,15.4)	13.8 (12.1,15.5)
Bhutan	Diagnosis scenario	12.3 (11.3,13.3)	11.9 (10.8,13.0)	12.1 (10.9,13.3)	11.7 (10.4,13.0)	11.8 (10.4,13.3)
Bhutan	Treatment scenario	12.4 (11.5,13.4)	12.0 (10.9,13.1)	12.3 (11.1,13.5)	11.7 (10.4,13.0)	11.9 (10.5,13.3)
Botswana	Diagnosis scenario	10.8 (9.1,12.5)	9.1 (7.0,11.2)	9.0 (6.6,11.3)	9.5 (6.3,12.6)	7.8 (5.8,9.7)
Botswana	Treatment scenario	10.6 (8.9,12.3)	9.2 (7.1,11.3)	8.9 (6.6,11.3)	9.2 (6.1,12.3)	7.8 (5.9,9.8)
Brazil	Diagnosis scenario	10.7 (10.3,11.1)	10.3 (9.8,10.8)	9.9 (9.3,10.4)	8.9 (8.5,9.2)	8.8 (8.4,9.2)
Brazil	Treatment scenario	10.6 (10.2,11.0)	10.2 (9.7,10.7)	9.9 (9.3,10.4)	8.8 (8.5,9.2)	8.8 (8.4,9.2)
Cambodia	Diagnosis scenario	15.0 (13.1,16.8)	16.0 (14.3,17.7)	16.0 (14.1,17.9)	18.0 (16.2,19.7)	16.4 (14.7,18.2)
Cambodia	Treatment scenario	14.7 (12.9,16.6)	16.1 (14.5,17.8)	15.7 (13.9,17.6)	17.6 (15.9,19.4)	16.4 (14.7,18.2)
China	Diagnosis scenario	23.4 (21.7,25.2)	19.3 (17.9,20.8)	19.3 (17.5,21.1)	18.8 (17.2,20.3)	19.1 (17.4,20.7)
China	Treatment scenario	23.2 (21.5,25.0)	19.2 (17.8,20.6)	19.2 (17.4,21.0)	18.6 (17.1,20.2)	19.1 (17.4,20.7)
Ecuador	Diagnosis scenario	7.9 (6.7,9.1)	7.4 (6.8,8.1)	7.1 (6.0,8.2)	6.9 (6.0,7.9)	7.7 (6.8,8.7)
Ecuador	Treatment scenario	7.7 (6.5,9.0)	7.4 (6.7,8.0)	7.0 (5.9,8.0)	6.8 (5.8,7.8)	7.9 (7.0,8.8)
Eritrea	Diagnosis scenario	18.4 (16.2,20.6)	17.6 (13.3,21.9)	15.2 (13.0,17.4)	16.2 (13.6,18.7)	17.3 (14.1,20.5)
Eritrea	Treatment scenario	18.2 (16.0,20.3)	17.7 (13.4,22.1)	15.3 (13.1,17.6)	16.2 (13.6,18.7)	17.2 (14.0,20.4)
Eswatini	Diagnosis scenario	14.0 (11.4,16.6)	16.3 (12.3,20.4)	14.8 (9.6,19.9)	14.0 (10.8,17.2)	11.7 (7.9,15.6)
Eswatini	Treatment scenario	13.7 (11.2,16.3)	16.0 (12.0,20.1)	14.4 (9.5,19.5)	13.9 (10.7,17.1)	11.7 (7.9,15.6)
Ethiopia	Diagnosis scenario	10.6 (8.8,12.5)	10.9 (8.7,13.2)	11.3 (9.6,13.1)	8.6 (6.8,10.4)	9.4 (7.8,11.0)
Ethiopia	Treatment scenario	10.5 (8.7,12.3)	10.9 (8.7,13.2)	11.3 (9.5,13.0)	8.5 (6.7,10.3)	9.3 (7.8,10.9)
Gambia	Diagnosis scenario	11.9 (10.3,13.5)	11.6 (9.5,13.6)	11.7 (9.8,13.6)	9.9 (8.5,11.3)	12.9 (11.2,14.7)
Gambia	Treatment scenario	12.1 (10.5,13.6)	11.7 (9.7,13.8)	11.8 (9.9,13.7)	10.0 (8.7,11.4)	12.9 (11.1,14.7)
Ghana	Diagnosis scenario	14.4 (12.2,16.6)	15.1 (12.8,17.4)	12.6 (11.2,14.1)	14.6 (12.6,16.7)	13.5 (11.6,15.3)
Ghana	Treatment scenario	14.1 (12.0,16.3)	15.2 (12.8,17.5)	12.6 (11.1,14.0)	14.6 (12.6,16.7)	13.5 (11.6,15.3)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario	13.8 (13.3,14.3)	13.5 (13.1,13.9)	13.7 (13.3,14.1)	13.6 (13.3,14.0)	12.9 (12.5,13.2)
India	Treatment scenario	13.7 (13.2,14.1)	13.3 (12.9,13.7)	13.5 (13.1,14.0)	13.6 (13.2,14.0)	12.9 (12.5,13.2)
Indonesia	Diagnosis scenario	27.4 (25.6,29.1)	25.2 (24.1,26.2)	25.6 (24.6,26.6)	23.3 (22.6,23.9)	21.9 (20.9,23.0)
Indonesia	Treatment scenario	26.6 (24.9,28.3)	24.7 (23.7,25.7)	25.2 (24.2,26.2)	23.1 (22.4,23.7)	21.9 (20.9,23.0)
Jordan	Diagnosis scenario	10.5 (9.5,11.6)	10.0 (8.8,11.3)	9.9 (8.9,10.8)	9.1 (7.4,10.7)	10.5 (9.1,11.9)
Jordan	Treatment scenario	10.4 (9.3,11.4)	10.1 (8.8,11.3)	9.8 (8.8,10.7)	9.0 (7.4,10.7)	10.4 (9.1,11.8)
Kenya	Diagnosis scenario	7.1 (6.1,8.2)	6.9 (6.0,7.9)	7.3 (6.4,8.2)	6.0 (5.2,6.7)	6.7 (4.7,8.6)
Kenya	Treatment scenario	7.1 (6.0,8.1)	6.9 (5.9,7.9)	7.4 (6.5,8.3)	5.9 (5.2,6.7)	6.7 (4.7,8.6)
Kiribati	Diagnosis scenario	9.0 (6.5,11.6)	12.4 (9.6,15.2)	11.7 (9.4,14.0)	12.6 (9.1,16.3)	15.7 (8.4,23.1)
Kiribati	Treatment scenario	9.2 (6.6,11.7)	13.0 (10.4,15.5)	11.6 (9.2,13.9)	12.6 (9.1,16.3)	15.7 (8.4,23.1)
Kyrgyzstan	Diagnosis scenario	18.2 (16.0,20.5)	21.3 (18.8,23.8)	19.4 (17.0,21.7)	17.5 (15.1,19.8)	17.6 (15.2,20.0)
Kyrgyzstan	Treatment scenario	18.0 (15.8,20.3)	21.3 (18.8,23.8)	18.6 (16.3,21.0)	17.0 (14.7,19.4)	17.2 (14.8,19.5)
Laos	Diagnosis scenario	17.7 (13.7,21.9)	19.1 (16.2,22.2)	17.2 (14.5,20.0)	18.0 (14.8,21.1)	16.9 (13.4,20.4)
Laos	Treatment scenario	17.7 (13.7,21.8)	19.5 (16.5,22.5)	16.7 (14.1,19.5)	18.0 (14.8,21.1)	16.8 (13.4,20.3)
Lesotho	Diagnosis scenario	7.6 (6.1,9.2)	7.8 (6.1,9.5)	8.9 (7.1,10.7)	7.7 (5.8,9.7)	7.8 (6.4,9.1)
Lesotho	Treatment scenario	7.7 (6.1,9.3)	7.6 (6.0,9.3)	8.7 (7.0,10.5)	7.8 (5.8,9.7)	7.8 (6.4,9.1)
Moldova	Diagnosis scenario	19.5 (18.1,20.9)	21.3 (19.7,22.8)	19.3 (17.7,20.9)	17.4 (15.4,19.4)	16.8 (15.2,18.5)
Moldova	Treatment scenario	19.2 (17.9,20.6)	21.1 (19.6,22.7)	19.3 (17.7,20.9)	17.5 (15.5,19.5)	16.7 (15.1,18.4)
Morocco	Diagnosis scenario	11.9 (11.1,12.8)	12.0 (10.2,13.8)	11.7 (10.2,13.2)	12.5 (10.5,14.4)	11.7 (10.6,12.8)
Morocco	Treatment scenario	12.0 (11.2,12.9)	12.0 (10.3,13.8)	11.7 (10.2,13.2)	12.3 (10.4,14.3)	11.7 (10.6,12.9)
Myanmar	Diagnosis scenario	14.5 (12.6,16.3)	13.6 (12.6,14.6)	12.3 (11.3,13.2)	12.3 (11.1,13.5)	11.7 (10.2,13.3)
Myanmar	Treatment scenario	13.8 (12.1,15.6)	13.4 (12.4,14.5)	12.1 (11.1,13.0)	12.3 (11.1,13.4)	11.7 (10.2,13.3)
Namibia	Diagnosis scenario	6.9 (6.0,7.8)	7.1 (6.3,7.8)	7.9 (6.9,8.9)	7.9 (6.7,9.2)	8.4 (7.1,9.6)
Namibia	Treatment scenario	6.9 (6.0,7.7)	7.0 (6.2,7.7)	7.9 (6.9,9.0)	8.0 (6.8,9.3)	8.4 (7.1,9.6)
Niger	Diagnosis scenario	9.8 (8.5,11.1)	10.0 (8.7,11.2)	9.4 (8.0,10.8)	10.3 (9.0,11.7)	10.4 (8.8,12.0)
Niger	Treatment scenario	9.8 (8.5,11.1)	9.8 (8.5,11.0)	9.3 (8.0,10.7)	10.3 (8.9,11.6)	10.4 (8.8,12.0)
Russian Federation	Diagnosis scenario	33.7 (29.8,37.7)	32.9 (28.8,37.0)	32.8 (28.6,36.9)	21.3 (13.3,29.2)	26.8 (20.8,32.8)
Russian Federation	Treatment scenario	32.5 (28.6,36.5)	32.1 (27.8,36.3)	32.6 (28.5,36.8)	21.3 (13.4,29.2)	26.9 (20.9,32.9)
Rwanda	Diagnosis scenario	10.6 (9.1,12.1)	8.8 (7.3,10.2)	8.0 (6.7,9.2)	9.1 (7.7,10.5)	8.7 (7.5,9.8)
Rwanda	Treatment scenario	10.6 (9.1,12.1)	8.8 (7.4,10.3)	7.9 (6.6,9.2)	9.0 (7.6,10.5)	8.7 (7.5,9.8)
Samoa	Diagnosis scenario	13.6 (11.7,15.5)	10.8 (9.0,12.7)	11.3 (9.0,13.6)	8.5 (6.4,10.6)	11.8 (9.9,13.7)
Samoa	Treatment scenario	13.9 (12.0,15.8)	11.2 (9.4,13.1)	11.3 (9.0,13.6)	8.3 (6.2,10.4)	11.8 (9.9,13.7)
Sao Tome and Principe	Diagnosis scenario	9.6 (8.7,10.4)	9.0 (8.2,9.8)	7.6 (6.8,8.3)	8.7 (8.0,9.4)	8.9 (8.4,9.5)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	9.5 (8.7,10.4)	8.9 (8.1,9.6)	7.6 (6.9,8.4)	8.6 (7.9,9.4)	9.0 (8.5,9.6)
Solomon Islands	Diagnosis scenario	15.2 (11.8,18.7)	14.5 (11.3,17.7)	12.3 (9.9,14.7)	12.7 (10.1,15.4)	14.6 (12.4,16.7)
Solomon Islands	Treatment scenario	14.8 (11.5,18.3)	14.2 (11.1,17.3)	12.1 (9.7,14.5)	12.2 (9.7,14.9)	14.6 (12.4,16.7)
South Africa	Diagnosis scenario	17.2 (15.3,19.1)	17.8 (16.2,19.5)	18.1 (16.1,20.1)	19.3 (17.3,21.4)	20.5 (18.9,22.2)
South Africa	Treatment scenario	17.0 (15.1,18.9)	17.7 (16.1,19.4)	18.1 (16.1,20.2)	19.3 (17.3,21.4)	20.5 (18.9,22.2)
Sri Lanka	Diagnosis scenario	17.4 (16.1,18.6)	17.2 (16.1,18.2)	15.2 (13.9,16.6)	15.6 (14.3,16.8)	16.0 (14.5,17.5)
Sri Lanka	Treatment scenario	17.3 (16.1,18.6)	17.2 (16.1,18.2)	15.4 (14.0,16.7)	15.7 (14.5,17.0)	16.0 (14.5,17.5)
St. Vincent & the Grenadines	Diagnosis scenario	17.5 (15.7,19.3)	15.9 (13.1,18.8)	13.2 (11.1,15.4)	13.4 (11.9,14.9)	12.6 (11.4,13.8)
St. Vincent & the Grenadines	Treatment scenario	17.4 (15.6,19.3)	15.4 (12.6,18.3)	13.0 (10.9,15.1)	13.1 (11.6,14.7)	12.6 (11.4,13.8)
Sudan	Diagnosis scenario	18.4 (16.9,20.0)	19.3 (18.1,20.4)	18.4 (17.3,19.6)	19.5 (17.6,21.4)	23.9 (21.1,26.6)
Sudan	Treatment scenario	17.9 (16.4,19.4)	18.9 (17.7,20.0)	17.8 (16.7,18.9)	18.9 (17.0,20.8)	23.9 (21.1,26.6)
Tanzania	Diagnosis scenario	8.1 (7.2,9.1)	7.6 (6.8,8.5)	8.0 (7.1,8.9)	7.5 (6.7,8.4)	10.8 (6.1,15.6)
Tanzania	Treatment scenario	8.1 (7.2,9.1)	7.7 (6.8,8.5)	7.9 (7.0,8.8)	7.3 (6.5,8.1)	10.5 (5.9,15.3)
Timor Leste	Diagnosis scenario	20.7 (16.0,25.5)	22.2 (19.3,25.1)	19.8 (16.5,23.2)	16.0 (13.0,19.0)	15.3 (12.4,18.2)
Timor Leste	Treatment scenario	19.9 (15.3,24.6)	22.4 (19.5,25.3)	20.0 (16.7,23.4)	16.4 (13.4,19.4)	15.3 (12.4,18.2)
Togo	Diagnosis scenario	11.9 (9.0,14.8)	10.1 (7.4,12.9)	12.1 (9.4,14.7)	10.5 (8.9,12.0)	10.4 (8.5,12.3)
Togo	Treatment scenario	11.7 (8.8,14.6)	10.0 (7.3,12.8)	12.0 (9.3,14.7)	10.2 (8.7,11.7)	10.4 (8.5,12.3)
Uganda	Diagnosis scenario	9.7 (7.0,12.7)	10.8 (8.7,13.0)	9.1 (7.2,10.9)	7.5 (6.0,9.0)	11.0 (8.1,13.9)
Uganda	Treatment scenario	10.4 (7.4,13.3)	10.8 (8.7,13.0)	9.3 (7.4,11.3)	7.6 (6.1,9.1)	11.0 (8.1,13.9)
Vanuatu	Diagnosis scenario	10.5 (9.5,11.4)	9.7 (8.7,10.7)	11.4 (10.1,12.8)	10.6 (9.4,11.8)	12.3 (10.8,13.8)
Vanuatu	Treatment scenario	10.6 (9.6,11.5)	9.7 (8.7,10.7)	11.4 (10.1,12.8)	10.6 (9.3,11.8)	12.3 (10.8,13.9)
Zambia	Diagnosis scenario	7.6 (6.2,9.1)	8.1 (6.4,9.9)	6.4 (5.2,7.7)	7.8 (6.0,9.7)	8.2 (6.1,10.3)
Zambia	Treatment scenario	7.6 (6.2,9.1)	8.3 (6.6,10.0)	6.4 (5.2,7.6)	7.7 (5.9,9.5)	8.2 (6.1,10.3)

Supplementary Table 27. Within-country targets sensitivity analysis: Absolute (percentage point) difference in mean 10-year cardiovascular disease risk comparing the bottom (Q1) and top (Q5) wealth quintiles by country and modelled scenario, either Baseline, Diagnosis or Treatment scenario

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Afghanistan	Baseline	-2.7
Afghanistan	Diagnosis scenario	-2.9
Afghanistan	Treatment scenario	-3.3
Albania	Baseline	-0.6
Albania	Diagnosis scenario	-0.7
Albania	Treatment scenario	-0.8
Algeria	Baseline	-0.3
Algeria	Diagnosis scenario	-0.3
Algeria	Treatment scenario	-0.4
Azerbaijan	Baseline	2.5
Azerbaijan	Diagnosis scenario	2.4
Azerbaijan	Treatment scenario	2.5
Benin	Baseline	1.3
Benin	Diagnosis scenario	0.9
Benin	Treatment scenario	1.2
Bhutan	Baseline	0.6
Bhutan	Diagnosis scenario	0.5
Bhutan	Treatment scenario	0.5
Botswana	Baseline	3.1
Botswana	Diagnosis scenario	3.0
Botswana	Treatment scenario	2.8
Brazil	Baseline	2.1
Brazil	Diagnosis scenario	1.9
Brazil	Treatment scenario	1.9
Cambodia	Baseline	-0.8
Cambodia	Diagnosis scenario	-1.5
Cambodia	Treatment scenario	-1.7
China	Baseline	4.8
China	Diagnosis scenario	4.3
China	Treatment scenario	4.2
Ecuador	Baseline	0.3

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Ecuador	Diagnosis scenario	0.1
Ecuador	Treatment scenario	-0.2
Eritrea	Baseline	1.4
Eritrea	Diagnosis scenario	1.1
Eritrea	Treatment scenario	0.9
Eswatini	Baseline	2.5
Eswatini	Diagnosis scenario	2.3
Eswatini	Treatment scenario	2.0
Ethiopia	Baseline	1.3
Ethiopia	Diagnosis scenario	1.3
Ethiopia	Treatment scenario	1.1
Gambia	Baseline	-0.7
Gambia	Diagnosis scenario	-1.1
Gambia	Treatment scenario	-0.8
Ghana	Baseline	1.4
Ghana	Diagnosis scenario	0.9
Ghana	Treatment scenario	0.7
India	Baseline	1.4
India	Diagnosis scenario	0.9
India	Treatment scenario	0.8
Indonesia	Baseline	5.6
Indonesia	Diagnosis scenario	5.4
Indonesia	Treatment scenario	4.7
Jordan	Baseline	-0.0
Jordan	Diagnosis scenario	0.0
Jordan	Treatment scenario	-0.0
Kenya	Baseline	0.7
Kenya	Diagnosis scenario	0.5
Kenya	Treatment scenario	0.4
Kiribati	Baseline	-6.5
Kiribati	Diagnosis scenario	-6.7
Kiribati	Treatment scenario	-6.6
Kyrgyzstan	Baseline	0.9
Kyrgyzstan	Diagnosis scenario	0.6

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Kyrgyzstan	Treatment scenario	0.9
Laos	Baseline	1.4
Laos	Diagnosis scenario	0.9
Laos	Treatment scenario	0.9
Lesotho	Baseline	0.2
Lesotho	Diagnosis scenario	-0.1
Lesotho	Treatment scenario	-0.1
Moldova	Baseline	2.7
Moldova	Diagnosis scenario	2.7
Moldova	Treatment scenario	2.5
Morocco	Baseline	0.3
Morocco	Diagnosis scenario	0.2
Morocco	Treatment scenario	0.3
Myanmar	Baseline	3.0
Myanmar	Diagnosis scenario	2.7
Myanmar	Treatment scenario	2.0
Namibia	Baseline	-0.8
Namibia	Diagnosis scenario	-1.5
Namibia	Treatment scenario	-1.5
Niger	Baseline	-0.5
Niger	Diagnosis scenario	-0.7
Niger	Treatment scenario	-0.6
Russian Federation	Baseline	7.7
Russian Federation	Diagnosis scenario	6.9
Russian Federation	Treatment scenario	5.6
Rwanda	Baseline	2.0
Rwanda	Diagnosis scenario	1.9
Rwanda	Treatment scenario	2.0
Samoa	Baseline	2.1
Samoa	Diagnosis scenario	1.8
Samoa	Treatment scenario	2.0
Sao Tome and Principe	Baseline	0.6
Sao Tome and Principe	Diagnosis scenario	0.6

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Sao Tome and Principe	Treatment scenario	0.5
Solomon Islands	Baseline	0.9
Solomon Islands	Diagnosis scenario	0.7
Solomon Islands	Treatment scenario	0.2
South Africa	Baseline	-2.5
South Africa	Diagnosis scenario	-3.3
South Africa	Treatment scenario	-3.5
Sri Lanka	Baseline	1.8
Sri Lanka	Diagnosis scenario	1.3
Sri Lanka	Treatment scenario	1.3
St. Vincent & the Grenadines	Baseline	4.9
St. Vincent & the Grenadines	Diagnosis scenario	4.9
St. Vincent & the Grenadines	Treatment scenario	4.8
Sudan	Baseline	-4.1
Sudan	Diagnosis scenario	-5.5
Sudan	Treatment scenario	-6.0
Tanzania	Baseline	-2.6
Tanzania	Diagnosis scenario	-2.7
Tanzania	Treatment scenario	-2.4
Timor Leste	Baseline	6.1
Timor Leste	Diagnosis scenario	5.4
Timor Leste	Treatment scenario	4.6
Togo	Baseline	1.7
Togo	Diagnosis scenario	1.5
Togo	Treatment scenario	1.4
Uganda	Baseline	-0.5
Uganda	Diagnosis scenario	-1.3
Uganda	Treatment scenario	-0.6
Vanuatu	Baseline	-1.7
Vanuatu	Diagnosis scenario	-1.8
Vanuatu	Treatment scenario	-1.7
Zambia	Baseline	-0.3
Zambia	Diagnosis scenario	-0.6

(continued)

Country	Scenario	Absolute (percentage point) difference in mean CVD risk (Q1-Q5)
Zambia	Treatment scenario	-0.6

Supplementary Table 28. Within-country targets sensitivity analysis: Mean difference (95% uncertainty interval) in CVD cases per 1,000 people living with hypertension compared to baseline by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	2.3 (-0.8,9.3)	7.8 (-0.1,23.9)	7.3 (0.5,18.1)	0.0 (0.0,0.0)	0.0 (0.0,0.0)
Afghanistan	Treatment scenario	5.4 (0.1,14.1)	11.8 (1.5,28.9)	24.1 (10.3,39.2)	10.4 (3.1,19.9)	0.0 (0.0,0.0)
Albania	Diagnosis scenario	0.5 (-0.0,1.3)	0.8 (0.1,1.8)	0.4 (-0.1,1.3)	0.3 (-0.1,0.9)	0.0 (0.0,0.0)
Albania	Treatment scenario	1.8 (0.6,3.3)	1.6 (0.6,3.0)	1.4 (0.4,3.0)	0.7 (0.0,1.8)	0.0 (0.0,0.0)
Algeria	Diagnosis scenario	0.4 (-0.0,0.9)	1.1 (0.4,2.0)	0.7 (0.0,1.5)	0.0 (0.0,0.0)	0.0 (0.0,0.0)
Algeria	Treatment scenario	0.9 (0.3,1.7)	2.0 (0.9,3.5)	0.5 (-0.0,1.3)	0.0 (0.0,0.0)	0.1 (-0.1,0.5)
Azerbaijan	Diagnosis scenario	4.1 (1.6,7.2)	5.5 (0.8,12.8)	4.5 (1.4,9.6)	0.0 (0.0,0.0)	2.7 (-0.2,9.3)
Azerbaijan	Treatment scenario	1.0 (-0.1,3.1)	1.0 (-0.5,5.2)	0.0 (0.0,0.0)	0.3 (-0.3,1.8)	1.4 (-0.5,5.8)
Benin	Diagnosis scenario	4.3 (0.2,26.0)	2.7 (0.5,6.6)	5.5 (2.0,10.4)	2.2 (0.2,5.8)	0.0 (0.0,0.0)
Benin	Treatment scenario	1.1 (-0.3,4.3)	2.5 (0.3,6.8)	1.5 (-0.0,4.4)	0.3 (-0.2,1.6)	0.0 (0.0,0.0)
Bhutan	Diagnosis scenario	2.3 (0.6,4.7)	1.6 (0.3,3.2)	3.8 (0.9,7.8)	0.0 (0.0,0.0)	1.3 (-0.1,4.0)
Bhutan	Treatment scenario	1.2 (0.1,3.0)	0.4 (-0.2,1.6)	2.1 (0.1,5.3)	0.0 (0.0,0.0)	0.8 (-0.3,2.9)
Botswana	Diagnosis scenario	0.8 (-0.3,6.0)	1.5 (-0.1,4.6)	0.0 (0.0,0.0)	0.5 (-0.3,2.9)	0.2 (-0.2,2.1)
Botswana	Treatment scenario	3.0 (-0.1,11.6)	0.0 (0.0,0.0)	0.3 (-0.2,1.5)	3.7 (-0.0,12.5)	0.0 (0.0,0.0)
Brazil	Diagnosis scenario	2.1 (1.5,2.9)	1.0 (0.5,2.2)	0.2 (0.0,0.6)	0.0 (0.0,0.0)	0.2 (0.0,0.5)
Brazil	Treatment scenario	2.4 (1.7,3.2)	1.6 (0.9,2.8)	0.3 (0.1,0.8)	0.0 (-0.0,0.2)	0.0 (0.0,0.0)
Cambodia	Diagnosis scenario	7.2 (2.7,14.3)	7.3 (3.0,12.0)	5.4 (1.3,10.9)	2.2 (-0.1,6.7)	0.0 (0.0,0.0)
Cambodia	Treatment scenario	9.4 (4.3,17.1)	6.2 (2.2,11.0)	7.8 (2.7,14.3)	5.8 (1.7,12.1)	0.0 (0.0,0.0)
China	Diagnosis scenario	4.5 (2.6,6.7)	2.8 (1.4,4.5)	4.6 (2.9,6.6)	1.2 (0.3,2.4)	0.0 (0.0,0.0)
China	Treatment scenario	6.3 (4.0,8.8)	4.2 (2.4,6.4)	5.6 (3.6,7.7)	2.3 (1.0,3.9)	0.0 (0.0,0.0)
Ecuador	Diagnosis scenario	3.5 (0.8,8.8)	1.5 (0.4,2.9)	0.2 (-0.2,1.5)	0.0 (0.0,0.0)	1.4 (0.1,3.4)
Ecuador	Treatment scenario	5.2 (2.0,10.6)	1.9 (0.7,3.6)	1.4 (-0.1,4.3)	1.0 (-0.1,2.8)	0.0 (0.0,0.0)
Eritrea	Diagnosis scenario	3.4 (1.2,6.4)	4.1 (-1.2,13.1)	2.8 (0.5,6.3)	0.0 (0.0,0.0)	0.4 (-0.4,2.0)
Eritrea	Treatment scenario	5.7 (2.7,9.8)	2.9 (-1.5,10.7)	1.4 (-0.1,3.8)	0.0 (0.0,0.0)	1.7 (-0.2,5.0)
Eswatini	Diagnosis scenario	2.5 (-0.1,7.5)	3.0 (-0.6,14.1)	0.0 (0.0,0.0)	0.5 (-0.4,3.2)	0.0 (0.0,0.0)
Eswatini	Treatment scenario	5.4 (1.5,11.3)	6.8 (0.7,19.4)	3.7 (-0.5,21.3)	1.4 (-0.4,8.1)	0.0 (0.0,0.0)
Ethiopia	Diagnosis scenario	0.7 (-0.2,3.3)	0.0 (0.0,0.0)	1.8 (-0.3,5.7)	0.3 (-0.2,1.8)	0.2 (-0.2,1.7)
Ethiopia	Treatment scenario	2.1 (0.1,6.1)	0.0 (0.0,0.0)	2.4 (-0.1,6.8)	1.1 (-0.2,4.0)	0.5 (-0.3,2.4)
Gambia	Diagnosis scenario	4.0 (1.0,7.8)	2.2 (-0.1,5.7)	3.2 (0.4,8.5)	1.5 (-0.2,4.6)	0.0 (0.0,0.0)
Gambia	Treatment scenario	2.2 (-0.0,5.5)	1.0 (-0.5,3.9)	2.3 (-0.1,6.9)	0.0 (0.0,0.0)	0.4 (-0.4,2.3)
Ghana	Diagnosis scenario	5.6 (3.0,8.9)	7.7 (4.5,11.6)	4.6 (2.5,7.4)	0.0 (0.0,0.0)	1.2 (0.2,3.1)
Ghana	Treatment scenario	8.4 (5.2,12.3)	7.5 (4.4,11.3)	5.0 (2.7,8.0)	0.0 (0.0,0.0)	1.4 (0.3,3.4)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario	5.5 (4.3,6.9)	3.8 (2.9,4.9)	2.0 (1.4,2.9)	1.6 (1.0,2.3)	0.0 (0.0,0.0)
India	Treatment scenario	6.6 (5.2,8.1)	5.1 (4.1,6.3)	3.3 (2.4,4.4)	2.3 (1.6,3.2)	0.0 (0.0,0.0)
Indonesia	Diagnosis scenario	2.1 (1.0,3.4)	2.0 (0.9,3.3)	0.8 (0.2,1.7)	0.2 (-0.0,0.6)	0.0 (0.0,0.0)
Indonesia	Treatment scenario	9.7 (7.2,12.6)	6.1 (4.1,8.4)	5.0 (3.3,6.9)	2.1 (1.1,3.4)	0.0 (0.0,0.0)
Jordan	Diagnosis scenario	2.3 (0.2,5.4)	0.5 (-0.1,1.5)	0.0 (0.0,0.0)	2.9 (0.6,6.0)	2.8 (1.0,5.0)
Jordan	Treatment scenario	3.8 (1.1,7.3)	0.0 (0.0,0.0)	1.0 (-0.1,3.1)	3.3 (0.9,6.4)	3.7 (1.0,9.1)
Kenya	Diagnosis scenario	2.6 (0.6,5.9)	2.0 (0.4,5.0)	1.9 (0.2,5.6)	1.1 (0.0,3.2)	0.0 (0.0,0.0)
Kenya	Treatment scenario	3.2 (1.0,6.5)	2.5 (0.6,5.6)	0.9 (-0.2,3.3)	1.4 (0.1,3.7)	0.0 (0.0,0.0)
Kiribati	Diagnosis scenario	2.2 (-0.7,8.9)	5.4 (-1.3,28.5)	0.0 (0.0,0.0)	1.5 (-0.9,13.2)	0.0 (0.0,0.0)
Kiribati	Treatment scenario	0.7 (-0.6,3.4)	0.0 (0.0,0.0)	1.3 (-0.5,11.6)	1.3 (-0.8,11.4)	0.0 (0.0,0.0)
Kyrgyzstan	Diagnosis scenario	3.4 (0.7,7.3)	0.0 (0.0,0.0)	0.6 (-0.3,2.5)	0.8 (-0.3,2.7)	0.9 (-0.4,3.8)
Kyrgyzstan	Treatment scenario	5.6 (2.0,10.3)	0.0 (0.0,0.0)	8.0 (1.9,19.9)	5.1 (1.8,9.5)	5.5 (1.2,12.8)
Laos	Diagnosis scenario	10.1 (0.3,26.4)	7.3 (-0.5,26.5)	3.5 (0.2,8.3)	0.0 (0.0,0.0)	5.3 (0.0,18.9)
Laos	Treatment scenario	10.5 (0.3,26.4)	4.0 (-1.0,19.3)	8.2 (1.6,22.1)	0.0 (0.0,0.0)	6.0 (0.4,19.5)
Lesotho	Diagnosis scenario	3.8 (0.5,8.3)	1.4 (-0.4,4.8)	5.4 (1.0,11.5)	0.4 (-0.3,2.8)	0.0 (0.0,0.0)
Lesotho	Treatment scenario	3.3 (0.3,7.7)	3.2 (0.2,7.9)	6.9 (2.0,13.3)	0.0 (0.0,0.0)	0.0 (0.0,0.0)
Moldova	Diagnosis scenario	1.3 (0.2,3.1)	0.1 (-0.1,0.8)	0.0 (0.0,0.0)	1.1 (-0.2,4.1)	1.1 (-0.0,3.1)
Moldova	Treatment scenario	4.1 (1.9,6.9)	1.5 (0.2,3.7)	0.6 (-0.1,2.2)	0.0 (0.0,0.0)	2.1 (0.4,4.6)
Morocco	Diagnosis scenario	1.1 (0.4,2.0)	1.1 (-0.1,3.3)	0.0 (0.0,0.0)	0.6 (-0.3,2.4)	0.7 (0.0,1.9)
Morocco	Treatment scenario	0.3 (-0.0,0.9)	1.0 (-0.1,3.1)	0.0 (0.0,0.0)	2.0 (0.1,4.9)	0.1 (-0.1,0.7)
Myanmar	Diagnosis scenario	2.9 (0.7,6.5)	2.1 (0.3,7.2)	0.6 (-0.1,2.5)	1.5 (0.2,4.0)	0.0 (0.0,0.0)
Myanmar	Treatment scenario	9.7 (4.4,18.0)	4.2 (1.3,10.1)	2.3 (0.4,5.5)	1.8 (0.3,4.3)	0.0 (0.0,0.0)
Namibia	Diagnosis scenario	6.4 (4.1,9.1)	4.3 (2.7,6.1)	3.5 (1.6,6.7)	4.5 (2.0,8.2)	0.0 (0.0,0.0)
Namibia	Treatment scenario	7.1 (4.5,10.1)	5.2 (3.5,7.2)	3.0 (1.2,5.9)	3.9 (1.6,7.3)	0.0 (0.0,0.0)
Niger	Diagnosis scenario	1.2 (-0.2,3.5)	0.0 (0.0,0.0)	0.7 (-0.4,2.7)	0.6 (-0.3,2.2)	0.0 (0.0,0.0)
Niger	Treatment scenario	0.6 (-0.3,2.2)	2.0 (0.2,4.7)	1.4 (-0.2,4.0)	1.2 (-0.2,3.5)	0.0 (0.0,0.0)
Russian Federation	Diagnosis scenario	8.8 (2.1,19.7)	0.0 (0.0,0.0)	0.9 (-0.2,3.2)	8.6 (3.6,14.6)	0.8 (-0.1,2.2)
Russian Federation	Treatment scenario	21.0 (10.7,33.7)	8.0 (3.0,15.8)	2.4 (0.4,5.8)	8.0 (3.2,13.9)	0.0 (0.0,0.0)
Rwanda	Diagnosis scenario	0.3 (-0.3,1.6)	0.6 (-0.3,2.4)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.0 (0.0,0.0)
Rwanda	Treatment scenario	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.5 (-0.3,2.1)	0.7 (-0.4,2.9)	0.0 (0.0,0.0)
Samoa	Diagnosis scenario	4.5 (-0.2,13.7)	10.1 (2.3,21.2)	0.0 (0.0,0.0)	0.6 (-0.6,3.4)	1.4 (-0.8,6.6)
Samoa	Treatment scenario	2.0 (-0.7,8.0)	6.3 (0.4,16.3)	0.0 (0.0,0.0)	2.6 (-0.4,7.8)	1.4 (-0.7,6.4)
Sao Tome and Principe	Diagnosis scenario	0.9 (-0.2,3.2)	1.2 (0.0,3.2)	2.2 (0.4,4.8)	0.0 (0.0,0.0)	0.8 (-0.1,2.1)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	1.0 (-0.2,3.9)	2.7 (0.6,5.6)	1.8 (0.2,4.2)	1.0 (-0.1,2.8)	0.0 (0.0,0.0)
Solomon Islands	Diagnosis scenario	2.4 (-0.7,11.1)	2.7 (-0.4,7.8)	2.1 (-0.6,6.6)	0.8 (-0.8,4.0)	0.0 (0.0,0.0)
Solomon Islands	Treatment scenario	6.5 (0.6,18.1)	6.2 (0.8,14.1)	3.8 (-0.1,9.3)	5.7 (0.5,14.8)	0.0 (0.0,0.0)
South Africa	Diagnosis scenario	8.6 (5.2,12.8)	7.1 (4.0,10.7)	1.3 (0.1,4.4)	0.0 (0.0,0.0)	0.2 (-0.1,1.2)
South Africa	Treatment scenario	10.4 (6.7,14.7)	8.1 (4.9,11.9)	1.0 (0.0,3.7)	0.1 (-0.1,0.6)	0.0 (0.0,0.0)
Sri Lanka	Diagnosis scenario	4.6 (2.2,7.7)	6.6 (3.8,10.0)	6.2 (3.2,9.8)	2.4 (0.4,5.1)	0.0 (0.0,0.0)
Sri Lanka	Treatment scenario	4.7 (2.3,7.8)	6.7 (3.7,10.1)	4.9 (2.3,8.3)	0.6 (-0.3,2.4)	0.0 (0.0,0.0)
St. Vincent & the Grenadines	Diagnosis scenario	0.0 (0.0,0.0)	1.3 (-0.3,6.2)	2.3 (-0.2,6.2)	3.7 (0.6,8.0)	0.0 (0.0,0.0)
St. Vincent & the Grenadines	Treatment scenario	0.5 (-0.2,1.9)	6.1 (1.4,15.4)	4.8 (0.8,10.1)	6.1 (2.1,11.0)	0.0 (0.0,0.0)
Sudan	Diagnosis scenario	13.1 (8.5,18.3)	9.9 (6.6,14.3)	6.0 (3.4,9.7)	5.9 (1.9,11.9)	0.0 (0.0,0.0)
Sudan	Treatment scenario	18.4 (13.1,24.2)	13.9 (10.2,18.7)	12.8 (8.8,17.8)	12.2 (6.1,20.2)	0.0 (0.0,0.0)
Tanzania	Diagnosis scenario	1.6 (0.4,3.7)	0.1 (-0.1,0.8)	0.7 (-0.1,2.5)	0.4 (-0.1,1.5)	0.0 (0.0,0.0)
Tanzania	Treatment scenario	1.4 (0.2,3.7)	0.0 (0.0,0.0)	1.5 (0.2,3.7)	3.1 (1.1,5.8)	3.1 (0.0,17.1)
Timor Leste	Diagnosis scenario	6.8 (-0.6,18.2)	11.5 (4.5,19.6)	7.7 (1.5,16.1)	5.7 (0.5,12.9)	0.0 (0.0,0.0)
Timor Leste	Treatment scenario	14.8 (3.6,29.5)	9.6 (3.4,17.1)	6.1 (0.7,13.6)	1.6 (-0.9,6.1)	0.0 (0.0,0.0)
Togo	Diagnosis scenario	1.7 (-0.3,5.2)	1.5 (-0.5,6.8)	1.2 (-0.4,4.9)	0.5 (-0.4,2.9)	0.0 (0.0,0.0)
Togo	Treatment scenario	3.2 (0.1,8.0)	2.6 (-0.1,10.6)	1.3 (-0.5,5.3)	3.1 (-0.1,8.4)	0.0 (0.0,0.0)
Uganda	Diagnosis scenario	7.9 (2.3,19.8)	2.4 (-0.2,8.0)	2.9 (0.1,7.0)	2.5 (0.2,6.8)	0.0 (0.0,0.0)
Uganda	Treatment scenario	1.7 (-0.2,8.2)	2.2 (-0.3,7.4)	0.0 (0.0,0.0)	1.5 (-0.2,5.0)	0.0 (0.0,0.0)
Vanuatu	Diagnosis scenario	1.2 (0.2,3.0)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.2 (-0.1,0.9)
Vanuatu	Treatment scenario	0.3 (-0.1,1.1)	0.2 (-0.2,1.0)	0.3 (-0.3,1.7)	0.4 (-0.2,1.6)	0.0 (0.0,0.0)
Zambia	Diagnosis scenario	2.4 (0.5,5.5)	2.5 (-0.2,7.1)	2.3 (0.5,4.7)	0.2 (-0.2,1.4)	0.0 (0.0,0.0)
Zambia	Treatment scenario	2.7 (0.6,5.8)	1.0 (-0.5,4.2)	2.6 (0.3,6.3)	1.5 (-0.4,6.7)	0.0 (0.0,0.0)

Supplementary Table 29. Within country targets sensitivity analysis: Mean (95% uncertainty interval) relative decline (%) in CVD risk compared to baseline by country, wealth quintile, and scenario

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Afghanistan	Diagnosis scenario	2.6 (0.3,6.4)	4.3 (1.3,8.1)	4.4 (1.2,8.4)	1.2 (-0.1,3.4)	1.8 (-0.0,4.6)
Afghanistan	Treatment scenario	2.1 (0.2,5.6)	4.2 (1.3,7.8)	10.0 (5.0,15.1)	4.4 (1.4,8.1)	0.0 (0.0,0.0)
Albania	Diagnosis scenario	5.8 (3.5,8.3)	7.5 (5.1,10.0)	7.3 (5.0,9.6)	8.4 (5.7,11.2)	8.4 (5.7,11.1)
Albania	Treatment scenario	17.2 (14.1,20.2)	16.6 (13.7,19.4)	16.1 (13.4,18.8)	15.2 (12.1,18.2)	12.9 (10.0,15.8)
Algeria	Diagnosis scenario	5.5 (4.1,6.8)	6.0 (4.4,7.6)	5.9 (4.2,7.5)	4.8 (3.4,6.3)	5.0 (3.5,6.5)
Algeria	Treatment scenario	10.1 (8.5,11.8)	11.4 (9.5,13.3)	9.5 (7.5,11.5)	8.6 (6.9,10.4)	8.8 (7.1,10.6)
Azerbaijan	Diagnosis scenario	4.2 (2.5,5.9)	5.8 (2.6,9.4)	4.3 (2.2,6.6)	0.9 (0.0,2.0)	3.3 (1.2,5.5)
Azerbaijan	Treatment scenario	7.7 (5.5,10.0)	8.1 (4.6,11.9)	6.8 (4.3,9.4)	7.0 (4.6,9.6)	7.3 (4.3,10.4)
Benin	Diagnosis scenario	13.3 (5.4,24.1)	10.1 (7.0,13.5)	16.9 (13.5,20.5)	11.3 (8.1,14.5)	7.3 (4.6,10.1)
Benin	Treatment scenario	17.7 (8.4,26.8)	18.3 (14.9,21.7)	17.4 (14.0,21.0)	16.2 (12.9,19.6)	16.3 (12.8,19.7)
Bhutan	Diagnosis scenario	4.6 (2.7,6.8)	4.3 (2.3,6.4)	5.9 (3.0,9.1)	2.2 (0.5,4.2)	3.9 (1.8,6.4)
Bhutan	Treatment scenario	12.4 (9.7,15.2)	11.6 (8.8,14.5)	13.3 (9.7,17.0)	11.2 (7.6,15.0)	11.8 (8.5,15.1)
Botswana	Diagnosis scenario	3.5 (0.4,10.9)	5.2 (1.7,10.5)	2.5 (0.4,5.5)	3.4 (0.7,6.7)	3.2 (0.9,5.9)
Botswana	Treatment scenario	10.2 (4.9,17.4)	7.1 (3.2,12.5)	7.1 (3.7,10.9)	11.2 (6.7,15.9)	7.2 (3.9,10.8)
Brazil	Diagnosis scenario	3.8 (3.1,4.6)	2.7 (2.1,3.4)	2.0 (1.4,2.7)	1.8 (1.3,2.4)	2.0 (1.4,2.6)
Brazil	Treatment scenario	3.3 (2.6,4.1)	2.5 (1.9,3.3)	1.5 (1.0,2.1)	1.2 (0.8,1.7)	1.1 (0.7,1.6)
Cambodia	Diagnosis scenario	8.3 (5.4,11.2)	8.9 (5.8,12.1)	7.2 (4.1,10.4)	4.9 (2.6,7.3)	4.0 (1.8,6.4)
Cambodia	Treatment scenario	13.9 (10.7,17.2)	12.0 (8.8,15.4)	12.5 (8.8,16.2)	11.2 (8.2,14.3)	8.4 (5.3,11.6)
China	Diagnosis scenario	7.8 (6.6,9.0)	7.5 (6.4,8.7)	8.7 (7.5,9.9)	6.7 (5.6,7.9)	6.1 (5.0,7.2)
China	Treatment scenario	8.7 (7.5,10.0)	8.6 (7.3,9.8)	9.2 (8.0,10.5)	7.6 (6.4,8.8)	6.0 (4.8,7.1)
Ecuador	Diagnosis scenario	5.5 (2.8,8.5)	3.7 (2.1,5.5)	2.2 (0.5,4.3)	1.6 (0.1,3.4)	3.7 (1.4,6.5)
Ecuador	Treatment scenario	9.0 (5.8,12.4)	5.5 (3.6,7.6)	4.7 (2.2,7.5)	4.3 (1.9,7.0)	2.9 (0.9,5.5)
Eritrea	Diagnosis scenario	7.9 (5.8,10.1)	11.4 (5.9,17.0)	9.7 (6.5,13.1)	6.3 (3.9,8.8)	6.0 (3.4,8.8)
Eritrea	Treatment scenario	15.6 (13.1,18.2)	14.3 (8.7,20.0)	13.1 (9.7,16.7)	11.8 (8.8,15.0)	13.1 (9.5,16.6)
Eswatini	Diagnosis scenario	5.0 (2.2,8.5)	4.8 (1.7,9.4)	3.2 (0.8,6.2)	4.3 (0.7,9.2)	3.4 (0.6,6.8)
Eswatini	Treatment scenario	11.3 (7.5,15.3)	11.4 (7.0,16.0)	10.1 (5.4,15.3)	9.2 (3.9,14.8)	7.1 (2.9,11.8)
Ethiopia	Diagnosis scenario	6.2 (3.5,9.1)	7.6 (3.7,12.0)	8.6 (4.6,13.0)	5.9 (2.5,10.0)	8.1 (4.0,12.8)
Ethiopia	Treatment scenario	17.7 (14.0,21.2)	15.4 (10.6,20.2)	17.5 (12.8,22.2)	17.0 (12.2,21.5)	16.6 (11.7,21.3)
Gambia	Diagnosis scenario	9.8 (6.6,13.1)	8.3 (4.9,11.8)	8.6 (5.6,11.9)	8.4 (4.4,13.0)	4.5 (2.0,7.4)
Gambia	Treatment scenario	15.6 (12.0,19.2)	14.0 (9.8,18.0)	15.3 (11.7,19.0)	13.4 (8.8,18.3)	13.7 (9.6,17.9)
Ghana	Diagnosis scenario	11.0 (6.7,15.8)	14.9 (10.2,19.5)	13.0 (8.7,17.4)	9.3 (5.7,13.3)	9.8 (6.2,13.8)
Ghana	Treatment scenario	18.2 (13.5,22.4)	17.6 (12.8,22.1)	16.7 (12.3,20.9)	12.5 (8.5,16.6)	13.1 (9.2,17.1)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
India	Diagnosis scenario	9.9 (9.2,10.7)	8.6 (7.9,9.3)	7.4 (6.7,8.1)	7.4 (6.7,8.1)	6.7 (6.1,7.3)
India	Treatment scenario	15.1 (14.3,15.9)	14.2 (13.4,14.9)	12.9 (12.1,13.7)	12.2 (11.4,13.0)	10.6 (9.9,11.2)
Indonesia	Diagnosis scenario	3.4 (2.7,4.1)	4.3 (3.6,5.1)	3.8 (3.1,4.6)	4.0 (3.3,4.8)	4.5 (3.6,5.3)
Indonesia	Treatment scenario	18.1 (16.9,19.3)	17.1 (16.0,18.3)	16.7 (15.5,18.0)	15.6 (14.4,16.8)	14.5 (13.4,15.6)
Jordan	Diagnosis scenario	2.0 (0.3,4.7)	0.8 (0.0,2.1)	0.1 (-0.1,0.7)	3.2 (1.2,5.5)	2.9 (1.4,4.6)
Jordan	Treatment scenario	3.3 (1.2,6.1)	0.0 (0.0,0.0)	1.3 (0.1,3.0)	3.5 (1.4,5.8)	3.1 (1.5,5.0)
Kenya	Diagnosis scenario	5.8 (3.2,8.7)	5.5 (2.8,8.6)	6.3 (3.0,10.9)	5.0 (2.0,9.4)	2.7 (0.4,6.0)
Kenya	Treatment scenario	19.1 (15.4,22.8)	17.6 (14.0,21.1)	16.1 (11.6,20.5)	17.4 (12.7,21.8)	14.2 (9.0,18.9)
Kiribati	Diagnosis scenario	4.8 (-0.3,13.8)	8.1 (-0.4,22.6)	1.6 (-0.5,9.7)	3.1 (-1.1,11.8)	2.4 (-1.0,11.9)
Kiribati	Treatment scenario	15.6 (6.2,23.7)	16.8 (3.7,31.3)	16.5 (4.1,25.8)	16.5 (6.2,25.7)	16.9 (5.1,28.5)
Kyrgyzstan	Diagnosis scenario	6.5 (4.2,8.9)	4.6 (2.7,6.6)	3.5 (1.6,5.8)	4.3 (2.3,6.4)	4.0 (1.8,6.9)
Kyrgyzstan	Treatment scenario	12.6 (9.9,15.3)	9.2 (6.7,11.7)	13.6 (9.5,18.0)	12.8 (9.9,15.7)	12.1 (8.7,15.5)
Laos	Diagnosis scenario	10.2 (4.1,17.5)	8.4 (2.7,16.0)	5.9 (2.7,9.5)	4.0 (1.6,6.6)	7.4 (3.3,12.2)
Laos	Treatment scenario	15.6 (8.9,22.8)	12.0 (5.5,19.1)	14.2 (9.6,19.1)	9.1 (5.7,12.7)	12.4 (7.6,17.4)
Lesotho	Diagnosis scenario	8.3 (4.3,12.6)	5.9 (2.9,9.0)	10.2 (5.6,15.2)	5.1 (1.8,9.1)	4.8 (2.3,7.4)
Lesotho	Treatment scenario	8.7 (4.4,13.4)	8.2 (4.6,11.9)	12.3 (7.4,17.4)	4.8 (1.5,8.7)	4.9 (2.3,7.8)
Moldova	Diagnosis scenario	3.6 (2.4,5.0)	3.0 (1.8,4.4)	3.1 (1.8,4.6)	4.2 (2.2,6.5)	3.6 (2.1,5.3)
Moldova	Treatment scenario	11.5 (9.6,13.4)	10.1 (8.0,12.3)	9.7 (7.5,12.0)	9.1 (6.4,11.9)	10.2 (8.0,12.5)
Morocco	Diagnosis scenario	7.1 (5.9,8.4)	6.7 (4.4,9.2)	5.4 (3.4,7.4)	5.5 (3.2,7.8)	6.4 (4.7,8.1)
Morocco	Treatment scenario	11.2 (9.8,12.6)	11.7 (9.1,14.4)	11.1 (8.6,13.6)	12.8 (9.9,15.7)	10.8 (8.9,12.7)
Myanmar	Diagnosis scenario	4.1 (2.2,6.2)	4.6 (2.1,8.8)	3.3 (1.3,6.4)	4.3 (2.3,6.9)	3.1 (1.4,5.3)
Myanmar	Treatment scenario	15.5 (11.9,19.5)	12.9 (9.4,17.1)	11.2 (7.8,15.2)	10.7 (8.0,13.8)	9.5 (6.4,13.3)
Namibia	Diagnosis scenario	10.8 (8.6,13.1)	7.9 (6.0,10.0)	6.3 (4.5,8.2)	6.7 (4.7,9.0)	1.8 (0.7,3.0)
Namibia	Treatment scenario	11.9 (9.6,14.2)	10.0 (7.8,12.2)	6.1 (4.2,8.1)	6.6 (4.6,8.8)	2.4 (1.1,3.9)
Niger	Diagnosis scenario	15.2 (12.0,18.5)	0.0 (0.0,0.0)	7.8 (4.8,10.7)	8.4 (5.8,11.1)	10.6 (7.5,13.8)
Niger	Treatment scenario	20.6 (17.4,23.7)	22.2 (19.2,25.2)	22.2 (18.8,25.6)	20.9 (17.9,23.9)	20.2 (16.8,23.5)
Russian Federation	Diagnosis scenario	2.8 (0.8,5.6)	0.0 (0.0,0.0)	0.3 (-0.1,1.1)	5.8 (1.3,15.5)	0.4 (-0.0,1.6)
Russian Federation	Treatment scenario	7.2 (4.0,10.8)	3.3 (1.0,7.3)	1.1 (0.2,2.2)	5.2 (1.2,14.8)	0.2 (-0.1,0.8)
Rwanda	Diagnosis scenario	9.0 (6.2,11.7)	12.3 (9.0,15.6)	4.3 (2.1,6.5)	1.5 (0.0,3.0)	6.1 (3.7,8.6)
Rwanda	Treatment scenario	19.3 (16.3,22.3)	19.5 (16.2,22.8)	19.7 (16.6,22.8)	19.5 (16.1,22.9)	19.5 (16.4,22.6)
Samoa	Diagnosis scenario	15.5 (10.0,21.1)	22.3 (15.3,27.7)	9.3 (4.0,15.1)	7.7 (2.1,13.9)	10.1 (4.9,15.8)
Samoa	Treatment scenario	15.7 (9.9,21.5)	18.8 (11.4,25.4)	13.7 (7.6,20.1)	16.9 (10.4,23.2)	14.8 (9.2,20.4)
Sao Tome and Principe	Diagnosis scenario	6.8 (4.1,9.5)	6.2 (3.9,8.6)	9.1 (6.4,11.8)	4.7 (2.3,7.1)	8.2 (5.7,10.8)

(continued)

Country	Scenario	Q1	Q2	Q3	Q4	Q5
Sao Tome and Principe	Treatment scenario	15.1 (11.9,18.3)	16.8 (13.7,20.0)	15.8 (12.7,19.0)	14.9 (11.4,18.5)	14.2 (11.3,17.2)
Solomon Islands	Diagnosis scenario	3.0 (0.4,6.7)	3.9 (1.1,7.2)	3.5 (0.8,6.6)	1.7 (-0.3,4.5)	2.1 (-0.1,4.8)
Solomon Islands	Treatment scenario	17.7 (12.7,22.4)	17.9 (13.3,22.6)	16.4 (11.6,21.0)	17.8 (12.6,22.9)	13.4 (8.0,18.9)
South Africa	Diagnosis scenario	9.6 (7.8,11.4)	8.6 (7.0,10.1)	5.8 (4.1,7.6)	4.8 (3.4,6.3)	5.0 (3.5,6.5)
South Africa	Treatment scenario	9.9 (8.1,11.9)	8.2 (6.7,9.8)	4.5 (3.1,6.2)	4.0 (2.7,5.4)	3.8 (2.5,5.2)
Sri Lanka	Diagnosis scenario	6.0 (4.3,7.7)	7.1 (5.5,8.7)	7.6 (5.7,9.6)	5.2 (3.2,7.4)	3.3 (1.5,5.3)
Sri Lanka	Treatment scenario	9.9 (7.9,12.0)	10.8 (9.0,12.6)	10.3 (8.3,12.3)	7.5 (5.2,10.0)	7.3 (4.6,10.2)
St. Vincent & the Grenadines	Diagnosis scenario	2.3 (0.9,4.0)	3.0 (1.0,5.7)	3.6 (1.1,6.5)	4.8 (2.1,7.7)	2.2 (0.9,4.3)
St. Vincent & the Grenadines	Treatment scenario	4.8 (2.8,7.1)	8.4 (5.1,11.8)	7.7 (4.2,11.5)	8.9 (5.4,12.3)	4.3 (2.3,7.1)
Sudan	Diagnosis scenario	12.2 (9.8,14.7)	10.8 (9.3,12.5)	8.1 (6.5,9.8)	8.2 (5.6,10.9)	6.0 (1.7,10.7)
Sudan	Treatment scenario	15.8 (13.4,18.2)	13.3 (11.7,15.0)	13.0 (11.1,14.9)	12.3 (9.3,15.3)	6.2 (1.9,10.9)
Tanzania	Diagnosis scenario	12.4 (9.1,15.6)	10.3 (7.0,13.9)	8.5 (5.2,12.4)	4.2 (1.9,6.9)	4.9 (1.0,12.2)
Tanzania	Treatment scenario	18.4 (15.1,21.7)	16.3 (12.7,20.0)	18.5 (14.6,22.5)	20.2 (16.4,23.8)	20.1 (12.9,29.1)
Timor Leste	Diagnosis scenario	5.4 (2.2,8.7)	8.2 (5.5,11.0)	8.2 (4.9,11.5)	8.3 (4.8,11.8)	3.4 (1.2,5.7)
Timor Leste	Treatment scenario	18.1 (13.8,22.4)	15.3 (12.2,18.5)	14.2 (10.5,17.9)	12.5 (8.7,16.4)	11.6 (7.8,15.3)
Togo	Diagnosis scenario	6.1 (2.9,9.6)	5.7 (2.1,10.2)	6.7 (3.4,10.5)	3.9 (0.8,8.2)	5.5 (2.4,8.8)
Togo	Treatment scenario	17.7 (13.3,22.1)	18.2 (13.0,23.4)	16.2 (11.8,20.5)	18.5 (13.0,23.9)	14.1 (10.0,18.2)
Uganda	Diagnosis scenario	13.0 (8.6,17.6)	5.3 (1.9,9.6)	6.8 (3.1,11.0)	6.7 (2.8,11.9)	2.1 (-0.3,5.7)
Uganda	Treatment scenario	16.9 (12.4,21.4)	18.2 (13.2,23.0)	15.4 (10.7,20.1)	17.0 (11.9,22.1)	15.7 (9.3,23.2)
Vanuatu	Diagnosis scenario	6.2 (4.2,8.3)	1.7 (0.5,3.2)	2.1 (0.5,4.2)	1.2 (0.2,2.4)	3.4 (1.9,5.1)
Vanuatu	Treatment scenario	19.6 (17.1,22.0)	19.3 (16.5,22.2)	19.3 (15.9,22.6)	20.1 (17.3,22.9)	19.4 (16.9,21.8)
Zambia	Diagnosis scenario	5.4 (2.6,8.7)	6.5 (2.2,11.4)	6.2 (2.5,10.6)	2.0 (0.1,5.4)	2.2 (0.0,4.9)
Zambia	Treatment scenario	15.4 (11.5,19.3)	13.5 (7.5,19.8)	15.7 (10.7,20.7)	14.1 (9.0,19.4)	12.3 (6.7,18.2)

Supplementary Table 30. Education group targets sensitivity analysis: Mean proportion (%) of people living with hypertension aware of their diagnosis, on treatment, and with controlled blood pressure by education category across countries

Country	Cascade Step	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Afghanistan	Aware	65.1	50.6	52.4	10.9	43.7
Afghanistan	Treated	52.4	30.3	51.5	10.9	35.1
Afghanistan	Controlled	15.9	1.2	4.9	1.4	15
Albania	Aware	-	8.6	21.6	19.8	23.1
Albania	Treated	-	5.6	9.5	12.5	13.5
Albania	Controlled	-	1.5	1.4	4.6	4.4
Algeria	Aware	53.5	48.1	48.4	41	51
Algeria	Treated	40.6	31.1	32	27.2	33.1
Algeria	Controlled	14.4	11.6	13.8	12.2	15
Azerbaijan	Aware	-	-	63.7	56	62.9
Azerbaijan	Treated	-	-	49.8	37.5	43.5
Azerbaijan	Controlled	-	-	5.8	10.3	10.1
Benin	Aware	16.1	13.5	33.6	20.9	50.1
Benin	Treated	11.4	8.4	15.3	15.4	34.4
Benin	Controlled	1.8	2.1	2.8	4.7	4.2
Bhutan	Aware	41.6	49.4	50.6	-	-
Bhutan	Treated	20.9	21	20.9	-	-
Bhutan	Controlled	5	4.3	8.2	-	-
Botswana	Aware	61.2	55.1	54.8	71.4	56.1
Botswana	Treated	40.7	40.1	36.1	48.2	39.9
Botswana	Controlled	10.7	11	13.5	21.1	14.9
Brazil	Aware	65.9	71.1	61.5	63.6	68
Brazil	Treated	59.8	65.6	55.4	56.8	61.8
Brazil	Controlled	29.5	32.5	29.2	32	36.9
Cambodia	Aware	39.8	44.9	42.8	46.7	42.3
Cambodia	Treated	24.4	30.8	28.1	34.4	32.7
Cambodia	Controlled	12.1	18.5	20.3	23.9	10.4
China	Aware	45.7	41.2	43.7	39.4	47.2
China	Treated	40.8	36.8	37.2	31.6	40.7
China	Controlled	9.5	9.2	8.9	8.8	12.1

(continued)

Country	Cascade Step	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Ecuador	Aware	57.6	-	55.6	64.8	63.8
Ecuador	Treated	46.3	-	43.8	48.5	53.1
Ecuador	Controlled	27.9	-	26.5	28	30
Eritrea	Aware	25.8	-	40.5	33.1	36.3
Eritrea	Treated	15.6	-	28	21.9	26.8
Eritrea	Controlled	5	-	13.9	4.2	14.8
Eswatini	Aware	49.9	54	59.6	47.7	54
Eswatini	Treated	31.7	36.6	33.3	32.3	34
Eswatini	Controlled	3.2	13	9.8	8.8	7.7
Ethiopia	Aware	14.2	28.6	29	46.9	38.7
Ethiopia	Treated	7.2	13.6	6.6	22.6	13.9
Ethiopia	Controlled	2.4	3.3	0.7	0.4	2.4
Gambia	Aware	34.4	-	15.8	-	29.2
Gambia	Treated	20.5	-	13.3	-	22.4
Gambia	Controlled	4.7	-	5.1	-	6.5
Ghana	Aware	17	15.5	16.5	20.6	27.5
Ghana	Treated	11.7	11.2	5.9	19.7	23.8
Ghana	Controlled	3.4	1.8	1.1	7.2	4.6
India	Aware	26	24.7	30.7	31.5	35.2
India	Treated	16.7	16.9	19.4	19.8	24
India	Controlled	7.7	7.6	8.5	9.1	10.8
Indonesia	Aware	37.9	39.8	37.7	42.1	40
Indonesia	Treated	13.6	14.1	12.1	18.2	16.4
Indonesia	Controlled	1.5	3.4	2.3	3.8	3.9
Jordan	Aware	76.3	65.3	69.6	67.3	66.8
Jordan	Treated	66.3	56	64.1	60.7	54.5
Jordan	Controlled	35.1	32.7	35.5	41	34.5
Kenya	Aware	27.3	27.2	29.4	24.4	41.4
Kenya	Treated	12.5	10.7	12.4	5.9	15.3
Kenya	Controlled	5.2	3.8	2.6	0.6	9
Kiribati	Aware	-	21.8	33.2	30.1	30.8

(continued)

Country	Cascade Step	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Kiribati	Treated	-	3.5	8.6	8.8	24
Kiribati	Controlled	-	3.1	3.4	0.5	7.7
Kyrgyzstan	Aware	-	49.8	-	45.5	46.2
Kyrgyzstan	Treated	-	42.8	-	26.2	24.5
Kyrgyzstan	Controlled	-	3.6	-	3.2	2.8
Laos	Aware	29.9	45.8	41.9	32.6	38.4
Laos	Treated	13.4	29.7	24.4	27.9	29.6
Laos	Controlled	3.3	10.3	5	12	6.6
Lesotho	Aware	41.1	39.9	58.6	49.5	58.3
Lesotho	Treated	41.1	33.1	53.4	37.9	51.2
Lesotho	Controlled	26.1	14.8	23	13.9	16.2
Moldova	Aware	-	-	-	51.3	55
Moldova	Treated	-	-	-	28.3	33
Moldova	Controlled	-	-	-	4.7	4.1
Morocco	Aware	42.1	-	38	30.5	34.6
Morocco	Treated	27.2	-	21.7	18.9	24.9
Morocco	Controlled	7.3	-	4.5	6.6	7.3
Myanmar	Aware	48.8	50.5	54.3	58.2	59.4
Myanmar	Treated	30.1	26.6	40	31.3	45.1
Myanmar	Controlled	8.2	7.6	17.8	10.1	26
Namibia	Aware	43.2	44.8	47.9	51.2	57.4
Namibia	Treated	38.2	38.8	42.7	43.2	48
Namibia	Controlled	13	16.8	19.5	17.5	23.7
Niger	Aware	3.8	5.6	21.7	-	-
Niger	Treated	1.6	2.8	4.3	-	-
Niger	Controlled	0.4	0	0	-	-
Russian Federation	Aware	-	89	69.3	77	62.7
Russian Federation	Treated	-	80	62	68.8	50.4
Russian Federation	Controlled	-	4.7	10.5	10.3	10.6
Rwanda	Aware	7.4	8.5	8.5	16.9	-
Rwanda	Treated	2.4	3.2	3.1	3.2	-
Rwanda	Controlled	0.4	2	2.1	2.4	-

(continued)

Country	Cascade Step	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Samoa	Aware	-	-	13.1	11.1	31.2
Samoa	Treated	-	-	11.2	6.8	19.1
Samoa	Controlled	-	-	1.1	4.5	10.2
Sao Tome and Principe	Aware	41.1	44.1	34.2	31	31.1
Sao Tome and Principe	Treated	21.5	29.6	17.9	15.9	23.8
Sao Tome and Principe	Controlled	2.8	5	2.3	4.8	0
Solomon Islands	Aware	47.7	35.2	35.9	25.3	24
Solomon Islands	Treated	13.8	15.4	8.9	11.3	1.5
Solomon Islands	Controlled	7.4	5.2	0.4	8.2	1.5
South Africa	Aware	50	52.3	55.1	54.3	49
South Africa	Treated	46.9	48.7	49.4	50.1	45
South Africa	Controlled	16.5	16.3	18.5	19.4	16.1
Sri Lanka	Aware	31.1	48.2	41.7	47	46.4
Sri Lanka	Treated	22.1	35.8	33.5	33.7	35.2
Sri Lanka	Controlled	7.4	11.1	11	12.2	13.7
St. Vincent & the Grenadines	Aware	-	53.7	62.6	-	58.5
St. Vincent & the Grenadines	Treated	-	44.8	46.6	-	39.9
St. Vincent & the Grenadines	Controlled	-	15.5	21.2	-	18.5
Sudan	Aware	20.6	25.1	21.9	35.6	38
Sudan	Treated	16.2	16.3	18	22.8	26.1
Sudan	Controlled	3.3	4.7	3.7	8.4	7.7
Tanzania	Aware	17.7	20.2	20.3	33.2	27.3
Tanzania	Treated	8.2	8.1	8.3	18.7	6.3
Tanzania	Controlled	3.2	0.9	1.7	5.9	3.2
Timor Leste	Aware	22.5	27.2	55.2	46.7	-
Timor Leste	Treated	14.2	16.5	37.9	18.3	-
Timor Leste	Controlled	6.4	4.9	10.3	6.7	-
Togo	Aware	23.2	36	37	27	45.7
Togo	Treated	9.7	9.6	21.4	6.7	17.1
Togo	Controlled	3.6	4.3	10.4	2.5	0.6
Uganda	Aware	18.3	-	20.4	32.9	48.2
Uganda	Treated	8.5	-	10.2	15	22.9

(continued)

Country	Cascade Step	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Uganda	Controlled	1.1	-	4	1.5	7.8
Vanuatu	Aware	7.1	17.6	19.7	23.3	18.4
Vanuatu	Treated	1.5	2.9	1.8	3.5	7.5
Vanuatu	Controlled	0	0.6	0.5	0	0
Zambia	Aware	42.5	35.7	40.3	36.4	59.8
Zambia	Treated	15.5	12.9	22.4	20.3	35.2
Zambia	Controlled	2.1	7.8	6.9	7.1	8.2

Supplementary Table 31. Education group targets sensitivity analysis: Mean 10-year CVD risk by country and wealth quintile in Baseline, Diagnosis, and Treatment scenarios and CVD cases averted per 1,000 people living with hypertension compared to baseline by scenario and education category

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Afghanistan	Baseline	Mean CVD Risk	22.3	18.7	18.6	28.9	26
Afghanistan	Diagnosis scenario	Mean CVD Risk	21.6	17.9	17.6	23.2	23.6
Afghanistan	Diagnosis scenario	CVD Cases Averted Compared to Baseline	6.6	7.9	10.1	57.2	24.1
Afghanistan	Treatment scenario	Mean CVD Risk	21.1	16.7	17.9	23.7	23.1
Afghanistan	Treatment scenario	CVD Cases Averted Compared to Baseline	11.7	20.1	7	52.1	29.6
Albania	Baseline	Mean CVD Risk	-	4.7	4.7	5.5	5.6
Albania	Diagnosis scenario	Mean CVD Risk	-	4.1	4.3	4.9	5.2
Albania	Diagnosis scenario	CVD Cases Averted Compared to Baseline	-	6.1	3.2	6.2	4.9
Albania	Treatment scenario	Mean CVD Risk	-	3.9	3.8	4.6	4.8
Albania	Treatment scenario	CVD Cases Averted Compared to Baseline	-	8.4	8.2	9.8	8.9
Algeria	Baseline	Mean CVD Risk	9.8	9.3	7.9	7.5	7.3

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Algeria	Diagnosis scenario	Mean CVD Risk	9.3	8.8	7.5	7	6.9
Algeria	Diagnosis scenario	CVD Cases Averted Compared to Baseline	4.7	4.6	4.1	5	3.4
Algeria	Treatment scenario	Mean CVD Risk	9	8.3	7.1	6.6	6.5
Algeria	Treatment scenario	CVD Cases Averted Compared to Baseline	7.8	10.1	8.4	9.1	7.4
Azerbaijan	Baseline	Mean CVD Risk	-	-	22.3	13.6	15.7
Azerbaijan	Diagnosis scenario	Mean CVD Risk	-	-	21.7	13.1	15.4
Azerbaijan	Diagnosis scenario	CVD Cases Averted Compared to Baseline	-	-	6	5	3.8
Azerbaijan	Treatment scenario	Mean CVD Risk	-	-	20.9	12.4	14.6
Azerbaijan	Treatment scenario	CVD Cases Averted Compared to Baseline	-	-	13.8	12	11.1
Benin	Baseline	Mean CVD Risk	14.4	11.9	13.9	13.9	14.9
Benin	Diagnosis scenario	Mean CVD Risk	12.4	10.4	13	12	14.3
Benin	Diagnosis scenario	CVD Cases Averted Compared to Baseline	20	15	8.7	19.5	6.3

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Benin	Treatment scenario	Mean CVD Risk	11.8	9.6	11.4	11.5	13.5
Benin	Treatment scenario	CVD Cases Averted Compared to Baseline	26.4	23.4	25	24.8	14.2
Bhutan	Baseline	Mean CVD Risk	12.6	11.6	11.1	-	-
Bhutan	Diagnosis scenario	Mean CVD Risk	12	11.3	10.8	-	-
Bhutan	Diagnosis scenario	CVD Cases Averted Compared to Baseline	6.1	2.9	2.9	-	-
Bhutan	Treatment scenario	Mean CVD Risk	11	10.1	9.8	-	-
Bhutan	Treatment scenario	CVD Cases Averted Compared to Baseline	16.5	15	13.5	-	-
Botswana	Baseline	Mean CVD Risk	13	11.1	8.5	6.1	7.4
Botswana	Diagnosis scenario	Mean CVD Risk	12.6	10.7	8.1	6	7
Botswana	Diagnosis scenario	CVD Cases Averted Compared to Baseline	4.4	4.7	4	0.6	4.4
Botswana	Treatment scenario	Mean CVD Risk	11.7	10.2	7.5	5.7	6.7
Botswana	Treatment scenario	CVD Cases Averted Compared to Baseline	13.1	9.2	9.6	3.5	7.7

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Brazil	Baseline	Mean CVD Risk	12	11.2	8.7	7.6	8.4
Brazil	Diagnosis scenario	Mean CVD Risk	11.7	11	8.4	7.3	8.2
Brazil	Diagnosis scenario	CVD Cases Averted Compared to Baseline	3.3	1.8	3.7	2.6	2
Brazil	Treatment scenario	Mean CVD Risk	11.7	11.1	8.4	7.3	8.2
Brazil	Treatment scenario	CVD Cases Averted Compared to Baseline	2.9	1.1	3.6	3.1	1.7
Cambodia	Baseline	Mean CVD Risk	17.4	17	15.4	16.5	17.8
Cambodia	Diagnosis scenario	Mean CVD Risk	16.2	15.8	14.3	15.3	16.5
Cambodia	Diagnosis scenario	CVD Cases Averted Compared to Baseline	12.5	11.6	11.2	11.4	12.2
Cambodia	Treatment scenario	Mean CVD Risk	14.9	14.9	13.3	14.4	15.7
Cambodia	Treatment scenario	CVD Cases Averted Compared to Baseline	25.7	20.2	21.2	20.6	20.5
China	Baseline	Mean CVD Risk	29.5	24.6	21	14	16.3
China	Diagnosis scenario	Mean CVD Risk	27.5	22.6	19.6	13	15.3

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
China	Diagnosis scenario	CVD Cases Averted Compared to Baseline	20	19.7	14.3	9.6	9.3
China	Treatment scenario	Mean CVD Risk	27.5	22.6	19.3	12.7	15.2
China	Treatment scenario	CVD Cases Averted Compared to Baseline	20.1	19.7	16.4	12.5	10.6
Ecuador	Baseline	Mean CVD Risk	8.2	-	7.4	8.1	7
Ecuador	Diagnosis scenario	Mean CVD Risk	7.8	-	7	7.8	6.8
Ecuador	Diagnosis scenario	CVD Cases Averted Compared to Baseline	3.9	-	4	2.4	2.1
Ecuador	Treatment scenario	Mean CVD Risk	7.6	-	6.8	7.6	6.7
Ecuador	Treatment scenario	CVD Cases Averted Compared to Baseline	5.9	-	6	5.2	3.1
Eritrea	Baseline	Mean CVD Risk	17.5	-	15.8	14.2	19.8
Eritrea	Diagnosis scenario	Mean CVD Risk	16	-	14.6	12.9	18.1
Eritrea	Diagnosis scenario	CVD Cases Averted Compared to Baseline	15.1	-	11.8	13.2	17.5
Eritrea	Treatment scenario	Mean CVD Risk	14.8	-	13.8	12.1	17.5

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Eritrea	Treatment scenario	CVD Cases Averted Compared to Baseline	27	-	19.8	21.1	22.9
Eswatini	Baseline	Mean CVD Risk	17.7	15.7	14	12.9	11.3
Eswatini	Diagnosis scenario	Mean CVD Risk	16.9	15.1	13.6	11.9	10.9
Eswatini	Diagnosis scenario	CVD Cases Averted Compared to Baseline	8.3	6	3.7	10	4.6
Eswatini	Treatment scenario	Mean CVD Risk	15.5	14.3	12.6	11.3	10.1
Eswatini	Treatment scenario	CVD Cases Averted Compared to Baseline	21.8	13.4	13.3	16.3	12.5
Ethiopia	Baseline	Mean CVD Risk	9.9	10.8	9.3	10.1	8.7
Ethiopia	Diagnosis scenario	Mean CVD Risk	9	10.1	9	9.7	8.4
Ethiopia	Diagnosis scenario	CVD Cases Averted Compared to Baseline	9.2	6.6	3	3.9	3.1
Ethiopia	Treatment scenario	Mean CVD Risk	8	8.9	7.5	8.9	7.1
Ethiopia	Treatment scenario	CVD Cases Averted Compared to Baseline	18.9	18.5	17.5	12.1	15.6

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Gambia	Baseline	Mean CVD Risk	12.3	-	8.7	-	11.1
Gambia	Diagnosis scenario	Mean CVD Risk	11.3	-	7.3	-	10.1
Gambia	Diagnosis scenario	CVD Cases Averted Compared to Baseline	9.7	-	13.7	-	9.6
Gambia	Treatment scenario	Mean CVD Risk	10.3	-	7.1	-	9.6
Gambia	Treatment scenario	CVD Cases Averted Compared to Baseline	19.9	-	15.9	-	14.9
Ghana	Baseline	Mean CVD Risk	18.5	12.7	10.7	13.3	11.8
Ghana	Diagnosis scenario	Mean CVD Risk	16.5	11.1	10.1	11.3	10.5
Ghana	Diagnosis scenario	CVD Cases Averted Compared to Baseline	19.8	15.8	6.4	19.2	13.8
Ghana	Treatment scenario	Mean CVD Risk	15.7	10.5	8.8	11.5	10.4
Ghana	Treatment scenario	CVD Cases Averted Compared to Baseline	27.9	21.6	19.3	18	14.8
India	Baseline	Mean CVD Risk	12.5	14.9	14.4	14	13.7
India	Diagnosis scenario	Mean CVD Risk	11.4	13.4	13.2	12.9	12.6

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
India	Diagnosis scenario	CVD Cases Averted Compared to Baseline	11.6	14.6	11.7	11.1	10.6
India	Treatment scenario	Mean CVD Risk	10.7	12.7	12.3	12	12
India	Treatment scenario	CVD Cases Averted Compared to Baseline	18.7	21.5	20.5	19.2	16.9
Indonesia	Baseline	Mean CVD Risk	33.6	25.6	23.8	21.8	20.6
Indonesia	Diagnosis scenario	Mean CVD Risk	32.2	24.6	22.9	20.8	19.7
Indonesia	Diagnosis scenario	CVD Cases Averted Compared to Baseline	14	10.3	8.9	9.4	8.9
Indonesia	Treatment scenario	Mean CVD Risk	27.8	21	19.5	18.2	17.2
Indonesia	Treatment scenario	CVD Cases Averted Compared to Baseline	58	45.9	42.7	35.2	33.8
Jordan	Baseline	Mean CVD Risk	12.1	10	10.3	9.8	10.7
Jordan	Diagnosis scenario	Mean CVD Risk	12.1	9.8	10.1	9.6	10.5
Jordan	Diagnosis scenario	CVD Cases Averted Compared to Baseline	0.2	2.4	1.7	2.3	2.3
Jordan	Treatment scenario	Mean CVD Risk	12	9.7	10.1	9.6	10.3

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Jordan	Treatment scenario	CVD Cases Averted Compared to Baseline	0.8	3.4	1.3	2.2	4.1
Kenya	Baseline	Mean CVD Risk	7.9	7.6	6.2	6.1	6.6
Kenya	Diagnosis scenario	Mean CVD Risk	7.3	7.2	5.8	5.9	6.3
Kenya	Diagnosis scenario	CVD Cases Averted Compared to Baseline	5.5	4.5	4	2.5	2.5
Kenya	Treatment scenario	Mean CVD Risk	6.4	6.3	5	4.9	5.4
Kenya	Treatment scenario	CVD Cases Averted Compared to Baseline	14.6	13.7	11.7	12.4	11.9
Kiribati	Baseline	Mean CVD Risk	-	14.7	13	9.8	10.3
Kiribati	Diagnosis scenario	Mean CVD Risk	-	14.2	12.5	9.4	9.1
Kiribati	Diagnosis scenario	CVD Cases Averted Compared to Baseline	-	4.8	4.7	3.7	11.7
Kiribati	Treatment scenario	Mean CVD Risk	-	11.9	10.6	8.1	8.8
Kiribati	Treatment scenario	CVD Cases Averted Compared to Baseline	-	27.7	23.5	17.2	14.6

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Kyrgyzstan	Baseline	Mean CVD Risk	-	28.1	-	17.5	19.5
Kyrgyzstan	Diagnosis scenario	Mean CVD Risk	-	26.4	-	16.7	18.7
Kyrgyzstan	Diagnosis scenario	CVD Cases Averted Compared to Baseline	-	16.7	-	7.8	8.1
Kyrgyzstan	Treatment scenario	Mean CVD Risk	-	26.2	-	15.4	17.1
Kyrgyzstan	Treatment scenario	CVD Cases Averted Compared to Baseline	-	18.6	-	20.8	24.7
Laos	Baseline	Mean CVD Risk	21	18.4	17.5	18.9	14.4
Laos	Diagnosis scenario	Mean CVD Risk	19.8	17.4	16.7	16.5	13.2
Laos	Diagnosis scenario	CVD Cases Averted Compared to Baseline	11.7	10.1	8.6	24.5	11.3
Laos	Treatment scenario	Mean CVD Risk	17.3	16.3	15.4	16.4	12.9
Laos	Treatment scenario	CVD Cases Averted Compared to Baseline	37.2	21.5	21.2	25.3	14.2
Lesotho	Baseline	Mean CVD Risk	10.2	9.5	7	7.8	6.7
Lesotho	Diagnosis scenario	Mean CVD Risk	8.8	8.5	6.6	7.2	6.4

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Lesotho	Diagnosis scenario	CVD Cases Averted Compared to Baseline	14.7	10.2	3.6	5.6	3.2
Lesotho	Treatment scenario	Mean CVD Risk	9.1	8.3	6.6	6.9	6.4
Lesotho	Treatment scenario	CVD Cases Averted Compared to Baseline	11.6	11.5	3.7	9	3.6
Moldova	Baseline	Mean CVD Risk	-	-	-	20.4	18.6
Moldova	Diagnosis scenario	Mean CVD Risk	-	-	-	19.7	18
Moldova	Diagnosis scenario	CVD Cases Averted Compared to Baseline	-	-	-	7.5	6.2
Moldova	Treatment scenario	Mean CVD Risk	-	-	-	18.2	16.7
Moldova	Treatment scenario	CVD Cases Averted Compared to Baseline	-	-	-	22.4	19.5
Morocco	Baseline	Mean CVD Risk	13.5	-	9.8	8.3	10
Morocco	Diagnosis scenario	Mean CVD Risk	12.8	-	9.2	7.6	9.2
Morocco	Diagnosis scenario	CVD Cases Averted Compared to Baseline	7.4	-	5.4	6.2	7.6
Morocco	Treatment scenario	Mean CVD Risk	12.1	-	8.6	7.2	8.8

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Morocco	Treatment scenario	CVD Cases Averted Compared to Baseline	14.7	-	11.7	10.7	11.8
Myanmar	Baseline	Mean CVD Risk	14	13	13.3	12.3	10.4
Myanmar	Diagnosis scenario	Mean CVD Risk	13.3	12.4	12.5	11.9	9.9
Myanmar	Diagnosis scenario	CVD Cases Averted Compared to Baseline	7.1	5.9	8	3.6	4.7
Myanmar	Treatment scenario	Mean CVD Risk	12.1	11.1	11.9	10.7	9.5
Myanmar	Treatment scenario	CVD Cases Averted Compared to Baseline	18.9	18.7	14.6	15.6	8.9
Namibia	Baseline	Mean CVD Risk	9.9	8.2	7.7	7.7	6.9
Namibia	Diagnosis scenario	Mean CVD Risk	9	7.6	7	7.1	6.7
Namibia	Diagnosis scenario	CVD Cases Averted Compared to Baseline	9.3	6.2	6.8	5.7	2.6
Namibia	Treatment scenario	Mean CVD Risk	9	7.5	7.1	7	6.6
Namibia	Treatment scenario	CVD Cases Averted Compared to Baseline	9.3	7.3	6.5	6.5	3.6

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Niger	Baseline	Mean CVD Risk	10.2	9.8	8	-	-
Niger	Diagnosis scenario	Mean CVD Risk	9.1	8.5	7.6	-	-
Niger	Diagnosis scenario	CVD Cases Averted Compared to Baseline	11	12.7	3.3	-	-
Niger	Treatment scenario	Mean CVD Risk	7.8	7.5	6.3	-	-
Niger	Treatment scenario	CVD Cases Averted Compared to Baseline	23.5	23.3	17.1	-	-
Russian Federation	Baseline	Mean CVD Risk	-	47	54	40.8	24.4
Russian Federation	Diagnosis scenario	Mean CVD Risk	-	47	53.1	40.8	23.9
Russian Federation	Diagnosis scenario	CVD Cases Averted Compared to Baseline	-	0	8.7	0	5.4
Russian Federation	Treatment scenario	Mean CVD Risk	-	47	53.2	40.8	23.5
Russian Federation	Treatment scenario	CVD Cases Averted Compared to Baseline	-	0	8.5	0	9.6
Rwanda	Baseline	Mean CVD Risk	9.5	9.9	7.1	7.4	-
Rwanda	Diagnosis scenario	Mean CVD Risk	8.8	9	6.5	7.2	-

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Rwanda	Diagnosis scenario	CVD Cases Averted Compared to Baseline	6.7	8.2	5.6	2.6	-
Rwanda	Treatment scenario	Mean CVD Risk	7.5	7.7	5.6	5.8	-
Rwanda	Treatment scenario	CVD Cases Averted Compared to Baseline	19.7	21.2	14.6	16.5	-
Samoa	Baseline	Mean CVD Risk	-	-	13.9	10.4	11
Samoa	Diagnosis scenario	Mean CVD Risk	-	-	11.5	9	10
Samoa	Diagnosis scenario	CVD Cases Averted Compared to Baseline	-	-	24	13.4	9.3
Samoa	Treatment scenario	Mean CVD Risk	-	-	11.4	8.3	9.3
Samoa	Treatment scenario	CVD Cases Averted Compared to Baseline	-	-	25.2	20.8	16.3
Sao Tome and Principe	Baseline	Mean CVD Risk	11.2	10.5	9	6.4	7.9
Sao Tome and Principe	Diagnosis scenario	Mean CVD Risk	10.5	9.9	8.4	5.9	7.2
Sao Tome and Principe	Diagnosis scenario	CVD Cases Averted Compared to Baseline	6.9	6.2	6.3	4.7	7.2
Sao Tome and Principe	Treatment scenario	Mean CVD Risk	9.3	9	7.5	5.3	6.9

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Sao Tome and Principe	Treatment scenario	CVD Cases Averted Compared to Baseline	18.6	14.4	15.5	11.1	9.8
Solomon Islands	Baseline	Mean CVD Risk	13.3	15.4	13.8	15	17.7
Solomon Islands	Diagnosis scenario	Mean CVD Risk	13	14.5	13.4	13.8	17.5
Solomon Islands	Diagnosis scenario	CVD Cases Averted Compared to Baseline	2.8	9.3	4.6	12.1	1.7
Solomon Islands	Treatment scenario	Mean CVD Risk	11	12.7	11.3	12.2	14
Solomon Islands	Treatment scenario	CVD Cases Averted Compared to Baseline	23.1	26.7	25.6	27.7	37
South Africa	Baseline	Mean CVD Risk	25.7	20.7	19.6	16.6	16.6
South Africa	Diagnosis scenario	Mean CVD Risk	23.8	19.3	18.7	15.6	15.7
South Africa	Diagnosis scenario	CVD Cases Averted Compared to Baseline	19.1	14	9.2	9.2	9.4
South Africa	Treatment scenario	Mean CVD Risk	24.1	19.5	18.6	15.7	15.7
South Africa	Treatment scenario	CVD Cases Averted Compared to Baseline	16.5	12.2	10.1	8.5	9.2

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Sri Lanka	Baseline	Mean CVD Risk	16.6	19.2	21.7	16.9	16
Sri Lanka	Diagnosis scenario	Mean CVD Risk	15	18	19.6	15.8	14.9
Sri Lanka	Diagnosis scenario	CVD Cases Averted Compared to Baseline	15.5	11.8	20.8	10.9	10.3
Sri Lanka	Treatment scenario	Mean CVD Risk	14.3	17.3	19.1	15.1	14.5
Sri Lanka	Treatment scenario	CVD Cases Averted Compared to Baseline	22.4	18.5	26.1	17.8	14.9
St. Vincent & the Grenadines	Baseline	Mean CVD Risk	-	18.9	15.4	-	12.9
St. Vincent & the Grenadines	Diagnosis scenario	Mean CVD Risk	-	18.1	14.8	-	12.4
St. Vincent & the Grenadines	Diagnosis scenario	CVD Cases Averted Compared to Baseline	-	8.9	5.2	-	4.5
St. Vincent & the Grenadines	Treatment scenario	Mean CVD Risk	-	17.7	14.3	-	11.7
St. Vincent & the Grenadines	Treatment scenario	CVD Cases Averted Compared to Baseline	-	12.8	10.8	-	11.1
Sudan	Baseline	Mean CVD Risk	19.6	22.3	20.1	19.3	19.4

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Sudan	Diagnosis scenario	Mean CVD Risk	17.1	20.2	17.4	17.8	18
Sudan	Diagnosis scenario	CVD Cases Averted Compared to Baseline	24.4	21.4	27.6	14	14.1
Sudan	Treatment scenario	Mean CVD Risk	16.6	18.7	17	16.7	17.1
Sudan	Treatment scenario	CVD Cases Averted Compared to Baseline	29.6	35.9	30.8	25.5	23.1
Tanzania	Baseline	Mean CVD Risk	9	13.1	7	9.3	9.2
Tanzania	Diagnosis scenario	Mean CVD Risk	8.2	11.8	6.5	8.6	8.8
Tanzania	Diagnosis scenario	CVD Cases Averted Compared to Baseline	7.8	12.3	5.4	6.9	3.2
Tanzania	Treatment scenario	Mean CVD Risk	7.1	9.8	5.6	7.8	7.3
Tanzania	Treatment scenario	CVD Cases Averted Compared to Baseline	18.4	32.6	14.4	14.5	18.6
Timor Leste	Baseline	Mean CVD Risk	24.7	18.4	13.8	10.9	-
Timor Leste	Diagnosis scenario	Mean CVD Risk	22.1	16.8	13.2	10.5	-
Timor Leste	Diagnosis scenario	CVD Cases Averted Compared to Baseline	25.6	15.8	6	4.5	-

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Timor Leste	Treatment scenario	Mean CVD Risk	20.6	15.5	12.6	9	-
Timor Leste	Treatment scenario	CVD Cases Averted Compared to Baseline	40.9	28.9	12.7	19.9	-
Togo	Baseline	Mean CVD Risk	12.8	9.9	7.7	11.2	11.1
Togo	Diagnosis scenario	Mean CVD Risk	11.9	9.6	7.2	10.8	10.7
Togo	Diagnosis scenario	CVD Cases Averted Compared to Baseline	9.4	3.2	5.5	4.1	3.3
Togo	Treatment scenario	Mean CVD Risk	10.3	8.2	6.5	8.9	9.4
Togo	Treatment scenario	CVD Cases Averted Compared to Baseline	25.1	17.1	12.1	23.4	16.3
Uganda	Baseline	Mean CVD Risk	12	-	8.9	9.3	11.1
Uganda	Diagnosis scenario	Mean CVD Risk	10.9	-	8.1	8.7	10.6
Uganda	Diagnosis scenario	CVD Cases Averted Compared to Baseline	10.4	-	7.4	5.2	4.9
Uganda	Treatment scenario	Mean CVD Risk	9.6	-	7.3	7.7	9.4
Uganda	Treatment scenario	CVD Cases Averted Compared to Baseline	23.4	-	15.9	16	16.9

(continued)

Country	Scenario	Variable	No formal schooling	Less than primary school	Primary school completed	Some high school	High school or above
Vanuatu	Baseline	Mean CVD Risk	10.9	10.6	10.5	12.4	13.6
Vanuatu	Diagnosis scenario	Mean CVD Risk	10.4	10.3	10.3	12.1	12.5
Vanuatu	Diagnosis scenario	CVD Cases Averted Compared to Baseline	4.9	3.1	1.7	3	10.4
Vanuatu	Treatment scenario	Mean CVD Risk	8.6	8.5	8.2	9.8	11
Vanuatu	Treatment scenario	CVD Cases Averted Compared to Baseline	23	21.2	22.7	26	25.8
Zambia	Baseline	Mean CVD Risk	11.1	7.8	6.9	7	8.9
Zambia	Diagnosis scenario	Mean CVD Risk	10.7	7.5	6.4	6.6	8.7
Zambia	Diagnosis scenario	CVD Cases Averted Compared to Baseline	3.8	3.5	4.3	4.4	2.4
Zambia	Treatment scenario	Mean CVD Risk	9.2	6.4	5.8	5.9	8
Zambia	Treatment scenario	CVD Cases Averted Compared to Baseline	19.3	13.7	10.5	11	9.7

Methods

Supplementary Table 32. Information on country-specific surveys

Country	Survey	Source for survey information	Link
Afghanistan	STEPS 2018	Source: World Health Organization NCD Microdata Repository.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/782/related-materials
Albania	Demographic and Health Survey 2008-2009	Source: Institute of Statistics, Institute of Public Health, ICF Macro. 2010. Albania Demographic and Health Survey 2008-09. Tirana, Albania, Maryland, USA. Accessed May 18, 2022.	https://dhsprogram.com/pubs/pdf/fr230/fr230.pdf
Algeria	STEPS 2016	World Health Organization, STEPS Resources. 2019. Accessed May 18, 2022.	https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps
Azerbaijan	STEPS 2017	World Health Organization, STEPS Resources. 2019. Accessed May 18, 2022.	https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps
Benin	STEPS 2015	Source: Ministere de la Sante, Direction Nationale de la Sante Publique, Programme National de Lutte contre les Maladies Non Transmissibles (PNLMNT). Rapport final de l'enquete pour la surveillance des facteurs de risque des maladies non transmissibles par l'approche "STEPswise" de l'OMS. Enquete "STEPS 2015" au Benin. 2016. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/107/download/1044

(continued)

Country	Survey	Source for survey information	Link
Bhutan	STEPS 2014	Source: World Health Organization, Regional Office for South-East Asia. National survey for noncommunicable disease risk factors and mental health using WHO STEPS approach in Bhutan, 2014. Accessed May 16, 2022.	https://apps.who.int/iris/handle/10665/204659
Botswana	STEPS 2015	Source: Ministry of Health Republic of Botswana, WHO. Botswana STEPS Survey Report on Non-communicable Disease Risk Factors. 2015. Accessed May 18, 2022.	https://cdn.who.int/media/docs/default-source/ncds/ncd-surveillance/data-reporting/botswana/steps/steps-botswana-2014-report-final.pdf
Brazil	Pesquisa Nacional de Saúde 2013	This information was taken from the website of “Pesquisa Nacional de Saude”, where further information on the sampling procedure is provided. Accessed May 18, 2022.	https://www.pns.icict.fiocruz.br/index.php?pag=planoamostragem
Cambodia	STEPS 2010	University of Health Sciences and the Preventive Medicine Department of the Ministry of Health, Kingdom of Cambodia: Prevalence of Non-communicable Disease Risk Factors in Cambodia. 2010. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/378/related-materials
China	China Health and Nutrition Survey 2009	This information was taken from the following source, where further information on the sampling procedure is provided: Attard SM, Herring AH, Wang H, et al. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutr Diabetes. 2015;5(6):e166. Published 2015 Jun 22. doi:10.1038/nutd.2015.16	NA
Ecuador	STEPS 2018	Source: NCD Microdata Repository. Fact Sheet. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/774/related-materials

(continued)

Country	Survey	Source for survey information	Link
Eritrea	STEPS 2010	Source: NCD Microdata Repository. Study Description. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/589/study-description#page=sampling&tab=study-desc
Eswatini	STEPS 2014	Source: WHO STEPS: Noncommunicable Disease Risk Factor Surveillance Report Swaziland 2014. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/688/related-materials
Ethiopia	STEPS 2015	Source: Ethiopian Public Health Institute 2016: Ethiopia STEPS report on risk factors for noncommunicable diseases and prevalence of selected NCDs.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/794/download/5522
Gambia	STEPS 2010	The Gambia STEPS Survey 2010 Fact Sheet. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/616/related-materials
Ghana	Study on global AGEing and adult health (SAGE) 2007-8	Source: Biritwum R, Mensah G, Yawson A, Minicuci N. Study on global AGEing and adult health (SAGE) Wave 1: The Ghana National Report. 2013. Accessed May 18, 2022.	https://apps.who.int/healthinfo/systems/surveydata/index.php/catalog/6/download
India	National Family and Health Survey (NFHS-4) 2015-16	Source: International Institute for Population Sciences. 2017. National Family and Health Survey (NFHS-4) 2015-16. Accessed May 18, 2022.	https://dhsprogram.com/pubs/pdf/FR339/FR339.pdf
Indonesia	Indonesia Family Life Survey 2014-15	This information was taken from the following source, where further information on the sampling procedure is provided. Strauss, J, Witoelar F, Sikoki B. The Fifth Wave of the Indonesia Family Life Survey (IFLS5): Overview and Field Report, 2016. WR-1143/1-NIA/NICHD. Accessed May 18, 2022.	https://www.rand.org/content/dam/rand/pubs/working_papers/WR1100/WR1100.pdf

(continued)

Country	Survey	Source for survey information	Link
Jordan	STEPS 2019	Source: Centre of Strategic Studies - University of Jordan, Jordan Ministry of Health, World Health Organization: Jordan National Stepwise Survey (STEPS) for Noncommunicable Diseases Risk Factors 2019. STEPS Technical Report.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/853/download/6010
Kenya	STEPS 2015	Source: WHO. Kenya STEPwise Survey for Non Communicable Diseases Risk Factors 2015 Report. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/247/related-materials
Kiribati	STEPS 2015	Source: Kiribati NCD Risk Factors STEPS Report 2015-2016. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/724/related-materials
Kyrgyzstan	STEPS 2013	World Health Organization, STEPS Resources. 2019. Accessed May 18, 2022.	https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps
Laos	STEPS 2013	Source: NCD Microdata Repository. Study Description. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/588/study-description#page=sampling&tab=study-desc
Lesotho	STEPS 2012	Source: NCD Microdata Repository. Fact Sheet. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/491/related-materials
Moldova	STEPS 2013	Source: WHO. Prevalence of Noncommunicable Disease Risk Factors in the Republic of Moldova. STEPS 2013. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/230/related-materials
Morocco	STEPS 2017	Source: WHO: Enquete Nationale sur les Facteurs de Risque communs des Maladies Non Transmissibles 2017 – 2018: Rapport. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/544/related-materials

(continued)

Country	Survey	Source for survey information	Link
Myanmar	STEPS 2014	Source: Report on National Survey of Diabetes Mellitus and Risk Factors of Noncommunicable Diseases in Myanmar (2014). Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/634/related-materials
Namibia	Demographic and Health Survey 2013	Source: Namibia Ministry of Health and Social Services Windhoek. Namibia Demographic and Health Survey 2013. 2014. Accessed May 18, 2022.	https://dhsprogram.com/pubs/pdf/FR298/FR298.pdf
Niger	STEPS 2007	Source, translated from: Mesure des facteurs de risque des maladies non transmissibles Au Niger (Approche Step"wise" de l'OMS). Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/736/related-materials
Russian Federation	Study on global AGEing and adult health, Wave 1 (2007-2008)	Source: National Research Institute of Public Health, Russian Academy of Medical Sciences (RAMS). Study on global AGEing and adult health (SAGE) Wave 1: Russian Federation National Report. 2013. Accessed May 18, 2022.	http://apps.who.int/healthinfo/systems/surveydata/index.php/catalog/68/download
Rwanda	STEPS2012	Source: Rwanda Non-communicable Diseases Risk Factors Report November 2015. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/709/related-materials
Samoa	STEPS 2013	Source: Samoa STEPS Survey 2013 Fact Sheet. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/707
Sao Tome and Principe	STEPS 2009	Source: Sao Tome et Principe Enquete STEPS 2008 Note de synthese. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/735/related-materials
Solomon Islands	STEPS 2015	Source: NCD Microdata Repository. Study Description. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/710/study-description#page=sampling&tab=study-desc

(continued)

Country	Survey	Source for survey information	Link
South Africa	Demographic and Health Survey 2016	Source: National Department of Health. South Africa Demographic and Health Survey 2016. 2019. Accessed May 18, 2022.	https://www.dhsprogram.com/pubs/pdf/FR337/FR337.pdf
Sri Lanka	STEPS 2014	Source: Non Communicable Disease Risk Factor Survey Sri Lanka 2015. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/614/related-materials
St. Vincent & the Grenadines	STEPS 2013	Source: Ministry of Health, Wellness & the Environment. National Health & Nutrition Survey, Non-Communicable Disease Risk Factor Surveillance, Report for St. Vincent & the Grenadines. 2015. Accessed May 18, 2022.	https://www.who.int/publications/m/item/2013-2014-steps-country-report-saint-vincent-and-the-grenadines
Sudan	STEPS 2016	World Health Organization, STEPS Resources. 2019. Accessed May 18, 2022.	https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps
Tanzania	STEPS 2012	Source: Ministry of Health and Social Welfare & National Institute for Medical Research. Tanzania STEPS Survey Report. 2013. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/641/related-materials
Timor Leste	STEPS 2014	Source: WHO. Timor-Leste STEPS Survey Report. 2015. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/687/related-materials
Togo	STEPS 2010	Source: Ministere de la sante Togo. Rapport final de l'enquete STEPS Togo 2010. 2012. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/730/related-materials

(continued)

Country	Survey	Source for survey information	Link
Uganda	STEPS 2014	Source: Guwatudde D, Mutungi G, Wesonga R, et al. The Epidemiology of Hypertension in Uganda: Findings from the National Non-Communicable Diseases Risk Factor Survey. PLoS One. 2015;10(9):e0138991. Published 2015 Sep 25. doi:10.1371/journal.pone.0138991	NA
Vanuatu	STEPS 2011	Source: Ministry of Health Vanuatu, WHO. Vanuatu, NCD Risk Factors, STEPS Report. 2013. Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/714/related-materials
Zambia	STEPS 2017	Source: Zambia STEPS for Non Communicable Diseases Risk Factors (2017). Accessed May 18, 2022.	https://extranet.who.int/ncdsmicrodata/index.php/catalog/620/related-materials

Note. The STEPS survey reports from Algeria (2016), Azerbaijan (2017), Kyrgyzstan (2013), and Sudan (2016) were not available and we, thus, assumed that they used the STEPS sampling strategies provided on the official website of the World Health Organization. Source: World Health Organization, STEPS Resources. 2019.

Supplementary Table 33. Missing data percent (%) by country and variable

Country	Year	Survey	N	Age, missing, n (%)	Age, out of bounds, n (%)	Sex, missing, n (%)	SBP, missing, n (%)	Currently Smoking, missing, n (%)	BMI, missing, n (%)	Wealth Quintile, missing, n (%)
Afghanistan	2018	STEPS	3922	31 (0.8%)	2254 (57.5%)	3 (0.1%)	1 (0.1%)	0 (0.0%)	5 (0.7%)	118 (15.8%)
Albania	2008	DHS	6664	0 (0.0%)	4495 (67.5%)	0 (0.0%)	72 (3.3%)	0 (0.0%)	2 (0.3%)	0 (0.0%)
Algeria	2016	STEPS	6989	0 (0.0%)	3321 (47.5%)	0 (0.0%)	98 (2.7%)	2 (0.1%)	17 (1.1%)	369 (23.5%)
Azerbaijan	2017	STEPS	2801	0 (0.0%)	1016 (36.3%)	0 (0.0%)	7 (0.4%)	0 (0.0%)	42 (4.5%)	184 (19.7%)
Benin	2015	STEPS	5126	0 (0.0%)	3097 (60.4%)	0 (0.0%)	13 (0.6%)	0 (0.0%)	4 (0.4%)	20 (2.1%)
Bhutan	2014	STEPS	2815	3 (0.1%)	1464 (52.0%)	0 (0.0%)	3 (0.2%)	0 (0.0%)	5 (0.7%)	28 (3.9%)
Botswana	2014	STEPS	4070	0 (0.0%)	2552 (62.7%)	0 (0.0%)	24 (1.6%)	0 (0.0%)	10 (1.2%)	206 (24.6%)
Brazil	2013	Pesquisa Nacional de Saude(PNC)	205546	0 (0.0%)	136440 (66.4%)	0 (0.0%)	40091 (58.0%)	0 (0.0%)	207 (1.6%)	282 (2.1%)
Cambodia	2010	STEPS	5433	0 (0.0%)	2189 (40.3%)	0 (0.0%)	60 (1.8%)	0 (0.0%)	3 (0.5%)	34 (5.2%)
China	2009	CHNS	16837	0 (0.0%)	8362 (49.7%)	0 (0.0%)	1664 (19.6%)	1 (0.0%)	19 (0.8%)	46 (1.9%)
Ecuador	2018	STEPS	4638	0 (0.0%)	2282 (49.2%)	0 (0.0%)	47 (2.0%)	0 (0.0%)	5 (0.7%)	37 (5.1%)
Eritrea	2010	STEPS	6265	0 (0.0%)	2634 (42.0%)	0 (0.0%)	20 (0.6%)	0 (0.0%)	1 (0.1%)	214 (25.1%)
Ethiopia	2015	STEPS	9251	0 (0.0%)	6003 (64.9%)	0 (0.0%)	45 (1.4%)	0 (0.0%)	3 (0.3%)	262 (29.4%)
Gambia	2010	STEPS	4103	0 (0.0%)	2514 (61.3%)	0 (0.0%)	109 (6.9%)	0 (0.0%)	8 (1.2%)	174 (26.9%)
Ghana	2007/8	SAGE	5110	0 (0.0%)	862 (16.9%)	0 (0.0%)	57 (1.3%)	4 (0.2%)	62 (2.7%)	3 (0.1%)

(continued)

Country	Year	Survey	N	Age, missing, n (%)	Age, out of bounds, n (%)	Sex, missing, n (%)	SBP, missing, n (%)	Currently Smoking, missing, n (%)	BMI, missing, n (%)	Wealth Quintile, missing, n (%)
India	2015-2016	DHS	757655	0 (0.0%)	578403 (76.3%)	0 (0.0%)	3254 (1.8%)	0 (0.0%)	99 (0.2%)	0 (0.0%)
Indonesia	2014	IFLS	33410	7 (0.0%)	20518 (61.4%)	2 (0.0%)	24 (0.2%)	0 (0.0%)	89 (1.6%)	0 (0.0%)
Jordan	2019	STEPS	5713	0 (0.0%)	3112 (54.5%)	0 (0.0%)	151 (5.8%)	0 (0.0%)	22 (2.0%)	111 (10.2%)
Kenya	2015	STEPS	4488	16 (0.4%)	2717 (60.5%)	0 (0.0%)	30 (1.7%)	1 (0.1%)	7 (0.9%)	0 (0.0%)
Kiribati	2015	STEPS	2156	0 (0.0%)	1213 (56.3%)	0 (0.0%)	359 (38.1%)	1 (0.4%)	9 (3.3%)	79 (28.8%)
Kyrgyzstan	2013	STEPS	2623	0 (0.0%)	1018 (38.8%)	0 (0.0%)	4 (0.2%)	0 (0.0%)	3 (0.3%)	76 (7.3%)
Laos	2013	STEPS	2564	22 (0.9%)	1340 (52.3%)	22 (0.9%)	2 (0.2%)	0 (0.0%)	1 (0.3%)	3 (1.0%)
Lesotho	2014	DHS	5922	0 (0.0%)	4708 (79.5%)	0 (0.0%)	48 (4.0%)	0 (0.0%)	3 (0.8%)	0 (0.0%)
Moldova	2013	STEPS	4807	0 (0.0%)	1671 (34.8%)	0 (0.0%)	139 (4.4%)	0 (0.0%)	31 (1.6%)	98 (5.1%)
Morocco	2017	STEPS	5429	0 (0.0%)	2327 (42.9%)	0 (0.0%)	19 (0.6%)	0 (0.0%)	8 (0.6%)	196 (14.4%)
Myanmar	2014	STEPS	8271	0 (0.0%)	2757 (33.3%)	0 (0.0%)	175 (3.2%)	1 (0.0%)	7 (0.3%)	318 (13.8%)
Namibia	2013	DHS	4403	0 (0.0%)	1117 (25.4%)	0 (0.0%)	561 (17.1%)	44 (3.4%)	22 (1.7%)	0 (0.0%)
Niger	2007	STEPS	2757	0 (0.0%)	1519 (55.1%)	0 (0.0%)	1 (0.1%)	3 (0.5%)	6 (0.9%)	86 (13.4%)
Russian Federation	2007/8	SAGE	4355	0 (0.0%)	621 (14.3%)	0 (0.0%)	114 (3.1%)	16 (0.7%)	204 (8.6%)	4 (0.2%)
Rwanda	2012	STEPS	7226	0 (0.0%)	4760 (65.9%)	0 (0.0%)	34 (1.4%)	0 (0.0%)	0 (0.0%)	273 (35.3%)
Samoa	2013	STEPS	1766	0 (0.0%)	911 (51.6%)	0 (0.0%)	107 (12.5%)	0 (0.0%)	0 (0.0%)	23 (8.2%)

(continued)

Country	Year	Survey	N	Age, missing, n (%)	Age, out of bounds, n (%)	Sex, missing, n (%)	SBP, missing, n (%)	Currently Smoking, missing, n (%)	BMI, missing, n (%)	Wealth Quintile, missing, n (%)
Sao Tome and Principe	2009	STEPS	2457	0 (0.0%)	1393 (56.7%)	0 (0.0%)	7 (0.7%)	1 (0.2%)	23 (3.8%)	50 (8.3%)
Solomon Islands	2015	STEPS	2525	0 (0.0%)	1367 (54.1%)	0 (0.0%)	221 (19.5%)	0 (0.0%)	4 (1.3%)	35 (11.0%)
South Africa	2016	DHS	37925	293 (0.8%)	27238 (71.8%)	0 (0.0%)	6804 (65.5%)	105 (4.3%)	48 (2.0%)	0 (0.0%)
Sri Lanka	2014	STEPS	5188	0 (0.0%)	2038 (39.3%)	0 (0.0%)	149 (4.7%)	0 (0.0%)	40 (3.0%)	167 (12.5%)
St. Vincent & the Grenadines	2013	STEPS	3508	2 (0.1%)	1537 (43.8%)	0 (0.0%)	43 (2.2%)	0 (0.0%)	7 (0.8%)	230 (26.1%)
Sudan	2016	STEPS	7722	0 (0.0%)	4426 (57.3%)	0 (0.0%)	28 (0.8%)	0 (0.0%)	20 (1.2%)	176 (10.4%)
Swaziland	2014	STEPS	3531	0 (0.0%)	2166 (61.3%)	0 (0.0%)	142 (10.4%)	0 (0.0%)	15 (2.4%)	196 (30.7%)
Tanzania	2012	STEPS	5600	1 (0.0%)	2642 (47.2%)	0 (0.0%)	61 (2.1%)	0 (0.0%)	5 (0.4%)	143 (11.9%)
Timor Leste	2014	STEPS	2609	0 (0.0%)	1269 (48.6%)	0 (0.0%)	23 (1.7%)	0 (0.0%)	8 (1.7%)	109 (23.1%)
Togo	2010	STEPS	4373	20 (0.5%)	2896 (66.2%)	8 (0.2%)	53 (3.6%)	1 (0.2%)	2 (0.4%)	90 (18.6%)
Uganda	2014	STEPS	3987	0 (0.0%)	2644 (66.3%)	0 (0.0%)	33 (2.5%)	0 (0.0%)	7 (1.4%)	109 (21.6%)
Vanuatu	2011	STEPS	4643	0 (0.0%)	2305 (49.6%)	0 (0.0%)	50 (2.1%)	0 (0.0%)	8 (0.8%)	52 (5.5%)
Zambia	2017	STEPS	4302	0 (0.0%)	2696 (62.7%)	0 (0.0%)	48 (3.0%)	0 (0.0%)	4 (0.7%)	170 (30.6%)

Note. Age and sex missingness and out of bounds values are reported on the full survey sample. Systolic Blood Pressure (SBP) missingness is reported on the sample that meet the inclusion criteria for age and sex. Currently smoking, Body Mass Index (BMI), and wealth quintile missingness is reported among the population of people living with hypertension that meet inclusion criteria for age, sex, and have non-missing SBP values. These values do not distinguish between 'do not know/refuse to respond' and 'missing because not eligible/asked'. In some surveys, specific sets of questions were only asked to a subset of the full survey sample.

Supplementary Table 34. Details of blood pressure measurement methodology by country

Country	Measurement device	Number of measurements	Interval between measurements
Albania	Omron M6 Comfort and Omron HEM-711ac; Life Source Model UA-789 for individuals with a wide upper arm circumference	3	10 minutes
Algeria	Not specified	3	Not specified
Azerbaijan	Not specified	3	Not specified
Benin	Boso-Medicus Uno	3	3 minutes
Bhutan	Boso Medicus Control	3	3 minutes
Botswana	Not specified	3	Not specified
Brazil	G-TECH Model MA 100	3	2 minutes
Cambodia	NISSEI Digital Blood Pressure Monitor (Model DS-500)	3	Not specified
China	Manual mercury sphygmomanometer	3	10 minutes
Ecuador	Digital upper arm meter (model not specified)	2	Not specified
Eritrea	Not specified	3	Not specified
Eswatini	Boso Medicus PC (model not specified)	3	3-5 minutes
Ethiopia	Boso Medicus Uno	3	3 minutes
Gambia	Not specified	3	Not specified
Ghana	Boso Medistar wrist Blood Pressure Monitor Model S	3	1 minute
India	Omron Digital Monitor HEM-8712	3	5 minutes
Indonesia	Omron Digital Monitor HEM7203	3	First measurement taken at beginning of interview, subsequent two taken during the course of the interview
Jordan	Omron M3 Digital Monitor	3	3 minutes

(continued)

Country	Measurement device	Number of measurements	Interval between measurements
Kenya	Omron M2 Digital Monitor	3	3-5 minutes
Kiribati	Omron M4 Digital Monitor	3	2-3 minutes
Kyrgyzstan	Not specified	3	Not specified
Laos	Not specified	3	Not specified
Lesotho	Omron M3W Digital Monitor	3	10 minutes
Moldova	Boso-Medicus Uno	3	3 minutes
Morocco	Spengler ES 60	3	Not specified
Myanmar	Boso Medicus automatic digital blood pressure monitor	3	5 minutes
Namibia	Life Source Digital	3	Not specified
NA	Monitor Model UA-767	NA	NA
Niger	Omron (model not specified)	3	Not specified
Russian Federation	Omron R6 Wrist Blood Pressure Monitor HEM-6000-E	2	Not specified
Rwanda	Omron M4 Digital Automatic Blood Pressure Monitor	3	2-3 minutes
Samoa	Not specified	3	Not specified
Sao Tome and Principe	Not specified	3	Not specified
Solomon Islands	Not specified	3	Not specified
South Africa	Omron 1300 Digital Monitor	3	3 minutes or more
Sri Lanka	Not specified	3	Not specified
Sudan	Not specified	3	Not specified
St. Vincent and the Grenadines	Omron Digital Monitor M4 - I	3	3 minutes
Tanzania	Omron digital upper arm meter (model not specified)	3	Not specified

(continued)

Country	Measurement device	Number of measurements	Interval between measurements
Timor-Leste	Omron digital upper arm meter (model not specified)	3	2 minutes
Togo	Omron digital upper arm meter (model not specified)	3	5 minutes
Uganda	Boso Medicus Uno	3	3-5 minutes
Vanuatu	Omron M4	3	2-3 minutes
Zambia	Automated blood pressure machine (model not specified)	3	3-5 minutes

Supplementary Table 35. Household wealth measures by country

Wealth measure	Country
Wealth/asset index	Albania, Brazil, Ghana, India, Indonesia, Kenya, Namibia, Russian Federation, South Africa
Continuous income	Bhutan, China, Eritrea, Kiribati, Laos, Myanmar, Niger, Timor-Leste
Continuous income and quintiles	Azerbaijan, Botswana, Cambodia, Ecuador, Ethiopia, Gambia, Jordan, Lesotho, Rwanda, Samoa, Sao Tome and Principe, Solomon Islands, Tanzania, Zambia
Continuous income and categories	Algeria, Benin, Eswatini, Kyrgyzstan, Moldova, Morocco, Togo, Uganda, Vanuatu
Income categories only	St. Vincent and the Grenadines, Sudan, Sri Lanka

Supplementary Table 36. Relative risks from Law et al. (2009) by age group


Age group (years)	Stroke	CHD
40-49	0.36	0.49
50-59	0.38	0.50
60-69	0.43	0.54
70-79	0.50	0.60
80-89	0.67	0.67

Source.

Law et al. 2009 (Appendix Supplementary Table 3)


Country-specific Figures

Supplementary Figure 1. Country-specific plots of baseline hypertension care cascade performance, mean CVD risk (%), mean difference in CVD cases per 1,000 people living with hypertension, and mean relative decline (%) in CVD risk compared to baseline, by wealth quintile and scenario



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Afghanistan: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Afghanistan: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Albania: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Albania: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Albania: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Algeria: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Algeria: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Algeria: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Azerbaijan: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Azerbaijan: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Azerbaijan: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Benin: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Benin: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Benin: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Bhutan: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Bhutan: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Bhutan: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Botswana: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Botswana: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Botswana: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Brazil: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Brazil: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Brazil: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Cambodia: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Cambodia: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Cambodia: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




China: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


China: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

China: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Ecuador: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Ecuador: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Ecuador: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Eritrea: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Eritrea: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Eritrea: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Ethiopia: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Ethiopia: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Ethiopia: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Gambia: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Gambia: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Gambia: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Ghana: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Ghana: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Ghana: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




India: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


India: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

India: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Indonesia: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Indonesia: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Indonesia: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Jordan: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Jordan: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Jordan: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Kenya: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Kenya: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Kenya: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Kiribati: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Kiribati: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Kiribati: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Kyrgyzstan: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Kyrgyzstan: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Kyrgyzstan: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Laos: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Laos: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Laos: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Lesotho: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Lesotho: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Lesotho: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Moldova: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Moldova: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Moldova: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Morocco: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Morocco: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Morocco: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Myanmar: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Myanmar: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Myanmar: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Namibia: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Namibia: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Namibia: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Niger: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Niger: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Niger: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Russian Federation: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Russian Federation: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Russian Federation: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Rwanda: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Rwanda: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Rwanda: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Samoa: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Samoa: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Samoa: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Sao Tome and Principe: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Sao Tome and Principe: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Sao Tome and Principe: Mean Difference in CVD Case per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Solomon Islands: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Solomon Islands: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Solomon Islands: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




South Africa: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


South Africa: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

South Africa: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Sri Lanka: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Sri Lanka: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Sri Lanka: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




St. Vincent & the Grenadines: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


St. Vincent & the Grenadines: Mean Decline (%) in CVI from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

St. Vincent & the Grenadines: Mean Difference in CVD per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Sudan: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Sudan: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Sudan: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Eswatini: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Eswatini: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Eswatini: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Tanzania: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Tanzania: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Tanzania: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Timor Leste: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Timor Leste: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Timor Leste: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Togo: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Togo: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Togo: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Uganda: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Uganda: Mean Decline (%) in CVD Risk from Baseline



● Diagnosis scenario ● Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Uganda: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




● Diagnosis scenario ● Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Vanuatu: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Vanuatu: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario


Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Vanuatu: Mean Difference in CVD Cases per 1,000 People Living with Hypertension




—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.




Zambia: Mean CVD Risk (%)



Note: Vertical bars represent 95% confidence intervals for Baseline and 95% uncertainty intervals for the Diagnosis and Treatment scenarios.


Zambia: Mean Decline (%) in CVD Risk from Baseline



—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.

Zambia: Mean Difference in CVD Cases per 1,000 People Living with Hypertension



—●— Diagnosis scenario —●— Treatment scenario

Note: Vertical bars represent 95% uncertainty intervals for the Diagnosis and Treatment scenarios.